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Summary of Thesis 
The metabolic and cardiovascular diseases are major health problems in many 
countries with significant health burden to the society. It has been recognized that 
endothelial dysfunction, caused by imbalance of responses to endothelium derived 
vasodilators and contracting factors, plays an important role in the pathogenesis of 
these diseases. Endothelial nitric oxide synthase (eNOS) uncoupling, occurred under 
oxidative stress due to excessive generation of reactive oxygen species, is a key 
driver to endothelial dysfunction. Functional eNOS requires adequate cofactors. 
Alterations of bioavailability of these cofactors in particular tetrahydrobiopterin 
(BH4) or other regulatory mechanisms such as heat shock protein (HSP) 90 can 
result in eNOS uncoupling. Identification of new agents to target eNOS uncoupling 
mechanism is an important direction for developing new therapies for treating 
endothelium dysfunction and related metabolic and cardiovascular diseases.  
 
Danshen is the dried root of Salvia miltiorrhiza Bunge. It has long been used in 
traditional medicine for the treatment of cardiovascular and cerebrovascular diseases. 
The active components of Danshen, such as tanshinones, have certain actions on the 
endothelium. However, their actions on eNOS uncoupling have not been investigated. 
In addition, the relationship between chemical characteristics of Danshen compounds 
and their potential drug capability and the profile of absorption, distribution, 
metabolism, extraction and toxicity (ADME/Tox) are not fully understood. Thus, this 
project aims to evaluate the effects of Danshen compounds on eNOS uncoupling and 
the ADME/Tox profiles of natural compounds/products.  
 
Firstly, the drug potential and toxicity risk of Danshen compounds were studied by 
using various established computational tools. Among 94 compounds evaluated, 76 
compounds showed drug-like properties including major tanshinones-tanshinone I 
(Tan I), tanshinone IIA (Tan IIA) and cryptotanshinone (CT). Irritating effect is a 
potential toxicity risk of these compounds. Literature analysis indicates a number of 
commonly used natural compounds including Danshen compounds are the substrate 
or ligand of drug metabolizing enzymes, transporters, and nuclear receptors both in 
experimental and computational studies. 
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Secondly, a biochemical approach was used to study eNOS uncoupling in human 
umbilical vein endothelial cell line (EA.hy926), by using a high glucose induced 
eNOS uncoupling model. The EA.hy926 cells were incubated with 35 mM D-
glucose for 24 hr or 48 hr. The cells were exhibited reduced nitric oxide (NO) and 
increased eNOS derived superoxide, reduced ratio of dimer/monomer of eNOS and 
BH4 bioavailability, and increased nicotinamide adenine dinucleotide phosphate 
oxidase 4 (NOX4) expression. Phosphoinositide 3-kinase (PI3K) signaling pathway 
was also enhanced and HSP90 expression was decreased.  
 
Using this cell model, three major tanshinones (Tan I, Tan IIA and CT) were then 
tested for their effects on eNOS uncoupling in EA.hy926. All three compounds 
significantly restored high glucose induced eNOS uncoupling, with increased BH4 
bioavailability and NO production, reduced superoxide generation and the expression 
of NOX4, the major source of reactive oxygen species in endothelium cells, up-
regulated the expressions of guanosine triphosphate cyclohydrolase I (GTPCH1), 
dihydrofolate reductase (DHFR) and HSP90, down-regulated the expression of PI3K. 
In addition, two synthetic analogues of tanshinones were also found with similar 
effects on eNOS uncoupling.  
 
The findings from these studies suggest that computational analysis of Danshen 
compounds is capable of predicting their drug potential and toxicity risk. The study 
has also demonstrated for the first time the mechanism of actions of tanshinones and 
two synthetic compounds on eNOS uncoupling via regulation of BH4 bioavailability 
and the expressions of GTPCH1 and DHFR, reduction of the expression of NOX4 
and up-regulation of HSP90. The regulation of NOX4 by tanshinones may be related 
to PI3K pathway. These findings indicate that tanshinones may be used as a protype 
to develop new agents to treat eNOS uncoupling-mediated cardiovascular and 
metabolic diseases. Finally, an integration of computational approaches with well-
established biochemical approaches make an important contribution in natural 
products research and drug discovery and development in the future. 
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1 Chapter 1. General Introduction 
1.1 Oxidative stress 
Oxidative stress plays a causal role in the development of many important 
cardiovascular and metabolic diseases (Figure 1. 1) (1, 2). It is a hallmark of the 
cardiovascular risk states, such as atherosclerosis and diabetes (3). Oxidative stress is 
caused by an increase in the generation of pro-oxidant molecules and/or a decrease in 
the antioxidants in a given cellular compartment, in which the pro-oxidants 
overweigh the capability of antioxidant systems, resulting in an imbalance in the 
amounts of oxidants and antioxidants.  
 
 
Figure 1. 1. Oxidative stress and diseases. 
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Under physiological conditions, cells produce certain amount of reactive oxygen 
species (ROS) such as superoxide (O2–) and hydrogen peroxide (H2O2) in a 
deliberately and tightly regulated manner to be used as second messengers in redox 
signalling pathways. However, under pathological conditions, the production of ROS 
in vascular cells is elevated. When these molecules are present at high concentrations 
and escape detoxification by cellular antioxidant pathways, they may undergo direct 
chemical interactions with other biomolecules. Of particular importance are the 
reactions between O2– and NO, which gives rise to peroxynitrite (ONOO–), and the 
iron-catalysed Haber-Weiss reaction between O2– and H2O2, which gives rise to 
hydroxyl radicals (•OH). ONOO– and •OH are extremely powerful oxidising species. 
Along with O2– and H2O2, they can cause endothelial dysfunction through direct 
oxidative damage to cellular macromolecules, impairment of the NO signalling 
pathway, and activation of pro-inflammatory signalling cascades. Consequently, the 
normal redox state of the biological compartment is shifted towards oxidising states, 
which may potentially lead to oxidative damage to macromolecules such as proteins, 
lipids, nucleotides and carbohydrates.  
 
Recently, accumulating evidence suggests that ROS production in vascular 
pathophysiology is a result of a complex feed-forward mechanism involving 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidases (NOXs), a primary 
source of ROS leads to dysfunction of endothelial nitric oxide synthase (eNOS), 
xanthine oxidoreductase (XOR), cytochrome P450 system (CYP450) and the 
mitochondrial electron transport chain. 
 
1.1.1 The sources of ROS 
ROS comprises of many O2 derived small molecules, including  oxygen radicals [O2–, 
•OH, peroxyl (RO2•), and alkoxyl (RO•)] and certain nonradicals that are either 
oxidizing agents and/or are easily converted into radicals, such as hypochlorous acid 
(HOCl), ozone (O3), singlet oxygen (1O2), and H2O2 (4). ROS can be generated from 
various sources (5). They can be produced under physiological conditions as 
intermediates in the cyclooxygenase (COX) or CYP450 (6); or as by-products of 
normal metabolism in the mitochondria (7). Under pathological condition, ROS 
generation is boosted through NOXs, XOR or NOS due to accidental electron 
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transfer onto O2 during substrates or cofactors shortage (8, 9). Among these, NOXs 
are the major ROS generating enzyme family present in plants, yeast, and animals 
(10).   
 
1.1.1.1 NOXs 
NOXs are multicomponent enzymes mediating the transfer of electrons from 
cytosolic NADPH to O2 to produce O2–. (11-13); it is a primary enzymatic source of 
ROS (4). NOXs are differentially expressed in the cardiovascular system and subject 
to regulation by various factors. Moreover, NOXs derived ROS are also important 
signalling molecules under physiological conditions. NOXs derived ROS serve as 
substrates for a variety of peroxidases such as myeloperoxidase, lactoperoxidase (14), 
and thyroid peroxidase (15). They also modulate signal transduction and gene 
expression (16). In addition, O2–, produced by NOXs, directly reacts with NO to 
form the highly oxidizing agent ONOO– (17). Accumulating evidence demonstrates 
that the endothelial NOX isoforms, including NOX1, 2, 4, 5, are the major 
contributors of ROS and they have been involved in the development of many 
cardiovascular diseases (18, 19). In addition, a cause-and-effect relationship among 
NOXs activity, vascular oxidative stress and diseases has been demonstrated using  
genetically modified mice that are deficient in either NOX1 (20-22) or NOX2 (23-
26), or in the NOX organiser subunit p47phox (27). Thus, collectively, the above 
findings indicate that NOXs serve as a primary source of ROS generation in the 
vessel wall in various disease states. More detail about the NOX family will be 
discussed in Section 1.3.    
 
1.1.1.2 XOR 
XOR is a ubiquitous homodimeric enzyme playing a critical role in purine 
degradation (28, 29). XOR consists of two inter-convertible but functionally distinct 
enzymes, namely xanthine dehydrogenase (XDH), which is constitutively expressed, 
and xanthine oxidase (XO), which is generated by the posttranslational modification 
of XDH (30). Functionally, XORs act as a rate-limiting enzyme for the oxidation of 
hypoxanthine into xanthine and further into urate (30). For these reactions, XDH 
requires NAD+ and XO instead of O2 as an electron acceptor, thereby producing 
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nicotinamide adenine dinucleotide (NADH), O2− and H2O2, respectively (30). Of 
note, under many conditions such as hypoxia, ischemia, or in the presence of various 
pro-inflammatory mediators, XD converts to XO either through reversible thiol 
oxidation of sulfhydryl residues on XD or via irreversible proteolytic cleavage of a 
segment of XD (30), which suggests that reversible thiol oxidation of sulfhydryl 
residues is a mechanism whereby XO activity may increase further oxidative stress 
(31). 
 
XORs are expressed in high levels in the gut and liver, but low levels in the blood 
vessel wall. The regulation of expression and activity on both the transcriptional and 
posttranslational level has been described (32). For example, pro-inflammatory 
stimuli and hypoxia can significantly up-regulate the transcription of XO (32). It has 
been found that patients with coronary artery disease had a significant increase in XO 
activity in coronary arteries with high O2– production, compared to control patients 
(33, 34). Furthermore, a variety of diseases such as coronary artery disease, heart 
failure, and hypertension have been shown with elevated XO levels. Interestingly, it 
has been demonstrated that there was a circulating form of XO, which can bind to 
glycosaminoglycans on the surface of ECs (35), and it has been shown that the 
activity of this endothelial bound XO dramatically increased by more than 200% in 
patients with chronic heart failure (36). Therefore, XO is most likely secondary to 
NOX as a source of ROS production in vascular pathophysiology. 
 
1.1.1.3 Mitochondrial respiratory chain 
Mitochondria is an important cellular organelle where the conversion of the oxido-
reduction energy of mitochondrial electron transport to high energy phosphate bond 
of adenosine-5'-triphosphate (ATP) takes place through a multicomponent NADH 
dehydrogenase (37). However, during abnormal mitochondrial respiration, there is a 
leakage of electrons to molecular O2 at complexes I (NADH dehydrogenase), II 
(succinate dehydrogenase) and III (ubiquinone-cytochrome bc1) of the electron-
transport chain resulting in the generation of O2– towards the mitochondrial matrix. 
As such, the mitochondrial respiratory chain can be a major source of O2–.  
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An increasing body of evidence suggests that increased mitochondrial ROS 
generation is involved in the development of many cardiovascular and metabolic 
diseases (38). For example, a number of stimuli that are able to induce endothelial 
dysfunction have been shown to increase mitochondrial ROS production, such as 
adipokine, leptin, CD40, hypoxia, cyclic strain, oxidised low density lipoprotein 
(LDL), electrophilic lipid oxidation products and high glucose (39). Of importance, it 
has been demonstrated that excessive ROS generation by the mitochondria directly 
contributes to endothelial dysfunction and vessel diseases (40). Ohashi et al. (41) 
reported a reduced NO bioavailability and accelerated atherosclerotic lesion 
development in a ApoE–/– mice model with genetic deletion of manganese SOD, 
whereas, Zhang et al. (42) showed a protective action on endothelial function against 
atherosclerosis in the same strain of mice by endothelial specific overexpression of 
the mitochondrial thioredoxin 2 gene. Moreover, it has been shown that 
mitochondrial derived O2– was increased in hypxia-reoxygenation and ischemia-
reperfusion (43). There are also potential interactions between difference sources of 
ROS. For example, H2O2 and ONOO– may directly increase mitochondrial ROS 
production (44-46), and Doughan et al. (47) demonstrated excessive ROS generation 
by mitochondria may occur in the presence of elevated NOXs activity. 
 
1.1.1.4 CYP450 
CYP450 is one of the most important drug metabolizing enzymes responsible for 
Phase I drug metabolism. It is capable of converting exogenous and endogenous 
substances. The extra-hepatic expression of CYPs has been reported, such as in the 
cardiovasculature (48). CYP2 and CYP4A families are able to metabolize 
arachidonic acid which has been implicated in vascular regulation through the 
generation of vasodilators and vasoconstrictors (49-51).  
 
There is evidence that vascular CYP enzymes can generate O2–, H2O2, and •OH 
during the CYP reaction cycle, when the electron flow is disturbed (49). The electron 
is transferred to the O2 instead of the central heme iron for reduction (49). It has been 
demonstrated that CYP2C is a significant source of ROS in cultured and native ECs 
and is involved in the endothelium derived hyperpolarizing factor (EDHF), a 
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vasodilator, response in porcine coronary arteries (52). Due to the capability of 
generating EDHF and ROS, it suggests that the outcome of altered CYP2 activity 
may be quite complex.  
 
Endothelial CYP activity and expression can be regulated by cyclic stretch, hormonal 
stimuli, and 3-Hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibitors 
(statins) (53), leading to both increased ROS and increased EDHF. Under 
pathological conditions such as hypertension and hypercholesterolemia, CYP 
expression has been reported to be increased (54). In the case of statins, an increase 
in eNOS expression may result in increased ONOO– formation. On the other hand, 
oxidized LDL reduces endothelial CYP2 family enzyme expressions via ROS, which 
is probably generated by NOX and acting through reduced expression of the 
transcriptional regulator neurofibromatosis-1 (NF-1) (55). 
 
1.1.1.5 eNOS 
eNOS is one of the most important athero-protective enzymes in the blood vessel 
wall. It catalyses the formation of endothelium derived NO, which plays a critical 
role in the maintenance of a healthy vasculature homeostasis via its vasorelaxant, 
anti-inflammatory and anti-clotting actions (more details will be discussed in Section 
1.4). However, under certain circumstances, eNOS may also act as a significant 
source of intracellular ROS (see Section 1.4), and contribute to vascular oxidative 
stress and endothelial dysfunctions in many cardiovascular and metabolic diseases 
(56-58).  
 
1.1.2 Pathophysiological role of ROS  
The pathophysiological function of ROS has been extensively investigated in the last 
decade (4, 59). It is known that ROS is involved in a wide range of cellular processes, 
implicated in a wide variety of pathophysiological conditions (4, 60-62), including 
host defence, inflammation, cellular signalling, gene expression, cellular death, 
cellular senescence, regulation of cell death, O2 sensing, biosynthesis, protein cross 
linking, regulation of cellular redox potential, reduction of metal ions, regulation of 
matrix metalloproteinases, angiogenesis, and cross link with the NO system.  
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Of particular importance, the role of ROS in endothelial function and vascular 
homeostasis has been reported (4). Firstly, ROS act as an oxygen sensing (63, 64). It 
has been reported that many types of acute and chronic O2-sensitive processes were 
involved in cardiorespiratory homeostasis and O2 sensitive alterations in endothelial 
function were essential for vascular homeostasis. For example, in the coronary 
circulation, a slight decrease in arterial O2 pressure would result in a rapid increase in 
endothelial production of NO and vasodilator prostanoids, which directly increase 
blood flow and thus O2 supply (65). Secondly, ROS can regulate vascular tone 
through interacting with NO and closely dependant on direct effects of H2O2 (4, 54). 
It is well established that endothelium derived NO underwent a very rapid reaction 
with O2– that led to inactivation of NO. On the other hand, a number of studies 
indicate that H2O2 was involved in flow induced dilation (66, 67), which suggest that 
H2O2 production contributed to the physiological regulation of vascular tone in 
certain vascular beds. In addition, ROS also have the capability of regulating EC 
growth, migration, proliferation, and survival, in which the physiological functions 
have been demonstrated (4).  
 
The pathological mechanisms of ROS are largely due to its capability of interacting 
with various molecules, such as proteins, lipids, carbohydrates and other small 
inorganic molecules to irreversibly destroy or alter the function of the target 
molecule. As a consequence, disturbed cellular processes such as uncontrolled 
cellular proliferation and apoptosis may occur in vasculature, which in turn results in 
endothelial dysfunction. It is suggested that all the alterations are crucial contributors 
to cardiovascular disease. 
 
Consequently, ROS have been increasingly identified as major contributors to 
numerous disorders or diseases such as hypertension, aortic aneurysm, myocardial 
infarction, ischemia-reperfusion disorders, pulmonary fibrosis, amyotropic lateral 
sclerosis, Alzheimer’s disease, Parkinson’s disease, ischemic stroke, diabetic 
nephropathy, and renal cell carcinoma (68-70). Moreover, under certain conditions, 
such as hyperglycaemia, hyperlipidaemia and hyperinsulinemia, the excessive ROS 
production can result in more complications and dysfunctions (71-74). 
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1.2 Endothelial dysfunction 
Endothelial dysfunction is characterized by the shift of endothelium mediated 
vasodilation due to a reduction of the bioavailability of vasodilators and an increase 
in endothelium derived contracting factors (75, 76). It has been implicated in the 
pathogenesis of many cardiovascular and metabolic diseases (Figure 1. 1), such as 
coronary artery disease, atherosclerosis, chronic heart failure, peripheral artery 
disease, hypertension, diabetes, obesity and chronic renal failure (56, 77, 78).  
 
It is proposed that the severity of endothelial dysfunction can be used as an 
independent predictor of cardiovascular events, providing valuable prognostic 
information. It has been known that certain cardiovascular risk factors and 
therapeutic intervention, including statins and angiotensin converting enzyme 
inhibitors, may modify endothelial function. Endothelial function may be an 
attractive primary target in the effort to optimize individualized therapeutic strategies 
to reduce cardiovascular morbidity and mortality. 
 
1.2.1 Pathogenesis of endothelial dysfunction 
The key mechanism of endothelial dysfunction is the disrupted balance of 
vasodilating and vasocontracting factors. Consequently, endothelium derived NO 
production is decreased and ROS generation is increased resulting in a decline in the 
bioavailability of NO and excessive accumulation of ROS, which in turn cause 
oxidative stress (1, 78).  
 
1.2.1.1 ROS 
A number of studies have been shown the causal role of excessive ROS in 
endothelial dysfunction resulting in the genesis and progression of cardiovascular 
diseases (79, 80). In an animal model, it has been shown that increased ROS 
production induced endothelial dysfunction, but supplementation of antioxidants 
improved endothelium-dependent relaxation by regulation of NOX and SOD (81). In 
hypertensive patients, Taddei et al. (82) showed that increased production of ROS 
impaired endothelium-dependent relaxation. Further to this, Heitzer et al. (83) 
showed that the relationship between NO and ROS was correlated with the degree of 
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impairment of endothelium-dependent vasodilation and cardiovascular events. In 
addition, this relationship was observed in chronic renal failure as well. In animal 
models, it has been demonstrated that increased ROS production resulted in 
decreased NO bioavailability and endothelial dysfunction, whereas pre-treatment 
with antioxidant may result in an improvement (84, 85). In patients, Annuk et al. (86) 
showed that oxidative stress markers were also correlated with endothelial 
dysfunction. Cross et al (87) observed improvement on endothelial dysfunction by 
the administration of vitamin C. Moreover, in diabetic animal models, it also has 
been shown that increased production of ROS caused endothelial dysfunction (88, 
89).  
 
1.2.1.2 NO 
NO is the most important vasodilating substance catalysed by NOS. It has been 
reported that reduced NO level is often accompanied by impaired endothelial 
function. There are many reasons for the reduction of NO bioavailability. The two 
basic reasons are decreased generation and increased degradation. The reduced 
generation may result from impaired activity of NOS or increased diminish by NO 
quencher(s) to decreased bioavailability of NO, eventually, leading to endothelial 
dysfunction. It is well known that ROS are capable of quenching NO resulting in the 
formation of ONOO– with cytotoxic effects on protein function and endothelial 
function via protein nitration (90, 91). Moreover, ONOO– is an important mediator of 
oxidation of LDL (90, 91) and is able to degrade eNOS cofactor tetrahydrobiopterin 
(BH4) causing eNOS uncoupling (92).  
 
1.2.1.3 Asymmetric dimethylarginine 
Asymmetric dimethylarginine (ADMA) is a relatively new and attractive mechanism 
resulting in a reduction of NO bioavailability (93). It is an endogenous competitive 
inhibitor of eNOS (94, 95). It has been demonstrated that ADMA uncoupled eNOS 
leading to oxidative stress in human umbilical vein endothelial cells (HUVECs) (93). 
The role of ADMA in endothelial dysfunction also has been studied in vivo. It has 
been demonstrated that plasma ADMA level was correlated with the inhibition of 
eNOS in ECs from patients with chronic renal disease (96, 97). Besides, it has been 
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shown that ADMA levels were inversely related to endothelium-dependent 
vasodilation in subjects with hypercholesterolemia, whereas infusion of L-arginine 
and competitor of ADMA can normalize endothelial function (98). It also has been 
suggested that accumulation of ADMA led to reduced effect on renal plasma flow 
and increased renovascular resistance and blood pressure (99). Moreover, it has been 
demonstrated that supplementation with L-arginine, BH4 and vitamins can alleviate 
ADMA induced endothelial dysfunction (93, 100, 101).  
 
1.2.1.4 Angiotensin II 
Angiotensin II (Ang II) is a key vasoactive compound and has been implicated in the 
pathogenesis of many cardiovascular diseases (25). It has been reported that Ang II 
stimulated the activity and expression of NOXs resulting in increased ROS 
production, which in turn led to eNOS uncoupling (102-106). Ang II induced 
endothelial dysfunction also has been observed in animal models (107-109). On the 
other hand, the beneficial effects on endothelial function by antagonising Ang II 
receptors have been demonstrated (110). Sarr et al. (111) showed that red wine 
polyphenol can prevent Ang II induced hypertension and endothelial dysfunction, 
and normalize vascular ROS production and NOX subunit expression in rats. Zhang 
et al. (112) also reported that simvastatin can ameliorate Ang II induced endothelial 
dysfunction through restoration of Rho-BH4-eNOS-NO pathway. In hypertensive 
patients, it also has been shown that interruption of the renin-angiotensin system with 
angiotensin-converting enzyme inhibitors or angiotensin receptor blockers restoreed 
endothelial function (113-115). 
 
1.2.1.5 Hyperhomocysteinemia 
Hyperhomocysteinemia has been recognized as a non-traditional cardiovascular risk 
factor causing endothelial dysfunction in both animal and human studies (95, 116). It 
has been shown that hyperhomocysteinemia induced endothelial dysfunction in 
methylenetetrahydrofolate reductase-deficient mice (116) and normotensive patients 
(117). Conversely, reducing homocysteine level can ameliorate endothelial function 
in both animal and human studies. For instance, a reduction of homocysteine levels 
and improvement of endothelial function can be observed after folic acid (FA) 
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supplementation in children with chronic renal failure (118). In addition, it has been 
demonstrated that homocysteine may inhibit dimethylarginine 
dimethylaminohydrolase leading to ADMA accumulation (119). Consistently, it has 
been confirmed that hyperhomocysteinemia induced endothelial dysfunction is via 
accumulation of ADMA (95, 120). These findings may explain the increased 
cardiovascular risk of patients with hyperhomocysteinemia. This is of special 
importance for patients with chronic renal failure, who often have increased 
homocysteine levels (121). 
 
1.2.1.6 Others 
Other mechanisms may also be implicated in the pathogenesis of endothelial 
dysfunction. For example, under conditions of insulin resistance, insulin signalling 
pathway is altered with significant down-regulation of phosphoinositide 3-kinase 
(PI3K), phosphoinositide-dependent kinase-1, and Akt/protein kinase B to 
phosphorylation and activation of eNOS, whereas the pathway leading to mitogenic 
effects and growth via mitogen activated protein kinase (MAPK) is unaffected (122-
125).  
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1.3 NOX Family 
NOX is a major superoxide generating enzyme family, which was firstly identified in 
phagocytic cells (126). The function of NOX was observed before the identification. 
It was responsible for the respiratory burst (127), and essential to the microbicidal 
function of these cells (11, 12, 128-131). NOXs transfer electrons from the cytosolic 
donor, NADPH, to flavin adenine dinucleotide (FAD), then sequentially to each of 
the two heme groups and then to O2 on the opposite side of the membrane to 
generate ROS (132). Although all NOXs use this mechanism to generate ROS, 
modes of activation, subunit requirements, and subcellular localizations differ 
between isoforms (Table 1. 1).  
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Table 1. 1. Characteristics of NOX isoforms. 
Isoform Human gene 
locus 
Coupling 
components 
Major distribution 
sites 
Induction Signalling molecules 
NOX1 Xq22 p22phox 
NOXA1/p67phox 
NOXO1/p47phox 
Rac 
colon epithelium 
VSMC 
 
IFN-γ, flagellin, IL-1β, TNF-
α (CEC); 
Ang II, PDGF, PGF2α, TPA, 
serum, 
aldosterone/high salt (VSMC); 
LPS (macrophage, gastric mucosal 
cell);  
IL-1α (mast cell) 
GATA-6, HNF-1A, Cdx1 
(constitutive expression in CEC); 
STAT1 (induction in CEC); 
PKCδ, EGF receptor, PI3K, 
ATF-1, MEF2B, ERK1/2, JunB 
(induction in VSMC); 
NF-κB (induction by LPS); 
LTB4-BLT2 receptor (induction 
by IL-1β in mast cell) 
NOX2 Xp21.1 p22phox 
p67phox 
p47phox 
p40phox 
Rac 
phagocyte IFN-γ, LPS (phagocyte); 
TPA, retinoic acid/DMF (myeloid 
cell) 
 
BID, IRF-1, IRF-2, CP1, Elf-1, 
PU.1 (phagocyte); 
HoxA9 (myeloid differentiation); 
GATA-1 (eosinophil); 
NF-κB (induction by LPS) 
NOX3 6q25.3 p22phox 
NOXA1/p67phox 
NOXO1/p47phox 
Rac 
inner ear 
 
  
NOX4 11q14.2-q21 p22phox kidney (many 
other organs) 
 
hypoxia (PASMC); 
TGF-β (cardiac fibroblast, SMC);  
7-ketocholesterol (VSMC); 
cannabidiol (leukemia cell) 
 
HIF-1α (induction by hypoxia); 
Smad3 (induction by TGF-β); 
IRE-1, JNK, AP-1 (induction by 
7-ketocholesterol); 
E2F1 (constitutive expression in 
VSMC) 
NOX5 15q22.31  spleen, testis, 
lymph node 
PAF (Barrett’s esophageal 
adenocarcinoma) 
STAT5 (induction by PAF) 
 
DUOX1 15q21 DUOXA1  thyroid IL-4, IL-13 (airway epithelial cell)  
DUOX2 15q15.3 DUOXA2  thyroid IFN-γ (airway epithelial cell)  
Adapted from Katsuyama et al. (60, 133).  
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Abbreviation: Ang II, angiotensin II; AP-1, activator protein 1; ATF, Activating transcription factor; BID, BH3 interacting domain; 
BLT2, leukotriene B4 receptor; CEC, circulating endothelial cells; DMF, dimethylformamide; E2F1, E2F transcription factor 1; EGF, 
epidermal growth factor; Elf-1, E74-like factor 1; ERK, extracellular signal regulated kinases; HIF-1α, hypoxia-inducible factor 1alpha; 
HNF-1A, hepatocyte nuclear factor 1 homeobox A; HoxA9, homeobox A9; IFN-γ, interferon-gamma; IL-1α, interleukin-1alpha; IL-
1β, interleukin-1beta; IRE-1, inositol-requiring enzyme 1; IRF, interferon regulatory factor; JNK, c-Jun NH2-terminal kinase; LPS, 
lipopolysaccharide; MEF2B, MADS box transcription enhancer factor 2, polypeptide B; NF-κB, nuclear factor-kappaB; NOX, NADPH 
oxidase; PAF, platelet-activating factor; PASMC, pulmonary artery smooth muscle cell; PDGF, platelet derived growth factor; PGF2α, 
prostaglandin F2-alpha; PI3K, phosphoinositide 3-kinase; PKCδ, protein kinase C delta; SMC, smooth muscle cell; TGF-β, 
transforming growth factor beta; TNF-α, tumor necrosis factor-alpha; TPA, 12-O-tetradecanoylphorbol-13-acetate; VSMC, vascular 
smooth muscle cell. 
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Currently, the differential expression of various isoforms has been described in 
mammalian species (4), and four of these isoforms were observed in vasculature. 
They are NOX1 expressed in ECs and VSMCs, NOX2 expressed in ECs, adventitial 
fibroblasts, neutrophils, macrophages, T cells and platelets, NOX4 expressed in ECs, 
VSMCs and adventitial fibroblasts, and NOX5 expressed in ECs.  
 
1.3.1 NOXs structure 
To date, seven members of the NOX family have been distinguished on the basis of 
the membrane spanning catalytic subunits of NOX or DUOX which they utilise to 
transfer electrons from NADPH to O2 and produce ROS (Figure 1. 2). They are 
NOX1, 2, 3, 4, 5 as well as DUOX1- and 2-containing oxidases (4, 134-137). The 
core structure of all NOX isoforms consists of six conserved transmembrane domains 
and a cytosolic C-terminal. Some conservative structural properties of NOX isoforms 
are common to all family members, including an NADPH-binding site and a FAD-
binding region at C-terminal, four highly conserved heme-binding histidines. In 
DUOX proteins, the histidines are in the fourth and sixth transmembrane domains. 
Additional features, such as EF hands, an additional N-terminal transmembrane 
domain, and/or a peroxidase homology domain, are limited to DUOX isoforms 
(Figure 1. 2).   
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Figure 1. 2. Seven mammalian NOX isoforms.  
The catalytic core subunits of the enzymes (NOX1-NOX5, DUOX1 and DUOX2) 
are shown in pink. All the required subunits and regulatory protein are labelled. EF 
hand motifs are also shown, which bind to Ca2+ and thereby regulate the activity of 
NOX5, DUOX1 and DUOX2 oxidases. The figure also illustrates the putative 
additional amino-terminal transmembrane domain and extracellular peroxidase-like 
region on DUOX1 and DUOX2. Although NOX3 oxidase activity is enhanced by the 
expression of organizer and activator proteins, the enzyme displays constitutive 
activity in their absence. 
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It has been demonstrated that NOXs may require up to five additional protein 
subunits for their function, including a small membrane-bound protein (p22phox), 
which forms a heterodimer with certain NOX proteins to stabilise their expression 
within biological membranes; cytosolic ‘organiser’ (p47phox or Noxo1) and 
activator (p67phox or Noxa1) proteins; a third cytosolic protein (p40phox) that is 
known to associate with the NOX2-containing enzyme complex but whose function 
remains to be defined; and a small GTPase (Rac1 or 2) (4, 135, 138-140). 
Additionally, the activity of each NOX is associated with regulatory proteins with the 
NOX catalytic subunits in variable manners (Table 1. 1). For example, NOX1 and 
NOX2 are constitutively associated with p22phox; and the full activity of 
NOX1/p22phox requires several cytosolic proteins including Rac, NOXO1 (or its 
homolog, p47phox) and NOXA1 (or its homolog, p67phox); Rac, p40phox, p47phox, 
and p67phox are required for activation of NOX2/p22phox. Conversely, there is no 
requirement of additional cytosolic proteins for NOX4 and NOX5 activation. NOX4 
is constitutively associated with p22phox (141); whereas NOX5 is activated in a 
Ca2+-dependent manner (142, 143). 
 
1.3.2 NOX isoforms 
1.3.2.1 NOX1 
Human NOX1 gene is located on the X chromosome. The molecular mass of NOX1 
is in the range of 55-60 kDa and it is the first homology of NOX2 reported (144-146). 
There are several binding elements in the 5’-region of the human NOX1 gene, 
including signal transducers and activators of transcription (STATs), interferon 
regulatory factor (IRF), activator protein 1 (AP-1), nuclear factor-kappaB (NF-κB), 
CRE-binding protein (CREB), CREB binding protein/p300 elements (147), and 
GATA factors (148). It is suggested that NOX1 can be induced under certain 
circumstance (147). In addition, Functional NOX1 requires cytosolic and membrane 
subunits to reduce O2 and produce O2– (4, 144, 149). 
 
The expression of NOX1 was found in a variety of cell types and tissues, including 
VSMCs (150, 151), ECs (152, 153), uterus (151, 154), placenta (146), prostate (151, 
154), osteoclasts (155), and retinal pericytes (156). In addition, NOX1 was also 
18 
 
expressed in several cell lines, such as the colon tumor cell line Caco-2 (157, 158), 
DLD-1 (157), HT-29 (157) and the pulmonary epithelial cell line A549 (159). Above 
all, NOX1 was the most highly expressed in colon epithelium (151, 160, 161).  
 
In addition to the constitutive expression, NOX1 expression can be induced by 
PDGF, prostaglandin F2α, and Ang II in VSMCs (150, 151, 162, 163). An increased 
expression of NOX1 was also observed in carotid artery after injury (164) and in 
prostate in response to castration (165).  
 
Since the expression of NOX1 was found in vasculature (150, 151), increasing 
interest has been attracted on the role of NOX1 in vascular function. It has been 
demonstrated that NOX1 played a role in the pathogenesis of many cardiovascular 
diseases (4, 20, 166-169). Recently, Youn et al. (170) showed that activation of 
NOX1 caused eNOS uncoupling in a streptozotocin induced murine model of 
diabetes. Sheehan et al. (167) demonstrated that NOX1 was implicated in the 
development of atherosclerosis by using apolipoprotein E-knockout (ApoE-/-) and 
NOX2-knockout/apolipoprotein E-knockout (ApoE-/-/NOX1-/y) mice. Lee et al. (166) 
showed that increased expression and activation of NOX1 in VSMCs led to 
increased degradation of extracellular matrix, cellular migration, and proliferation. 
Additionally, in a murine model of hypertension, the overexpression of NOX1 in 
VSMCs resulted in increased blood pressure and aortic hypertrophy compared to 
control mice receiving Ang II (20, 168). Moreover, NOX1 deficient mice were 
protected from Ang II induced hypertension and exhibited increased NO 
bioavailability, reduced aortic VSMCs hypertrophy, and decreased extracellular 
matrix deposition (21, 171). These studies indicate that NOX1 may act a potential 
therapeutic target for the treatment of cardiovascular diseases. 
 
1.3.2.2 NOX2 
NOX2, also known as gp91phox, is the first NOX isoform discovered in neutrophils 
and macrophages and it was highly expressed in leukocytes (4). Its C- and N-
terminals face towards the cytoplasm (4). Human NOX2 gene is located on the X 
chromosome and the expression of NOX2 gene can be regulated by a number of 
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repressing and activating factors (4). Human NOX2 is a highly glycosylated protein 
(172, 173). NOX2 has the widest distribution among the NOX isoforms, including 
thymus, small intestine, colon, spleen, pancreas, ovary, placenta, prostate, and testis 
(174). The wide distribution is partly due to the presence of phagocytes. Moreover, 
NOX2 is also expressed in many other nonphagocytic cells, including neurons (175), 
cardiomyocytes (176), skeletal muscle myocytes (177), hepatocytes (178), ECs (17, 
179, 180), and hematopoietic stem cells (181).  
 
Like NOX1, it also has been demonstrated that NOX2 plays an important role in the 
pathogenesis of vascular diseases (4). Sorescu et al (182) reported a positive 
correlation between the levels of the NOX2/p22phox mRNAs and the severity of 
atherosclerosis in atherosclerotic human coronary arteries. It also has been reported 
that active NOX2 is required for upregulation of inflammatory cytokines, such as 
tumor necrosis factor alpha (TNF-α); adhesion molecules, such as vascular cell 
adhesion molecule-1 (VCAM-1), E-selectin, and intercellular adhesion molecule-1 
(ICAM-1); and proinflammatory transcription factors, such as NF-κB. All these 
factors were involved in vascular inflammation and atherogenesis (183, 184).  
 
Moreover, Judkins et al. (185) showed an increase in NO generation and a decrease 
in O2– production and a reduction of neointimal formation and atherosclerotic lesion 
of the abdominal aorta in NOX2-/-/ApoE-/- model compared to single ApoE knockout 
model. Jung et al. (24) reported that NOX2 deficiency abolished Ang II induced 
increase in blood pressure and vascular hypertrophy, and protected endothelial 
function in a NOX2 deficient mice model. Bendall et al. (186) showed that NOX2 
knockout mice were less vulnerable to Ang II induced cardiac hypertrophy and 
interstitial cardiac fibrosis. Looi et al. (187) demonstrated that NOX2 deletion in 
mice protected against post-myocardial infarction hypertrophy, fibrosis, and left 
ventricular dysfunction. Krijnen et al. (188) reported that NOX2 expression was 
higher in infarcted than noninfarcted myocardium from patients who have died from 
myocardial infarction.  
 
Therefore, like NOX1, NOX2 appears to be an attractive therapeutic target for the 
treatment of cardiovascular disease. However, inhibition of NOX2 in leukocytes may 
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result in immune dysfunction. For example, NOX2 deficiency led to an X-linked 
chronic granulomatous disease, an immune disorder (189). So, although NOX2 
seems to be a desirable therapeutic target, the potential side effect of 
immunodeficiency highlights the importance of therapeutics that selectively target 
pathological NOX2 activation in cardiovascular cell types while leaving physiologic 
NOX2 activation in neutrophils intact. 
 
1.3.2.3 NOX4 
Human NOX4 gene is located on chromosome 11 and NOX4 was originally 
identified in the kidney with ~39% identity to NOX2 (190, 191).  NOX4 is a 
p22phox-dependent enzyme without requirement of cytosolic subunits (190-192) and 
is a constitutively active NOX isoform (4). It is highly expressed in the kidney. In 
addition, NOX4 is distributed in osteoclasts (193, 194), ECs (153, 195, 196), smooth 
muscle cells (145, 150, 197-200), hematopoietic stem cells (181), fibroblasts (201-
203), keratinocytes (204), melanoma cells (205), and neurons (206).  
 
The expression NOX4 is also subject to regulation under many circumstances. For 
example, the expression of NOX4 mRNA or protein can be induced under the 
conditions of  endoplasmic reticulum stress (199), shear stress (207), carotid artery 
injury (164), hypoxia and ischemia (206, 208), and transforming growth factor beta1 
(TGF-β1) and TNF-α stimulation of smooth muscle (200, 209), Ang II stimulation 
(163, 210, 211). Downregulation of NOX4 mRNA and protein was also observed in 
response to peroxisome proliferator-activated receptor (PPAR)-γ ligands (212) 
 
Recently, the role of NOX4 in the development of cardiovascular diseases has been 
drawn a great deal of attention. Due to the constitutively active profile, the 
expression of NOX4 is more suspicious in the pathogenesis of cardiovascular 
diseases. NOX4 has multiple roles and sometimes plays contradictory roles in ECs, 
VSMCs, cardiomyocytes, and fibroblasts, suggesting that the role of NOX4 is 
inconclusive in the development of cardiovascular diseases (213). For example, 
NOX4 exerted a vicious effect in ECs by promoting the expression of endothelial 
surface adhesion molecules, adhesion of monocytes, and the transmigration of 
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leukocytes into the vasculature (214); in addition, NOX4 played a vicious role in 
promoting the migration, proliferation, and differentiation of both VSMCs and ECs 
(215, 216). However, recently, Ray et al. (217) showed a beneficial effect of NOX4 a 
transgenic model of NOX4 overexpression in ECs, such as NOX4-dependent 
vasodilation. Moreover, It has been shown that NOX4 overexpression in 
cardiomyocytes protected against contractile dysfunction and hypertrophy, whereas 
NOX4 deletion promoted these deleterious cardiac effects (218). Although the 
function of NOX4 in cardiovascular diseases remains incompletely understood, 
available evidence suggests that NOX4 may have a complex role in cardiovascular 
diseases development. 
 
1.3.2.4 NOX5 
NOX5 is the most recently characterized NOX isoform (143, 174). The human 
NOX5 gene is located on chromosome 15 (4). NOX5 is without glycosylation and the 
molecular weight is 85 kDa (219). The mRNA expression of NOX5 was observed in 
a variety of tissues, including testis, spleen, lymph nodes, vascular smooth muscle, 
bone marrow, pancreas, placenta, ovary, uterus, stomach, and in various fetal tissues 
(143, 174, 220). NOX5 functions without the requirement of p22phox, which has 
been demonstrated by siRNA suppression of p22phox (149). The results showed that 
p22phox suppression led to a decrease in the activity of NOX1 to NOX4, but not of 
NOX5 (149). In addition, NOX5 does not require cytosolic organizer or activator 
subunits (143). It has been shown that NOX5 functions without the requirements of 
any cytosolic proteins (221).  
 
Since the expression of NOX5 was observed in ECs and VSMCs, the role of NOX5 
in the development of cardiovascular diseases has been focused. Montezano et al. 
(222) showed that NOX5 was activated by Ang II and endothelin 1 (ET-1) in ECs. 
Overexpression of NOX5 could result in ECs proliferation and lead to angiogenesis 
(142). Moreover, Jay et al. (223) showed that silencing NOX5 can decrease PDGF 
induced ROS production and inhibit proliferation of VSMCs. Furthermore, 
expression of NOX5 mRNA and protein was increased in human coronary arteries 
with atherosclerosis (224). These findings suggest that NOX5 has a significant role 
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in the pathogenesis of cardiovascular diseases. Further studies are needed to 
elucidate its specific role in the development of vascular diseases and determine 
whether it may act as an appropriate therapeutic target. 
 
The remaining three NOX isoforms are NOX3, DUOX1, and DUOX2, which are not 
known to be expressed in the human vasculature. In addition, to date, there is no 
correlation between these isoforms and the development of cardiovascular diseases 
(4). Therefore, these NOX isoforms are unlikely to have been implicated in the 
pathogenesis of cardiovascular diseases.  
 
1.3.2.5 NOX3 
NOX3 shares ~56% amino acid identity with NOX2. The human NOX3 gene is 
located on chromosome 6, and there is no splice variants of NOX3 reported (4). 
Although the expression of NOX3 cannot be found in human vasculature, the 
expression of NOX3 still has a wide distribution in a variety of tissues. A high level 
of NOX3 can be expressed in the inner ear, including the cochlear and vestibular 
sensory epithelia, and the spiral ganglion (225). Besides, to a lesser extent, NOX3 
was expressed in fetal spleen (226), fetal kidney (174, 225), skull bone, and brain 
(225). 
 
Like most of the NOX isoforms, subunits are required for functional NOX3. NOX3 
is a p22phox-dependent enzyme for activation (227, 228). Truncated p22phox 
inhibited NOX3 mediated ROS generation (227). NOXO1 was a required subunit for 
NOX3 activation which constitutively activates NOX3 (225, 228-230). p47phox and 
p67phox also have the capability of activating NOX3 (225, 228-230). In addition, it 
has been reported that the role of NOXA1 and Rac in NOX3 function is 
contradictory (228, 229).  
 
1.3.2.6 DUOX1 and DUOX2 
DUOX1 and DUOX2 were initially identified as H2O2-generating enzymes in the 
thyroid gland in a Ca2+- and NADPH-dependent manner (231-233). Both human 
DUOX genes are located on chromosome 15 (234). They are arranged in a head-to-
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head configuration but separated by a 16 kb region with the direction of transcription 
away from one another (234). The structure of DUOX consists of NOX-like region at 
the C-terminal, two EF-hands, a membrane-spanning region, and a peroxidase like 
domain at the N-terminal (235).  DUOX enzymes are glycosylated (236).  
 
Like the other NOX isoforms, DUOX isoforms are expressed in a variety of tissues. 
Both DUOX1 and DUOX2 are highly expressed in the thyroid (233, 237). In 
addition, DUOX1 has been described in airway epithelia (238-240) and in the 
prostate (241). DUOX2 is found in the ducts of the salivary gland (239); in rectal 
mucosa (239); all along the gastrointestinal tract including duodenum, colon, and 
cecum (242, 243); in airway epithelia ((238, 240); and in the prostate (241).  
 
DUOX generated H2O2 essential for the synthesis of thyroid hormones by thyroid 
peroxidase (244-246). Functionally, unlike the other NOX isoforms, DUOX does not 
require the other components of NOX except for two DUOX maturation factors 
called DUOXA1 and DUOXA2 (247). DUOXA1 and DUOXA2 are necessary for 
the formation of DUOX1 and DUOX2 functional complexes, respectively by playing 
an essential role in ER-to-Golgi transition, maturation, and targeting to the plasma 
membrane of DUOX1 and DUOX2 (247).  
 
Recently, differential regulation of DUOX enzymes has also been reported. Harper et 
al. (248) reported an induction of DUOX1 in response to interleukin- (IL) 4 and 13; 
whereas DUOX2 was induced by interferon-gamma (IFN-γ) in respiratory tract 
epithelium. Moreover, induction of DUOX2 was found in response to insulin in 
thyroid cell lines (235), and during spontaneous differentiation of postconfluent 
Caco-2 cells (243). Rigutto et al. (249) revealed a differential activation of DUOX1 
and DUOX2 by protein kinases. DUOX1 activity was stimulated by forskolin via 
protein kinase A (PKA) by phosphorylation on Ser955, phosphorylation of DUOX2 
was induced by 12-O-tetradecanoylphorbol-13-acetate (TPA) via PKC activation 
(249). Differential regulation of DUOX1 and DUOX2 might be important for host 
defence and inflammation. 
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1.3.3 NOX subunits and regulatory protein 
The NOX subunits and regulatory protein are essential for the superoxide generating 
function and activity of NOX isoforms. The subunits and regulatory proteins 
required for NOX activation include membrane bound and cytosolic proteins. 
p22phox, which is membrane bound protein helping stabilize the NOX proteins and 
dock cytosolic factors; p47phox, p67phox, the small GTPase Rac, and the 
modulatory p40phox, which are cytosolic proteins working together to activate the 
NOX enzymes (4, 60, 133). The requirement of other components for NOX isoforms 
varies. For example, NOX2 requires at least five extra components for its activation, 
including Rac, p40phox, p67phox, p47phox and p22phox; NOX5 activation is 
dependent on Ca2+, it does not need other components for its activation; DUOX1 and 
2 require DUOXA1 and DUOXA2, respectively.  
 
1.3.3.1 p22phox 
The human p22phox gene is located on chromosome 16 and p22phox is a membrane 
protein (250). p22phox is required for the activation of NOX1 (251, 252), NOX2 
(253, 254), NOX3 (149, 228), and NOX4 (144, 192). The p22phox gene and protein 
are widely expressed in both fetal and adult tissues (174) and cell lines (254), 
including phagocyte (255), ECs (256), VSMCs (257), and transfected cells (144, 
192). Induction of p22phox expression has been described. For instance, Ang II can 
induce the expression of p22phox (103). The expression of p22phox was increased 
under the conditions of streptozotocin induced diabetes (258), and hypertension 
(259),.  
 
Binding with NOX proteins to stabilize proteins and binding to organizer subunits 
are two major functions of p22phox. Of note, it is revealed that only heterodimer of 
NOX proteins and the p22phox protein are stable, while monomers are degraded by 
the proteasome (253). The role of p22phox in interaction with organizer subunits is 
referred to NOX1, NOX2, and NOX3, but not to NOX4. It is believed that the 
proline-rich C-terminal of p22phox is responsible for the interaction with SH3 
domains of the organizer subunits p47phox or NOXO1 (260, 261).  
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1.3.3.2 p47phox and NOXO1  
p47phox (alias NOXO2) and NOXO1are known as NOX organizers (262, 263). The 
human p47phox and NOXO1 genes are located on chromosomes 7 and 16, 
respectively (264). NOXO1 and p47phox share ~25% sequence identity and a high 
degree of similarity in their functional domains (4, 60, 133). Both NOXO1 and 
p47phox have two SH3 domains that interact with p22phox in C-terminal proline-
rich regions (252, 261). Besides, both NOXO1 and p47phox structures are also 
composed of a proline-rich region in C-terminal that enables NOXO1 and p47phox 
to interact with SH3 domains in NOXA1 and p67phox, respectively (252, 265). In 
addition, the structures of NOXO1 and p47phox contain phox domains that can 
interact with membrane phospholipids. Auto-inhibitory region is occurring in 
p47phox but not NOXO1(4, 60, 133).  
 
The expression of both NOXO1 and p47phox are detected in a variety of cells and 
tissues. p47phox is highly expressed in myeloid cells (266, 267), to a lesser extent, 
testis (264), inner ear (225, 264), lung (268), neurons (269), hepatocytes (178), 
hepatic stellate cells (270), glomerular mesangial cells (271), ECs (179), and VSMCs 
(272). The high expression level of NOXO1 is detected in the colon (160, 229, 252, 
273), to a lesser extent, testis, small intestine, liver, kidney, pancreas, uterus, and 
inner ear (160, 252, 264). In addition, the regulation of p47phox and NOXO1 has 
been described. The expression of p47phox was induced under the conditions of 
retinoic acid induced differentiation of monocytes and granulocytes (266), 
streptozotocin induced diabetic rat kidney (274), and thrombin stimulated SMCs 
(272). It also has been demonstrated that Helicobacter pylori lipopolysaccharide 
(LPS) activated transcription of NOXO1 in guinea pig gastric mucosa (275). 
 
1.3.3.3 p67phox and NOXA1 
p67phox (alias NOXA2) and NOXA1 are known as activator subunits of NOX 
isoforms. The human p67phox and NOXA1 genes are located on chromosomes 1 and 
9, respectively. There is no splice variants of p67phox and NOXA1 reported so far (4, 
60, 133). Both p67phox and NOXA1 are cytoplasmic proteins without glycosylation. 
The molecular weight of p67phox and NOXA1 is 67 and 51 kDa, respectively. 
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Despite of been only ~28% amino acid identity, both p67phox and NOXA1 have a 
high overall structural similarity. Both p67phox and NOXA1 have an N-terminal 
tetratricopeptide repeat, a highly conserved activation domain, a less conserved 
“Phox and Bem 1” domain, and a C-terminal SH3 domain (4, 60, 133).  
 
Both p67phox and NOXA1 are expressed in a variety of tissues and cell types. 
p67phox was expressed in phagocytes (276), B lymphocytes (277), glomerular 
mesangial cells (271), ECs (179), neurons (278), astrocytes (278), kidney (279), and 
hepatic stellate cells (270). NOXA1 was expressed in the spleen, inner ear (225), 
stomach, colon, small intestine, uterus (225, 273), prostate, lung, thyroid, salivary 
glands (273), guinea pig gastric mucosal cells (275), basilar arterial epithelial cells 
(153), airway-like normal human bronchial epithelial cells (280), and VSMCs (281). 
It has been shown that the expression of p67phox can be modulated under certain 
circumstance. The expression of p67phox could be induced in response to a variety 
of stimuli, including IFN-γ in myelomonocytic U937 cells (282) and promyelocytic 
HL60 cells (283), zinc in neurons and astrocytes (278), and Ang II in aortic 
adventitial fibroblasts (284). It has been demonstrated that p67phox can also be 
phosphorylated (277, 285-291). NOXO1 constitutively associates with the membrane 
and so far it is unknown whether NOXA1 can be phosphorylated (292).  
 
1.3.3.4 p40phox 
p40phox is a nonglycosylated cytosolic protein with a molecular weight of 40 kDa 
(293). It was detected by coimmunoprecipitation with p47phox and p67phox (293). 
The human p40phox gene is located on chromosome 22. So far, there is a splice 
variant of p40phox identified (294). p40phox structure contains a SH3 domain, a 
phox domain, and a phox and bem1 domain. It has been shown that p40phox 
interacted with p47phox and p67phox with a 1:1:1 stoichiometry (295). The 
expression of p40phox can be detected in a variety of tissues and cell types, 
including phagocytes (293), B lymphocytes (277), spermatozoa (296), hippocampus 
(269), and vascular smooth muscle (102). It has been shown that Ang II is capable of 
inducing p40phox expression in rostral ventrolateral medulla (297) and vascular 
smooth muscle (102). It also has been reported that p40phox is involved in the 
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regulation of NOX2. Evidence shows that p40phox enhanced oxidase function (298-
300). Of note, unlike p47phox and p67phox, it has been demonstrated that p40phox 
was indispensable for NOX2 activity (301), suggesting that p40phox is specific for 
NOX2.  
 
1.3.3.5 Rac GTPases 
Rac GTPases have a complex role in regulating cellular functions (302-306). There 
are three highly homologous Rac proteins in mammals, which are Rac1, ubiquitously 
distributed; Rac2, mostly expressed in myeloid cells; and Rac3, predominantly 
distributed in the central nervous system. It has been demonstrated that Rac proteins 
were involved in the NOX isoforms mediated O2– generating process (4). Rac1 
participated into the activation of NOX1 and NOX3 isoforms and Rac1 and Rac2 
proteins were involved in the regulation of NOX2 (60. The activation of NOX4 
appears to be Rac independent upon heterologous expression {Martyn, 2006 #2284, 
133). Moreover, it has been demonstrated that NOX5 and DUOX-dependent ROS 
generation did not require Rac proteins activation (307).  
 
1.3.4 Regulation of NOXs 
Increased activity and expression of NOX isoforms has been demonstrated in a wide 
variety of diseases and/or disorders. In particular, all cardiovascular pathologies were 
marked by the excessive NOX generated ROS which were resulted from up-
regulation of various NOX family members (64, 213, 308). In the past decade, 
extensive attention has been focused on the redox control and the underlying 
molecular mechanisms of NOX-dependent ROS generation. In addition, the 
regulation on NOX isoforms has also been studied (Table 1. 2). It has been shown 
that the regulation of NOX isoforms varies from transcriptional level to 
posttranslational level. Although the underlying mechanisms of NOX regulation 
have not been fully revealed, it has been reported that NOX1 and NOX2 can be 
induced by cytokines and mitogens, which may be implicated in the development of 
oxidative stress induced vasoconstriction, inflammation, and phenotypic alterations 
in the vessel wall. In addition, it has been shown that NOX4 can constitutively 
produce ROS and does not require regulatory subunits for the activation, unlike 
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NOX1 and NOX2. In this respect, it suggests that the regulation on NOX4 
transcriptional level is more important. Collectively, numerous pro-inflammatory and 
growth-related factors can regulate NOX1, NOX2, NOX4, and NOX5 in vitro and in 
vivo (163, 209, 222, 309, 310). 
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Table 1. 2. The activity, regulation, expression and function of the main NOXs in the cardiovascular system 
 NOX1  NOX2 NOX4 NOX5 
Constitutive 
activity 
Absent or very low Absent or very low  
 
High  Low 
Requirement 
for p22phox 
Yes  
 
Yes  Yes  No 
Essential 
regulatory 
subunits 
NOXO1, NOXA1, Rac p67phox, p47phox, p40phox, 
Rac 
None  
 
None 
Control Posttranslational modifications of 
regulatory subunits 
Posttranslational modifications 
of regulatory subunits 
Transcriptional. Can be regulated 
by Poldip2 
Calcium binding 
 
Cell 
expression 
 
Vascular smooth muscle, possibly 
ECs 
ECs, cardiomyocytes, 
fibroblasts, human vascular 
smooth muscle, inflammatory 
cells 
ECs, 
cardiomyocytes, fibroblasts, 
vascular smooth muscle cells 
Human endothelium, 
human vascular 
smooth muscle 
Function Constitutive low level superoxide 
production; VSMCs migration, 
proliferation; mitochondrial 
function 
Phagocytic respiratory burst; 
endothelial function and NO 
signalling; neointimal formation 
VSMCs growth and migration, 
angiogenesis; cardioprotective 
function? Constitutive source of 
H2O2? 
ECs/VSMCs 
proliferation, cell 
migration; 
angiogenesis 
Adapted from Touyz et al. (68) and Sirker et al. (311).  
Abbreviation: EC, endothelial cell; H2O2, hydrogen peroxide; NOX, nicotinamide adenine dinucleotide phosphate oxidase; Polidp 2, 
polymerase delta-interacting protein; VSMCs, vascular smooth muscle cells.  
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1.3.4.1 Gene expression 
The transcriptional regulation of NOX family members is essential to their function. 
It has been described that inflammation induced alterations on the gene expression of 
NOX isoforms are correlated with the increase in the production of ROS. Although 
the transcriptional mechanisms are not totally deciphered, it is suggested that 
multiple transcription factors were co-ordinately involved in the regulation of NOXs 
gene expression (60, 133).  
 
It has been shown that AP-1 was essential for the rat NOX1 promoter activity (312, 
313). Manea et al. (314) also reported that MAPK related pathways were involved in 
the modulation of NOX expression in human aortic smooth muscle cells.  In addition, 
it was identified that the GATA binding site at -135/-130 on human NOX1 gene was 
essential for the basal transcriptional activity (148). In murine macrophages, it has 
been shown that the induction of NOX1 by LPS is partially mediated by C/EBPβ and 
C/EBPδ (315). Katsuyama et al. (316) demonstrated that activating transcription 
factor 1 (ATF-1), a transcription factor of the CREB/ATF family, played a pivotal 
role in the up-regulation of NOX1 in rat VSMCs.  
 
The expression of NOX2 is also known to be modulated by multiple regulatory 
factors, such as PU.1, E74-like factor 1 (Elf-1), IRF-1, and interferon consensus 
sequence binding protein in the myelomonocytic cell lineage (312). In addition, a 
number of DNA-binding proteins also have the capability of interacting with the 
NOX2 promoter region, including BH3 interacting domain (BID), IRF-1, IRF-2, the 
CCAAT box binding protein CP1, and the transcriptional repressor CCAAT 
displacement protein (282, 317-321). It has been shown that IFN-γ and LPS were 
able to induce the expression of NOX2 in human monocyte derived macrophages and 
neutrophils (322). TPA, retinoic acid or DMF was also reported to be capable of 
increasing the NOX2 expression in myeloid cells (317). Moreover, NF-κB-dependent 
transcription of NOX2 has been reported by Anrather et al (323). 
 
To date there is no report on the mechanism of the inner ear specific expression of 
NOX3. The expression of NOX3 is almost restricted to the inner ear (225).  
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NOX4 is constitutively expressed in various cell types. Ubiquitous expression of 
NOX4 suggests that it acts as a housekeeping gene. Indeed, the promoter region of 
the NOX4 gene contains many G or C bases, which are characteristics of 
housekeeping genes (133). On the other hand, the induction of NOX4 has been 
reported (324). Recently, Diebold et al. (325) have reported that NOX4 mRNA and 
protein levels was induced in pulmonary artery smooth muscle cells (PASMCs) and 
pulmonary vessels from mice after exposed to hypoxia. This response was dependent 
on hypoxia inducible factor-1alpha (HIF-1α), which interacted directly with the 
NOX4 promoter. Therefore, the induction of NOX4 by HIF-1α may be an important 
mechanism to maintain ROS levels after hypoxia and the hypoxia induced 
proliferation of PASMCs. Zhang et al. (326) have demonstrated that growth-
promoting transcription factor E2F physically interacts with NOX4 promoter in A7r5 
cells and primary mouse aortic smooth muscle cells, thus it provides a new insight 
into the mechanism of NOX4 gene regulation.  
 
1.3.4.2 Phosphorylation 
The phosphorylation of NOX subunits and their assembly into active complexes are 
mediated by various mechanisms, and many of them are redox-sensitive. It has been 
demonstrated that a number of stimuli and pathways involved in the activation of 
NOX by phosphorylation. They comprise phospholipases (PLCβ/γ, PLD), 
arachidonic acid metabolites, GTP-binding proteins (Ras, Rac1/2), PKC, PI3K, 
MAPK, and non-receptor protein tyrosine kinases (327, 328). Functional NOX1 has 
been shown to require Noxo1, Noxa1, and Rac1 (4). Thus, the activation on the 
subunits and regulatory proteins by phosphorylation can result in an increase in the 
activity of NOX1. It has been demonstrated that PKA and c-Src mediated 
phosphorylation of Noxa1 regulates NOX1 activity in human embryonic kidney 293 
cells (329, 330). Likewise, NOX2 requires subunits and regulatory proteins for its 
ROS generation. It has been shown that the phosphorylation regulation of NOX2 is 
similar to NOX1 (137). NOX4 is constitutively active and does not require 
phosphorylation of regulatory subunits, whereas NOX5 activity is Ca2+-sensitive 
(137). 
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Because the phosphorylation status of NOX is tightly controlled by redox sensitive 
protein kinases and phosphatases, and AP-1, NF-κB, and STAT1/3 are redox 
sensitive transcription factors, thus, a positive feedback mechanism might exist 
whereby ROS (possibly generated by NOX) is important for sustained ROS 
formation in the cardiovascular system. Therefore, it suggests that NOX isoforms 
themselves are redox regulated at multiple levels.  
 
1.3.5 NOXs in diseases 
An accumulating body of evidence shows that enhanced activity and expression of 
NOX isoforms result in an increase in NOX-derived ROS production, which disturbs 
the balance between the oxidant and antioxidant system. As a consequence, in 
vasculature, increased ROS generation causes endothelial dysfunction and initiates a 
series of events that lead to many cardiovascular pathological states such as 
atherosclerosis, hypertension, congestive heart failure, ischemia-reperfusion injury, 
and diabetes associated vascular complications (63, 64). Therefore, the 
pathophysiological role of NOX isoforms in diseases has been drawn a great deal of 
attention.  
 
Under physiological condition, NOXs play an important role in regulating embryonic 
development and wound healing, promoting the transactivation of growth factor 
receptors, stimulating redox-sensitive signaling cascades, inhibiting phosphatases, 
activating transcription factors (331-337). In particular, in the vasculature, NOX 
derived ROS play an role in the maintenance of vascular tone and regulation of cell 
growth, proliferation, differentiation, apoptosis, cytoskeletal organization, and cell 
migration (325).  
 
On the other hand, NOX is the primary source of ROS and the main trigger of 
oxidative stress, it has a pivotal role in the pathology of vasculopathy (338, 339). A 
significant correlation between the up-regulation of NOX expression and activity and 
the development of vasculature disease has been reported in patients with 
cardiovascular and/or metabolic diseases. Table 1. 3 summarized the evidence of the 
participation of NOXs in various diseases.   
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Table 1. 3. Evidence for the participation of NOXs in diseases. 
Disease Isoform Evidence Comment 
Hypertension NOX1 
NOX4 
+++ NOX1 is a hub in pro-hypertensive signalling 
Atherosclerosis NOX1 
NOX2 
NOX4 
NOX5 
+ 
 
 
Aortic dissection and aneurysm NOX1 +++ Oxidative stress in vascular smooth muscle is crucial 
Cardiac hypertrophy, fibrosis, and heart 
failure 
NOX2 ++  
Myocardial infarction NOX2 +++ Ischemia–reperfusion injury 
Heart transplant NOX2 + Ischemia–reperfusion injury 
Doxorubicin cardiotoxicity NOX2 +++  
Asthma NOX4 + Both endogenous and pollen oxidase 
Chronic obstructive pulmonary disease NOX2 ++  
Emphysema NOX3 + Upregulation of NOX3 in an emphysema mouse model 
Pulmonary fibrosis NOX4 ++ NOX4 involved in fibroblast/myofibroblast transition and death of epithelial cells 
Pulmonary hypertension NOX4 ++  
Pulmonary infections NOX2 ++ NOX2-deficient mice show increased pathogen clearance for influenza virus, 
pneumococci 
Amyotrophic lateral sclerosis NOX2 
NOX1 
+++ Binding of mutant SOD1 to Rac1 is involved 
Alzheimer’s disease NOX2 +++ Microglial NOX2 is important 
Parkinson’s disease NOX2  +++ Microglial NOX2 is important 
Schizophrenia  NOX2 + ROS-dependent loss of phenotype of rapidly spiking interneurons 
Ischemic stroke NOX2 +++ Strong indication 
Diabetic nephropathy NOX4 +++ NOX4 involved in epithelial-mesenchymal transition 
Renal cancer NOX4  ++ NOX4 activates HIF-1α 
Preeclampsia NOX2 +  NOX-containing microparticles might be involved 
Hearing loss   NOX3 ++ Cisplatin enhances NOX3-dependent ROS generation 
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Table 1. 3. Continued. 
Hepatitis NOX2 + Evidence only for alcoholic hepatitis 
Liver ischemia and reperfusion injury NOX2  +++ Of interest for liver transplantation? 
Pancreatitis  NOX1 +  
Barrett’s esophagus NOX5  + Involvement in the development of esophagus cancer? 
Atrophic gastritis NOX2  +  
Inflammatory bowel disease NOX2 + Due to enhanced or decrease NOX activity? 
Rheumatoid arthritis NOX2 + Due to enhanced or decrease NOX activity? 
Osteoporosis NOX1  
NOX2  
NOX4 
+ 
 
NOX enzymes involved in osteoclast differentiation and in bone resorption 
Metabolic syndrome  NOX1 
NOX4 
+ Overshooting NOX activity in adipocytes 
Diabetes NOX1 
NOX4 
+ NOX derived ROS involved in β cell death 
Hyperthyroidism DUOX2  
DUOX1 
+++ Severe hypothyroidism in DUOX2-deficient patients 
Scleroderma NOX4 ++ Anti-PDGF receptor antibodies activate NOX in fibroblasts 
UV damage of skin NOX1 ++ UV activates NOX1 in lens keratinocytes 
Adapted from Touyz et al (68) and Lambeth et al. (340).  
+: preliminary evidence mainly based on indirect data and cellular studies; ++: intermediate level evidence, based at least in part on 
relevant disease models;+++: strong evidence based on relevant disease models using NOX-deficient mice and/or NOX inhibitors; in 
some cases also data on human mutations and polymorphisms. 
Abbreviation: HIF-1α, hypoxia inducible factor-1alpha; NOX, nicotinamide adenine dinucleotide phosphate oxidase; SOD, superoxide 
dismutase; UV, ultraviolet. 
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All this evidence indicates that NOX1, NOX2, NOX4, and NOX5 are important 
regulators of cellular pathways mediating ROS-dependent pathophysiological 
processes. Given that the different NOX subtypes are expressed concurrently in the 
vascular wall cells, and that several isoforms are similarly regulated, their subcellular 
localization might be an essential factor in determining NOX function (341, 342). In 
addition to catalytic components, several regulatory subunits, namely p22phox, 
p40phox, p47phox, p67phox, and Noxa1, have been shown to be up-regulated in vivo 
and in vitro by vasoactive agents, inflammatory cytokines, growth factors, high 
glucose, modified lipids and lipoproteins, hyperinsulinemia, homocysteine, and 
mechanical stress (163, 343-345). Thus, NOXs have a complex role in 
pathophysiological processes and their activities are subject to regulation in multiple 
levels by various stimuli.    
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1.4 eNOS 
A family of NOS enzymes catalyzes L-arginine to produce NO and L-citrulline with 
the requirement of substrate and cofactor. The three mammalian NOS isoforms are 
coded by different genes but share 50%–60% sequence identity. Although three 
isoforms share similar chemical and enzymatic properties, different isoforms are 
featured as distinctive catalytic and regulatory properties. eNOS is one of three 
distinct isoforms of NOS in mammalian tissues. It is constitutively expressed in ECs 
and is usually regulated by Ca2+/Calmodulin (CaM) as well as phosphorylation. The 
other NOS isoforms are neuronal NOS (nNOS), mainly expressed in the brain as 
well as skeletal muscle, and inducible NOS (iNOS), expression can be induced in 
macrophages, liver, and vascular smooth muscle (58, 346-348). 
 
1.4.1 Structure and function of eNOS 
Human eNOS is encoded by NOS3 and mapped on 7q35–7q36 of chromosome 7 
with 1,203 amino acid residues and the molecular weight is 133 kDa. Structurally, all 
NOS isoforms are homodimers and bidomain enzymes consisting of an N-terminal 
oxygenase domain (amino acid 1-491) and a C-terminal reductase domain (amino 
acid 492-1203) (349-351). The N-terminal oxygenase domain includes several 
binding sites for a prosthetic heme group, BH4, O2, and L-arginine to support the 
catalytic activity; the C-terminal reductase domain contains several binding sites for 
FAD, flavin mononucleotide (FMN), and NADPH. These two terminals are linked 
by CaM recognition site (Figure 1. 3) (349, 352, 353).  
 
With regard to the function, all the NOS isoenzymes catalyze the synthesis of NO at 
the active site requires a stepwise transfer of electrons from C-terminal reductase 
domain to N-terminal oxygenase domain (Figure 1. 3) (354). Within the reductase 
domain, the electron transfer initiates from NADPH to FAD then to FMN, in which 
CaM increases the electron transfer and facilitates electron transfer from reductase 
domain to the heme of the oxygenase domain and convert ferric heme to ferrous. At 
the heme, the electrons are coupled with L-arginine and reduce O2; NO and L-
citrulline are generated in two steps including NOS hydroxylases L-arginine to NG-
hydroxy-L-arginine and  NOS oxidizes NG-hydroxy-L-arginine to citrulline and NO 
(354-356).   
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Figure 1. 3. Functional eNOS.  
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1.4.2 Pathophysiological role of eNOS  
The physiological and pathological role of eNOS has been attracting a great deal of 
interest from lab and beyond because of the NO generating property. On the other 
hand, under certain circumstances, eNOS also functions as a ROS generating enzyme 
causing a series of vicious events. eNOS is constitutively expressed in ECs, and 
eNOS generated NO is a predominant regulator of endothelial function in 
endothelium playing a crucial role in regulating vascular tone and homeostasis, in 
particular, in mediating the expression of pro- and anti-atherosclerotic genes and 
protecting against thrombosis and atherosclerosis (357). 
 
NO is a free radical gas acting as a second messenger that diffuses rapidly from the 
endothelium to adjacent cells. It produces vasodilation by the activation of soluble 
guanylate cyclase, production of cGMP, and ultimately activation of a variety of 
downstream effectors, including cGMP-dependent protein kinase, cGMP-modulated 
ion channels, and phosphodiesterases (358). A number of other beneficial actions of 
NO also have been shown. Endothelium derived NO controls vascular tone and is 
able to relax blood vessels, prevent platelet aggregation and adhesion, limit oxidation 
of LDL cholesterol, inhibit proliferation of vascular smooth muscle cells, and 
decrease the expression of pro-inflammatory genes that advance atherogenesis, 
inhibits platelet function, prevents adhesion of leukocytes, and reduces proliferation 
of the intima. (45, 58, 357). An enhanced inactivation and/or reduced synthesis of 
NO are seen in conjunction with risk factors for cardiovascular disease.  
 
On the other hand, eNOS can become a ROS contributor under certain conditions, 
which is referred to eNOS uncoupling. It has been implicated in the pathogenesis of 
many metabolic and cardiovascular diseases, such as diabetes and atherosclerosis. 
This will be discussed in the eNOS Uncoupling section.  
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1.4.3 Regulation of eNOS 
With an important role in vasculature, the regulation of eNOS is gaining increasing 
attention. It has been demonstrated that eNOS is subject to modulation at multi-levels 
including transcription, posttranscription and posttranslation (347, 359).   
 
1.4.3.1 Transcriptional regulation  
The transcriptional regulation of eNOS involves multiple cis and trans regulatory 
elements which interact with eNOS promoter. Like many other constitutively 
expressed proteins, eNOS promoter consists of many potential cis-regulatory DNA 
sequences, including a CCAT box, Sp1 sites, GATA motifs, CACCC boxes, AP-1 
and AP-2 sites, a p53 binding region, NF-1 elements, acute phase reactant regulatory 
elements, sterol regulatory elements, and shear stress response elements (360). 
Moreover, two tightly clustered cis-regulatory regions are identified in the human 
eNOS proximal core promoter and those two regulatory regions are involved in 
eNOS basal transcription (361). They are positive regulatory domain I and II. In 
addition to the interaction with cis-regulatory elements, it has been shown that basal 
eNOS promoter activity was also dependent on functional interactions between the 
trans-acting factors that bind to these two regulatory domains (347, 359). 
 
It has been demonstrated that the expression of eNOS mRNA is mainly expressed in 
the vascular endothelium (362, 363), and the regulation of eNOS mRNA expression 
has been extensively studied (364). Collectively, it has been demonstrated that the 
transcriptional regulation of eNOS involves multiple signalling pathways including 
NF-κB and lung Küppel-like factor pathways (364-367). On the other hand, the 
repression of eNOS mRNA expression was also reported. Potente et al. (368) 
revealed that Foxo-1 acted as a transcriptional repressor of eNOS expression. In 
addition, small RNA regulated eNOS regulation has been described. Zhang et al. 
(369) reported that a 27-nt derived from 27-nt repeats within intron 4 of the NOS3 
gene inhibited eNOS expression.  
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1.4.3.2 Posttranscriptional regulation  
Posttranscriptional regulation is a regulatory process of newly transcribed RNA 
before it is translated into protein. The process includes modification of primary 
transcript, nucleocytoplasmic transport, subcellular localization, mRNA stability, and 
translation efficiency. Cis-acting RNA elements is a major regulator of 
posttranscriptional control in 5'- and 3'-mRNA untranslated regions (5'-UTR and 3'- 
UTR) (370, 371). A combination of primary and secondary structures of these 
elements and their recognition by trans-acting RNA binding proteins is essential for 
the posttranscriptional regulation (372). 
 
For eNOS, it has been reported that 3'-UTR is the posttranscriptional regulation site 
interacting with cis-elements (364). Searles et al. (373) reported that a 43-nt 
sequence located at the origin of the bovine 3'-UTR had a critical role in determining 
eNOS mRNA stability. The 43-nt region destabilizes eNOS mRNA, however, 
deletion of this 43-nt region is able to dramatically stabilize a transfected chimeric 
eNOS mRNA construct (373).  In addition, a 25-nt UC-rich sequence, approximately 
95 bases distal to the 43-nt sequence, has been reported to be an important modulator 
for eNOS stability as well (374, 375). For human eNOS mRNA, a CU-rich 158-
nucleotide sequence located in the medial portion of the 3'-UTR was identified as 
being important in regulating mRNA stability (376). The posttranscriptional 
regulation can also be modulated by growth factor, cytokines and even under 
pathological conditions. It has been shown that TGF-β1 treatment can increase 
steady stated eNOS mRNA levels in human ECs (377) and it can augment the 
expression of eNOS mRNA in a time- and dose-dependent manner in bovine aortic 
endothelial cells (378). Cyclosporine A treatment has been reported that it can 
increase the eNOS mRNA expression which may be dependent on the increased 
H2O2 generation (379). In addition, lysophosphatidylcholine also has been shown to 
increase ROS production (380) and to increase eNOS transcription (381). Cai et al. 
(382) also showed that H2O2 up-regulated eNOS expression via a calcium/CaM-
dependent protein kinase II (CaMKII)-mediated mechanism. On the other hand, it 
has been described that LPS and TNF-α decreased the steady state levels of eNOS 
mRNA (359, 373).   
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1.4.3.3 Posttranslational regulation 
The posttranslational regulation of eNOS has been extensively studied, which plays a 
critical role in controlling the eNOS function and activity (383). Accumulating 
evidence shows that alteration in eNOS activity and function are conferred by a 
variety of posttranslational regulatory factors, such as phosphorylation, BH4, heat 
shock protein  (HSP) 90, Ca2+, CaM, and caveolin-1.  
 
1.4.3.3.1 Phosphorylation 
There are multiple phosphorylation sites located on eNOS tyrosine (Tyr), serine (Ser), 
and threonine (Thr) residues, suggesting the potential role of phosphorylation in the 
regulation of eNOS activity. So far, there are a number of putative phosphorylation 
sites identified, which include Tyr 81, Tyr567, Ser114, Ser615, Ser633, Ser1177, and 
Thr495. The most well-known phosphorylation sites with functional consequences 
are Ser residue (human eNOS sequence: Ser1177: bovine Ser1179) in the reductase 
domain and a Thr residue (human eNOS sequence Thr495: bovine Thr497) within 
the CaM-binding domain.  
 
Threonine phosphorylation 
Phosphorylation on Thr at the position of 495 is constitutive and it is a negative 
regulatory site in ECs resulting in a decrease in enzymatic activity (384-386). The 
negative correlation between Thr495 phosphorylation and NO generation is caused 
by the interference with the binding of CaM to the CaM-binding domain. It was 
observed that in ECs stimulated with agonists such as bradykinin, histamine, or Ca2+ 
ionophore, consequently more CaM binds to eNOS when Thr495 is 
dephosphorylated (384). The underlying mechanism is a conformational change 
within eNOS itself, which is induced by the phosphorylation of eNOS at Thr495 
resulting in electrostatic repulsion of nearby glutamate residues within CaM and 
changes in eNOS Glu498 (387). In addition, Lin et al. (388) showed a link between 
dephosphorylation of Thr495 and eNOS uncoupling.    
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Tyrosine phosphorylation 
It has been demonstrated that there are multiple potentially phosphorylatable Tyr 
residues in eNOS via the observation of attenuation on endothelial NO production 
and flow induced vasodilatation by Tyr kinase inhibitors (389-391). The tyrosine-
phosphorylated residues are Tyr81 and Tyr657 with regulatory effect on NO 
production (392, 393). Intriguingly, these two residues exert opposite effects on 
eNOS activity. Tyr81, located in the oxygenase domain, is phosphorylated by v-Src 
resulting in an increase in the activity of eNOS (392, 393), and it is suggested that 
the increasing activity of eNOS by Tyr81 phosphorylation is not because of direct 
modification of eNOS activity but is due to the modulation of the sensitivity of the 
enzyme to Ca2+, alteration of protein-protein interactions or changes in its subcellular 
localization; Whereas, phosphorylation of Tyr 657 seems to attenuate eNOS activity 
(394). It is located in the FMN-binding domain and can be stimulated by proline-rich 
tyrosine kinase 2 (394), fluid shear stress (395)and the activation of Src (396).  
 
Serine phosphorylation 
Ser phosphorylation is a more considerable regulation of eNOS. There are multiple 
phosphorylation sites on Ser within eNOS, including Ser1177, Ser633, Ser615 and 
Ser114. Ser1177 can be rapidly phosphorylated in response to fluid shear stress (397), 
VEGF (398) and bradykinin (384). In addition, various kinases involved in the 
Ser1177 phosphorylation includes Akt (399), PKA (400) and AMPK (386, 401). 
Phosphorylation of Ser1177 plays a major role in the regulation of eNOS activity. It 
has been shown that hyperglycaemia (402), type 2 diabetes (125) and advanced 
glycation end products (AGE) (403) resulted in the modification of Ser1177 by O-
linked N-acetylglycosylation and thus attenuate eNOS activity and induce an 
decrease in NO production. Ser633, which is located within one of the auto-
inhibitory loops hindering the access of CaM to its binding domain and throttling the 
activity of eNOS. It is has been reported that the phosphorylation of Ser633 can be 
regulated by kinases in vitro including PKA and protein kinase G (404, 405), but the 
functional relevance has not been fully unveiled yet. The phosphorylation of Ser at 
the position of 615 was identified by phosphorpeptide mapping and the 
phosphorylation of Ser615 has been shown to be stimulated by both PKA and Akt 
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(406). Michell et al. (404) observed that mimicking phosphorylation at Ser615 
significantly increases the Ca2+/CaM sensitivity of eNOS, suggesting that it may 
promote eNOS activity and NO generation. On the other hand, it is suggested that 
Ser615 may exert an important role in regulating phosphorylation at other sites as 
well as protein-protein interactions and the assembly of the eNOS signalosome (385, 
407). eNOS can also be phosphorylated at Ser114 which is constitutively 
phosphorylated site and it is proposed to be a negative regulatory site. Indeed, 
phosphorylation of Ser114 leads to a decrease in eNOS activity (408).   
 
1.4.3.3.2 HSP90 
Protein-protein interaction is one of the most important posttranslational regulations 
of eNOS function and activity. HSP90 is a very important chaperone playing an 
essential role in modulating the activity and function of NOS. Structurally, it has 
been reported that HSP90 is required for the folding of NOS enzymes and determines 
the insertion of heme into the immature protein (409). Functionally, HSP90 
participates in numerous signal transduction cascades as a scaffolding molecule. To 
eNOS, it has been reported that enhanced interaction between HSP90 and eNOS can 
increase NO yield (410). Presley et al. (411) also showed that activation of HSP90-
eNOS interaction induced an increase in NO generation. On the other hand, 
inhibition of HSP90 is capable of uncoupling eNOS resulting in a decrease in NO 
production and an increase in ROS generation (412). Disassociation of HSP90 and 
eNOS impaired the activity of eNOS under hyperglycaemia (413). Similar findings 
have demonstrated the role of HSP90 in promoting NO generation and inhibiting 
ROS production as well (414).  
 
There are still various posttranslational regulations of eNOS and some of them have 
not fully deciphered yet. It has been shown that regulation of catalytic activity of 
eNOS at the posttranslational level is highly modulated by substrate and cofactor 
availability, S-glutathionylation, endogenous inhibitors, lipid modification, 
Ca2+/CaM, caveolin-1, O-linked glycosylation, and S-nitrosylation (347, 415-417). 
Disruption of those regulations leads to alterations on eNOS activity and NO output, 
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which is a drive of numerous pathophysiological disorders including cardiovascular 
and metabolic diseases.  
As described above, eNOS is subject to multiple levels of regulation including 
transcription, posttranscription and posttranslation. As such, it suggests that eNOS 
may act as a therapeutic target in preventing or treating vascular diseases. There are a 
number of clinical trials on the regulation of eNOS via supplementation with eNOS 
modulators reported (Table 1. 4). 
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Table 1. 4. Clinical trial of eNOS regulators.  
 Dose  Outcome  Ref. 
L-Arginine    
With low/high ADMA  
level 
3–8 g·day-1 
 
No acute pharmacological effects. Low ADMA, no 
effect; high ADMA, normalizes endothelial function 
(418) 
Post-MI 
 
3.0 g po, 3 times daily, for 6 
mon 
No serious adverse effects, possibly associated with 
higher mortality, no improvement of vascular stiffness 
measurements, left ventricular ejection fraction 
(419) 
Peripheral arterial disease 
 
3 g·day-1 po for 6 mon No improvement of vascular reactivity, no benefit, 
possible harm 
(420) 
FA/5-MTHF    
Diabetes mellitus 5-MTHF, 1 µg·100 ml FAV-
1
 ·min-1, local forearm intra-
arterial 
Improvement of endothelial dysfunction  
 
(421) 
Hyperhomocysteinemia FA, 10 mg·day-1 po for 8 wk Improvement of endothelium-dependent dilation, higher 
serum folate levels, lower total plasma homocystine 
levels 
(422) 
Coronary artery disease 
 
5-MTHF 0.13 mg·kg-1 body 
wt 
Improved NO-mediated endothelium-dependent 
vasomotor responses, reduced vascular superoxide 
(423) 
6R-BH4 (analogue of 
BH4) 
   
Hypertension 5 mg·kg-1 po, twice daily for 8 
wk 
Not statistically significant. Drop of 6.4 mmHg in 
patients’ SBP 
 
2008 BioMarin 
Pharmaceutical, 
NCT00325962 
(unpublished) 
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Table 1. 4. Continued. 
Pulmonary arterial 
hypertension 
 
2.5 mg·kg_1· day-1 for 2 wk, 
5 mg·kg-1·day-1 for 2 wk, 10 
mg·kg-1·day-1 for 4 wk, and 
then 20 mg·kg-1·day-1 for 2 
days 
 
 Unpublished, ongoing 
Vanderbilt University, 
The National Institutes of 
Health, GCRC& 
BioMarin Pharmaceutical, 
NCT00435331 
(unpublished) 
Endothelial dysfunction 
 
5 mg·kg-1 po, twice daily for 
13.5 days 
Not significant. 2009 BioMarin 
Pharmaceutical, 
NCT00532844 
(unpublished) 
Sickle cell disease 16-wk dose escalation phase 
po, every 4 wk as follows: 
2.5, 5, 10 (once daily), and 
20 mg·kg-1·day-1 (twice 
daily), and continued in an 
optional extension phase at 
the highest tolerated dose for 
up to a total of 2 yr 
Improvement of endothelial function 2009 BioMarin 
Pharmaceutical, 
NCT00445978 
(unpublished) 
 
Peripheral arterial disease 
 
400 mg po, twice daily for 24 
wk 
Not significant. 2009 BioMarin 
Pharmaceutical, 
NCT00403494 
(unpublished) 
Adapted from Zhang et al. (424).  
Abbreviation: 5-MTHF, 5-methyltetrahydrofolate; ADMA, asymmetric dimethyl-L-arginine; BH4, tetrahydrobiopterin; eNOS, 
endothelial nitric oxide synthase; FA, folic acid; FAV, forearm volume; MI, myocardial infarction; SBP, systolic blood pressure. 
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1.4.4 eNOS Uncoupling 
As we have described above, eNOS is a critical enzyme for the maintenance of 
vascular homeostasis. It catalyzes the formation of NO from L-arginine and O2 in a 
reaction requiring adequate substrates and cofactors including Ca2+/CaM, FAD, 
FMN, NADPH, and BH4. Electrons are transported through the reductase domain 
via NADPH, FAD and FMN in functional homodimerized form (58, 425, 426). 
However, under certain circumstances, eNOS can be uncoupled. The electron flown 
from the FMN group to the ferrous-dioxygen heme complex on the adjacent 
oxygenase domain is disturbed so that electrons are diverted to O2 leading to O2– 
production, and thus eNOS turns out to be O2– generating enzyme (Figure 1. 4) (427, 
428). In uncoupled state, NADPH consumption and O2 reduction are uncoupled from 
L-arginine oxidation and NO formation with subsequently decreased NO production 
and increased O2– generation (429-431). A further implication of this progressive 
eNOS uncoupling is that eNOS produces both NO and O2–, which form ONOO–. 
Thereby eNOS effectively becomes an ONOO– generating enzyme (432). ONOO– 
has significant implications both as a contributor to vascular oxidative stress per se, 
and also as a damaging factor of further BH4 depletion and eNOS uncoupling. 
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Figure 1. 4. eNOS uncoupling.  
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eNOS uncoupling is a mechanism resulting in endothelial dysfunction. Accumulating 
evidence shows the association between eNOS uncoupling and endothelial 
dysfunction in patients with hypercholesterolemia (433), diabetes (434), essential 
hypertension (435); chronic smokers (436); and in nitroglycerin treated patients 
(437). As such, the pathological risk factors which will lead to eNOS uncoupling is 
proposed to be responsible for the development of endothelial dysfunction in 
vascular disease. Therefore, it suggests that the approaches which enable the 
restoration of eNOS uncoupling is capable of improving endothelial dysfunction.  
 
1.4.4.1 Regulation of eNOS uncoupling 
Accumulating evidence suggests that eNOS uncoupling has been implicated in many 
cardiovascular and metabolic diseases with shift of nitroso-redox balance. Under 
physiological conditions, eNOS requires BH4 and L-arginine to generate NO. Under 
inadequate cofactors conditions, eNOS mediated O2 reduction no longer couples to 
L-arginine, resulting in the generation of O2– rather than NO. This eNOS uncoupling 
contributes to increased ROS production and decreased NO formation, consequently 
endothelial dysfunction (438). An increasing body of evidence shows that eNOS 
uncoupling can be modulated by directly or indirectly increasing the bioavailability 
of its cofactors and substrate, increasing its transcription and interfering with eNOS 
modulators, such as netrin-1, resulting in increased NO production and/or less eNOS-
dependent generation of free radicals.  
 
1.4.4.1.1 BH4 
BH4 (5,6,7,8-tetrahydrobiopterin) is an essential cofactor of enzymes that are of 
physiological importance, including three NOS isoenzymes (416). It is synthesized 
via de novo synthesis and salvage pathway (Figure 1. 5). BH4 is widely present in 
cells or tissues of higher organisms and plays a key role in a number of biological 
processes and pathological states, such as monoamine neurotransmitter formation, 
endothelial dysfunction, the immune response and pain sensitivity (439).  
 
With regards to eNOS, the NO generating function is highly correlated with the 
intracellular concentration of BH4 (439-441). In coupled state, BH4 is tightly bound 
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to eNOS and facilitates eNOS to catalyze the formation of L-citrulline and NO in the 
presence of its adequate substrates (L-arginine and oxygen) through easing the 
binding of L-arginine substrate to eNOS, shifting the heme iron into a high spin state 
to increase enzyme activity, involving in electron transfer, and stabilizing the NOS 
dimer (442-445). Whereas, in the presence of inadequate levels of BH4, the 
pleiotropic role of BH4 in NO generation is impaired and the electron transfer in 
eNOS becomes uncoupled from L-arginine oxidation and NO formation to form O2–. 
Moreover, inadequate bioavailability of BH4 causes a less tightly packed oxidase 
domain of eNOS dimer and a higher sensitivity to proteolysis (446).  
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Figure 1. 5. De novo synthetic and salvage pathways of BH4. 
BH4 biosynthesis initiates from GTP via 7,8-dyhydroneopterin (BH2) and 6-
pyruvoyl-tetrahydropterin. The first and rate-limiting step in de novo pathway is 
catalysation by guanosine triphosphate cyclohydrolase I (GTPCH1). Subsequent 
steps are catalyzed by the enzymes 6-pyruvoyl tetrahydropterin synthase and 
sepiapterin reductase. In salvage pathway, whereby 6-pyruvoyl-5,6,7,8-
tetrahydropterin is converted to sepiapterin by an enzyme termed “sepiapterin 
synthase.” Sepiapterin is reduced by sepiapterin reductase to BH2, and further by 
dihydrofolate reductase (DHFR) to form BH4. 
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Accumulating evidence shows that reduced BH4 bioavailability lead to eNOS 
uncoupling and endothelial dysfunction (439). Conversely, in many of these 
conditions, supplementation with exogenous BH4 has been shown to improve 
endothelial function and lower cardiovascular risks. It has been shown that BH4 
supplementation diminished the NOS-dependent generation of O2−(447), and restored 
endothelial function in  diabetic animal models of diabetes (448), insulin resistance 
(449), as well as in patients with hypercholesterolemia (433), diabetes (434), 
hypertension (435), and in chronic smokers (436). Moreover, it has been 
demonstrated that BH4 improved ischemia-reperfusion injury in isolated perfused rat 
hearts (430, 450). In ApoE-/- mice, BH4 supplementation reduced vascular immune 
cell infiltration and prevented the progression of atherosclerosis through maintaining 
eNOS coupling and NO bioavailability (451). In addition, exogenous BH4 given to 
mice can recouple an already uncoupled eNOS with a subsequent reversing of 
pressure overload induced cardiac hypertrophy, fibrosis, and myocardial dysfunction 
(452).  
 
On the other hand, it has been shown that up-regulation of BH4 synthesis produced 
beneficial effect on endothelial function. Ozaki et al. (453) showed that upregulation 
of the rate-limiting enzyme of BH4 synthesis, GTPCH1, led to a recovery of eNOS 
bioactivity, thereby improving endothelial function and reducing disease progression. 
Zhang et al. (454) reported that the increased expression of GTPCH1 prevented the 
decrease in BH4 levels in isolated cells and in atherosclerotic animal models. In 
addition, Crabtree et al. (455) showed that increased expression and activity of 
DHFR prevented eNOS from uncoupling.  Conversely, inhibition of GTPCH1 
resulted in eNOS uncoupling (456).  
 
1.4.4.1.2 L-Arginine 
Reduced availability of L-arginine has been suggested as a contributor of NOS 
uncoupling (457, 458). The beneficial effects of L-arginine supplement have been 
reported in both animal and human studies under a variety of pathophysiological 
conditions such as in patient with hypercholesterolemia (459), patients with essential 
and secondary hypertension  (460), in vessels (461, 462). It has been shown that 
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short- to medium-term administration of arginine improves NO mediated vascular 
function in elderly humans as well as a variety of clinical conditions, including 
hypercholesterolemia, coronary artery disease, congestive heart failure, and 
peripheral artery disease (418). Furthermore, it has been reported that L-Arginine is 
capable of stimulating O2 uptake by coupled eNOS (463), inhibiting O2– formation 
within uncoupled eNOS by electronic interaction with the heme-bound O2 (464), 
However, Non-beneficial effect of L-arginine was also observed in other trials (418) 
or the benefits did not continue with chronic therapy. This raises the question 
whether L-arginine concentrations can become critical as a substrate in vivo. 
Excessive arginase activity induced low L-arginine bioavailability in the vicinity of 
eNOS could partially explain the outcome of L-arginine supplementation (58). 
Moreover, competition of ADMA might be another explanation (465).  
 
1.4.4.1.3 Dimerization 
The dimeric form of eNOS is critical for eNOS activity and the ratio of eNOS dimer 
to monomer has been proposed to be a clue to eNOS uncoupling (Figure 1. 4B). The 
active form of eNOS enzyme comprises of two identical subunits that form a head to 
tail homodimer. Cys94 and Cys99 of eNOS form a zinc tetra-coordinated cluster 
(ZnS4) between each subunit. It has been shown that zinc bound to the tetrathiolate 
cluster stabilizes the dimer interface on the N-terminal region of eNOS (466, 467). 
ZnS4 is highly sensitive to oxidants such as ONOO–(53, 468, 469), and oxidation of 
the ZnS4 cluster results in monomerization of eNOS and inhibition of catalytic 
activity. Indeed, the uncoupling of eNOS has been associated to its monomerization. 
It has been shown that ONOO– treatment induces the monomerization of eNOS and 
thus reduces eNOS activity in ECs (53). Cai et al. (470) showed an enhance in eNOS 
homodimerization by increasing BH4 bioavailability. Whereas, it has been 
demonstrated that monomerized eNOS continued to produce O2– (471, 472). This 
would lead to the formation of reactive iron-oxygen complex within the heme and 
highly oxidative heme states, which in turn could result in oxidation of surrounding 
proteins with further self-amplification of oxidative damage. Thus, dimerization can 
play a important role in NO production and endothelial function.  
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1.5 Approaches to improve endothelial function 
Endothelial function is critical to maintain the vascular homeostasis. It is well known 
that endothelial function correlates with cardiovascular outcomes which can be 
predicted by the grade of endothelial function. On the other hand, endothelial 
dysfunction initiates the pathogenesis of vascular diseases including atherosclerosis 
with characterization of reduced NO production and increased ROS generation. Thus, 
in order to improve endothelial function and prevent or treat vascular diseases, 
approaches to increase NO availability and reduce ROS level have emerged. There 
are two ways to eliminate the excessive ROS, one is by scavenging either through the 
supplement of antioxidants or stimulation of endogenous antioxidant strategy; the 
other one is targeting on the enzymes involved in the process of ROS production to 
block the ROS generation. To increase NO availability can be achieved by enhancing 
the expression of NOS, increasing the activity of NOS and reducing NO degradation.  
 
1.5.1 Vitamins 
Vitamins, including vitamin A, C, and E, are the most commonly used antioxidant to 
remove excessive ROS (473). Their antioxidant activity has been demonstrated both 
in vitro and in vivo studies (474, 475). The large clinical trials of antioxidants have 
also been conducted (Table 1. 5). The beneficial effect of vitamin A has been 
demonstrated. Singh et al. (476) reported that vitamin A exhibited protective effect 
against cardiac necrosis and oxidative stress. It also has been demonstrated that 
vitamin C provided protection against oxidative stress induced cellular damage by 
scavenging ROS, protecting proteins from alkylation by electrophilic lipid 
peroxidation products (477). Vitamin C also played a role in regulating eNOS 
function by recycling the eNOS cofactor, BH4, which was relevant to arterial 
elasticity and blood pressure regulation (478, 479). Furthermore, vitamin E (α-
tocopherol) functioned as an essential lipophilic antioxidant scavenging 
hydroperoxyl radicals in a lipid milieu (475). It is suggested that vitamin E plays an 
important role in protecting erythrocyte membranes and nervous tissues by its 
antioxidant properties (475). Supplementation of antioxidant seems to be effective on 
scavenging excessive ROS and relive oxidative stress in some cases, however, under 
certain circumstances, administration of antioxidant does not produce beneficial 
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effects (480). This may be due to the different stages of diseases and the size of the 
trial. 
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Table 1. 5. Clinical trial of antioxidants.  
Clinical 
trials 
 
Dosage Effects Ref. 
 
Positive 
results 
   
ATBC α-tocopherol (50 mg). Daily. 
 
Marginal effect on the incidence of fatal coronary heart disease in male smokers with no 
history of myocardial infarction for median follow-up of 6.1 years. 
(481) 
ASAP 91mg (136 IU) of D-α-
tocopherol and 250 mg of slow-
release vitamin C. Twice daily. 
Significant retard of progression of common carotid atherosclerosis in men. No effect in 
women and lower atherosclerosis inhibition by individual vitamins use for three years. 
(482) 
CLAS Vitamin E (≥100 IU), vitamin C 
(≥250 mg). Daily. 
Less carotid atherosclerosis progression among nonsmoking men after coronary artery 
bypass graft surgery was found for high supplementary vitamin E use when compared 
with low vitamin E use. No effect of vitamin E with colestipol/niacin, as well as no effect 
of vitamin C with colestipol/niacin or placebo was found. 
(483) 
CHAOS α-tocopherol in the form of 
capsule containing 800 IU daily 
for first 546 patients; 400 IU 
daily for remainder. 
Reduction of non-fatal myocardial infarction in patients with angiographically proven 
coronary atherosclerosis. Non-significant excess of cardiovascular deaths. 
(484) 
Fang et al. Vitamin C (500 mg) plus 
vitamin E (400 IU), each twice 
daily. 
Retardation of the early progression of transplant-associated coronary arteriosclerosis 
after cardiac transplantation.  
(485) 
IEISS Vitamins A (50,000 IU), vitamin 
C (1000 mg), vitamin E (400 
mg), β-carotene (25 mg). Daily. 
Lower infarct size and oxidative stress in patients with suspected acute myocardial 
infarction on combined treatment.  
(476) 
SPACE Vitamin E (800 IU). Daily. Reduction of composite cardiovascular disease endpoints and myocardial infarction in 
haemodialysis patients with prevalent cardiovascular disease.  
(486) 
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Table 1. 5. Continued.  
WACS Vitamin E (600 IU every other 
day); ascorbic acid (500 
mg/day) and vitamin E (600 IU 
every other day). 
Marginally significant reduction in the combined outcome of myocardial infarction, 
stroke, coronary revascularization, or CVD death among women with prior CVD with 
active vitamin E treatment was observed. Fewer strokes were experienced in female with a 
history of CVD or 3 or more CVD risk factors with supplementation of ascorbic acid and 
vitamin E for ~9.4 years. 
(487) 
No effect    
ATBC β-carotene (20 mg), α-
tocopherol (50 mg). Daily. 
No primary preventive effect in male smokers with no history of myocardial infarction of 
20 mg/day of β-carotene on major coronary events and no influence of α-tocopherol on 
nonfatal myocardial infarction for median follow-up of 
6.1 years. No significant differences in the number of major coronary events in male 
smokers with previous myocardial infarction receiving α-tocopherol and/or β-carotene for 
median follow-up of 5.3 years. 
(481, 
488) 
 
CARET β-carotene (30 mg) and vitamin 
A (25,000 IU). Daily. 
No benefits in smokers, former smokers and workers exposed to asbestos from 
combination of β-carotene and vitamin A in the form of retinyl palmitate for ~4.0 years. 
(480) 
GISSI α-tocopherol (300 mg). Daily. No benefit in patients surviving recent (≤3 months) myocardial infarction.  (489) 
HATS 
 D-α-tocopherol, (400 IU), 
vitamin C (500 mg) and β-
carotene (12.5 mg of natural β-
carotene) and selenium (50 µg). 
Twice daily.  
No significantly lower atherosclerosis progression in patients with coronary disease and 
low plasma levels of HDL.  
Attenuation of benefits from simvastatin-niacin treatment. 
 
(490) 
HOPE Vitamin E (400 IU). No apparent effects in patients at high risk for cardiovascular events vitamin E for ~4.5 
years treatment.  
(491) 
HPS Vitamin E (600 mg) vitamin C 
(250 mg) and β-carotene (20 
mg). Daily. 
No significant reductions in mortality from or incidence of any type of vascular disease, 
cancer or other major outcome among adults with coronary disease, other occlusive 
arterial disease or diabetes for 5 years. 
(492) 
MICROHOP
E 
 
Vitamin E (400 IU). Daily. No effect on cardiovascular outcomes or nephropathy in middle-aged and elderly people 
with diabetes and CV disease and/or additional coronary risk factor(s) for ~4.5 years. 
(493) 
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Table 1. 5. Continued 
MVP β-carotene (30,000 IU), vitamin 
C (500 mg), vitamin E (700 IU), 
all given twice daily for four 
weeks before, and six months 
after angioplasty with extra 
vitamin E (2000 IU) 12 h before 
angioplasty. 
No significant reduction in luminal diameter reduction and restenosis rates per segment in 
patients after angioplasty. Attenuation of beneficial probucol effects. 
 
(494) 
PHS β-carotene (50 mg). Every other 
day. 
No early or late differences in the overall incidence of cardiovascular disease, malignant 
neoplasms or death from all causes among healthy men for 12 years. 
(495) 
PPP Vitamin E (300 mg). Daily. No beneficial effects in primary prevention of cardiovascular events in people.  (496) 
SCPS β-carotene (50 mg). Daily. No support for a strong effect in reducing mortality from cardiovascular disease or other 
causes during median follow-up of 8.2 years. 
(497) 
SU.VI.MAX Vitamin C (120 mg), vitamin E 
(30 mg), β-carotene (6 mg), 
selenium (100 µg), and zinc (20 
mg). Daily. 
No beneficial effects on carotid atherosclerosis and arterial stiffness in free of 
symptomatic chronic diseases and apparently healthy people for over ~7.2 years. 
(498) 
VEAPS D/L-α-tocopherol (400 IU). 
Daily. 
Null results to the IMT progression in people at low risk for CVD. (499) 
WACS Ascorbic acid (500 mg/d), 
vitamin E (600 IU every other 
day) or β−carotene (50 mg 
every other day) 
No overall effect on the myocardial infarction, stroke, coronary revascularization, or CVD 
death considered single or combined in female with a history of CVD or 3 or more CVD 
risk factors for ~9.4 years. 
(487) 
WAVE Vitamin E (400 IU) plus 
vitamin C (500 mg). Twice 
daily. 
No cardiovascular benefit in postmenopausal women with coronary stenosis. Potential for 
harm. 
(500) 
Negative 
results 
   
ATBC β-carotene (20 mg), or 
combination of α-tocopherol 
(50mg) and β-carotene (20 mg). 
Daily.  
Increased risk of fatal coronary heart disease in male smokers with previous myocardial 
infarction for median follow-up of 5.3 years. 
(488) 
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Table 1. 5. Continued. 
CARET β-carotene (30 mg) and vitamin 
A (25,000 IU). Daily. 
May have had an adverse effect on the incidence of lung cancer and on the risk of death 
from lung cancer, cardiovascular disease and any cause in smokers, former smokers and 
workers exposed to asbestos from combination for ~4.0 years.  
(480) 
WAVE Vitamin E (400 IU) and vitamin 
C (500 mg). Twice daily. 
Increased risk of death in postmenopausal women with coronary stenosis. (500) 
Adapted from Badimon et al. (501).  
Abbreviation: ATBC, Alpha-Tocopherol &  Beta-Carotene Trial; ASAP, Antioxidant Supplementation in Atherosclerosis Prevention 
Study; CLAS, Cholesterol Lowering Atherosclerosis Study; CHAOS, Cambridge Heart Antioxidant Study; IEISS, Indian Experiment of 
Infarct Survival Study; SPACE, Secondary Prevention with Antioxidants of Cardiovascular disease in Endstage renal disease; WACS, 
Women's Antioxidant and Cardiovascular Study; CARET, β-Carotene and Retinol Efficacy Trial; GISSI, Gruppo Italiano per lo Studio 
della Sopravvivenza nell′ Infarto miocardico; CVD, cardiovascular disease; HATS, HDL-Atherosclerosis Treatment Study; HDL, high 
density lipoprotein; HOPE, Heart Outcomes Prevention Evaluation Study; HPS, Heart Protection Study; MICRO-HOPE, 
Microalbuminuria, Cardiovascular, and Renal Outcomes in the HOPE study; MVP, MultiVitamins & Probucol Trial; PHS, Physicians' 
Health Study; PPP, Primary Prevention Project; SCPS, Skin Cancer Prevention Study; SU.VI.MAX, Supplementation in Vitamins and 
Mineral Antioxidants trial; VEAPS, Vitamin E Atherosclerosis Prevention Study; WAVE, Women's Angiographic Vitamin and 
Estrogen Trial. 
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1.5.2 NADPH inhibitor 
As described before, NOXs are the primary source of ROS in vasculature 
contributing to oxidative stress and consequently resulting in eNOS uncoupling, 
which renders NOXs to be a putatively potential therapeutic target to alleviate 
oxidative stress and restore eNOS uncoupling. It has been described that combating 
oxidative stress in vascular diseases by targeting NOX families enables the 
development of novel drugs to prevent and/or treat vascular diseases. A number of 
studies have been shown that inhibition of NOXs can improve endothelial function 
(213, 308, 340, 502-506). In addition, there are various NOXs gene depletion model 
showing the effect of regulation of NOXs. And there are a number of established and 
novel NOXs inhibitors identified (Table 1. 6), which suggests that regulation on the 
activity and/or expression of NOXs is a practical approach to tackle excessive ROS 
and improve endothelial function. 
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Table 1. 6. Mechanism of action and effects of NOXs inhibitors.   
Class of 
inhibitor 
Name Chemical structure Mechanism of action  Pharmacological effects Ref. 
Non-
peptide 
 
DPI 
 
Flavin containing protein inhibitor-
abstracts electrons from FAD and 
prevents electron flow through the 
flavocytochrome conduit. 
 
Inhibitor of NADH: 
ubiquinone oxidoreductase, 
NADH dehydrogenase, XO, 
CYP450, NOS, bacterial 
nicotine oxidase. 
(507-
512) 
Non-
peptide  
 
GK-136907 
 
Purported NOX1 and NOX4 oxidase 
inhibitor. Mechanism of action not 
defined. But structural similarity with 
NADPH suggests that it may act as a 
competitive substrate inhibitor of this 
enzyme. 
None reported. (513, 
514) 
Non-
peptide  
 
ML171 
 
A phenothiazine compound with 
selectivity for NOX1 oxidase over 
other NOXs. Does not scavenge ROS 
generated by xanthine oxidase 
activity. 
None reported. (515) 
Non-
peptide  
 
VAS3947 
 
A triazolopyrimidine that reduced 
NOXs derived ROS generation in 
several cell lines with low micromolar 
potency, irrespective of the specific 
isoforms expressed; showed no 
inhibitory effects against xanthine 
oxidase derived ROS and eNOS 
activity. 
None reported. (516) 
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Table 1. 6. Continued.  
Non-
peptide  
 
Apocynin  
 
 
Oxidase assembly inhibitor-inhibits 
association of p47phox with 
membrane heterodimer. 
Scavenger of H2O2. (517-
519) 
Peptide  
 
Gp91dstat  [H]-RKKRRQRRRCSTRIRQL-NH2 Oxidase assembly inhibitor-inhibits 
association of NOX2 with p47phox. 
Does not scavenge superoxide 
generated by cell free systems. 
No other reported effects. (260, 
520) 
Non-
peptide  
 
AEBSF 
 
Oxidase assembly inhibitor-inhibits 
association of NOX2 with p47phox. 
Does not scavenge superoxide 
generated in cell free systems. 
Non-selective serine 
protease inhibitor. 
 
(521) 
Peptide  
 
PR-39 RRRPRPPYLPRPRPPPFFPPRL 
PPRIPPGFPPRFPPRFP  
 
Binds to SH3 domains of the p47phox 
subunit and prevents binding to 
p22phox. 
Not selective for NOX as it 
is likely to inhibit other 
proteins containing SH3 
domains. 
(522) 
Non-
peptide  
 
Statins 
(e.g. 
mevastatin) 
 
Decrease superoxide production by 
inhibiting synthesis of 
farnesylpyrophosphate and 
geranylgeranylpyrophosphate which 
are crucial for membrane attachment 
of Rac and NOX assembly. May also 
decrease p22phox and NOX1 
expression. Likely to influence NOX1 
and NOX 2 activities. 
HMG-CoA reductase 
inhibitor. Decreases AT1 
receptor expression; 
increases eNOS expression. 
 
(523, 
524) 
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Table 1. 6. Continued. 
Non-
peptide  
 
AT1 receptor 
antagonists 
(e.g. losartan) 
 
Decrease Ang II-dependent activation 
of NOXs via AT1 receptors. Unlikely 
to display NOX selectivity as Ang II 
stimulates NOX1and NOX4 oxidases. 
 
 (107) 
Non-
peptide  
 
Nebivolol 
 
Inhibits membrane association and 
also interaction of p67phox and Rac 
and decreases oxidase expression. 
Inhibits NOX1-dependent superoxide 
production. 
 
β-adrenoceptor blocker. 
 
(525-
528) 
Non-
peptide  
 
Resveratrol 
OH
OH
HO
 
Decreases superoxide production in 
intact macrophages and homogenates. 
Does not scavenge superoxide in cell 
free systems. 
 
Inhibitor of PKC. 
 
(581-
583) 
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Table 1. 6. Continued. 
Non-
peptide  
 
Gliotoxin 
N
N
S
S
OH
O
HO
O
 
A fungal metabolite, thiol-modifying 
toxin thought to inhibit 
phosphorylation of p47phox by 
preventing PKC co-localization with 
p47phox. Also, inhibits electron 
transport through the flavocytochrome 
before oxidase activation. Low 
potency for blocking NOX4. 
Stimulation of cGMP 
release. Cytoskeletal re-
organisation. Disrupts the 
mitochondrial membrane 
potential. 
 
(529-
535) 
Non-
peptide  
 
S17834 
 
Flavonoid derivative proposed to 
directly inhibit NOXs activity; 
although the mechanism is still 
undefined. 
 
No other reported effects. (536) 
Peptide  
 
Clostridium 
difficile 
toxin B 
For structure see  
Jank et al. (537).  
Glucosylation of threonine-35 on Rac, 
which modifies GTPase activity. 
 
Likely to inhibit all Rac-
dependent protein activity. 
High toxicity. 
(538) 
Non-
peptide  
 
Nordihydrogu
aiaretic acid 
 
Blocks H2O2 production in 
macrophages in response to phorbol 
esters and in ECs in response to 
thrombin. 
 
Lipoxygenase inhibitor. 
Blocks arachidonic acid 
metabolism. 
 
(539-
541) 
Non-
peptide  
 
SKF525A 
 
Decreases superoxide and H2O2 
production in ECs. 
 
CYP inhibitor. 
 
(539, 
542) 
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Table 1. 6. Continued. 
Non-
peptide  
 
Metformin 
 
Scavenges hydroxyl radicals but not 
superoxide. Could also inhibit PMA 
and Ang II-dependent ROS 
production from NOXs. However, 
this is likely to be due to inhibition of 
PKC activity. 
Antihyperglycemic agent. 
PKC inhibitor. 
 
(543, 
544) 
Non-
peptide  
 
Sildenafil-
citrate 
N
N
S
O
O
O
N
H
N
N
N
O
 
Inhibits endothelial superoxide 
production and gp91phox expression 
in response to the thromboxane 
mimetic U46619 via increases in 
cGMP. 
 
An inhibitor of 
phosphodiesterase type 5. 
Unlikely to be selective for 
any particular isoform of 
NOX or a direct inhibitor of 
NOX enzyme. Its PDE 
inhibitory actions are likely 
to influence many cellular 
systems. Changes in 
gp91phox expression could 
influence immune system. 
(545-
548) 
Non-
peptide  
 
Bilirubin 
NH HN
O
OH
HO
O
NH HN
O O
 
Can inhibit superoxide production in 
neutrophil lysates when applied to 
cytosolic fractions prior to 
reconstitution with membrane 
fractions and SDS stimulation. 
Unlikely to influence expression of 
NOX2, p22phox and p47phox but 
may reduce p47phox phosphorylation. 
 
May also scavenge ROS. 
 
(549-
551) 
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Table 1. 6. Continued. 
Non-
peptide  
 
Minocycline 
 
A tetracycline derivative that inhibits 
NOX derived superoxide production 
in microglia and dopaminergic 
neurons in response to stimuli such as 
thrombin by down-regulating 
p67phox expression. 
Antibiotic. 
 
(552, 
553) 
Non-
peptide  
 
Perhexiline 
 
Inhibits superoxide production in 
intact neutrophils stimulated by 
FMLP or PMA, by an undefined 
mechanism. Does not inhibit enzyme 
assembly. 
 
Efficacious anti-anginal 
agent that inhibits carnitine-
palmitoyl-transferase. 
(554, 
555) 
Non-
peptide  
 
Roxithromyci
n 
 
Blocks superoxide generated by intact 
neutrophils activated by FMPL or 
PMA but not by cell lysates. Does not 
inhibit PKC-dependent 
phosphorylation. May inhibit 
translocation of p47phox and/or 
p67phox to the plasma membrane. 
 
Antibiotic belonging to the 
macrolide class. Inhibit 
RNA-dependent protein 
synthesis. Capable of 
inhibiting CYP450. 
(556-
558) 
Non-
peptide  
 
Taurine 
chloramine 
 
Reversible inhibition of PMA-
dependent superoxide anion 
production in human neutrophils by 
interfering with the translocation of 
p47phox and p67phox to the 
membrane. Also inhibits 
phosphorylation of p47phox. 
Inhibits inducible NOS in 
alveolar macrophages. 
 
(559-
561) 
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Table 1. 6. Continued. 
Peptide  
 
Mastoparan INLKALAALAKKIL Inhibition of superoxide production 
by neutrophil lysates most likely via 
interaction with N-terminal of 
p67phox. Does not interfere with 
translocation of p47phox and 
p67phox to membrane. 
An amphiphilic cationic 
tetradecapeptide isolated 
from wasp venom. Shows 
affinity towards SH3 
domains. May interact with 
G-proteins. 
(562-
565) 
Peptide  
 
Ghrelin GSSFLSEHQRVQQRLESL 
LPPAKLQPR 
Inhibits superoxide production by 
thoracic aorta most probably via 
release of NO. Does not scavenge 
superoxide. 
 
The peptide is capable of 
releasing growth hormone 
releasing peptide. 
Stimulates gastric acid 
secretion. 
(566-
568) 
Non-
peptide  
 
α-tocopherol 
 
Decreases stimulated superoxide 
production, inhibits p67phox-p47phox 
translocation and p47phox 
phosphorylation in monocytes, 
neutrophils and microglial cells. This 
effect is likely to be due to PKC 
inhibition. 
 
Quenches ROS. 
 
(569-
573) 
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Table 1. 6. Continued. 
Non-
peptide  
 
Benzylisothio
cyanate 
(BITC) 
 
Concentration-dependently blocks 
TPA induced superoxide production 
in a human leukemia cell line without 
influencing PKC activity and 
p47phox translocation. Mechanism 
may involve covalent cysteine 
modification of the NOX. 
May inhibit NO, PGE2 and 
TNF-α production. Can 
cause apoptosis via 
induction of Bak and Bax 
proteins. 
(574-
576) 
Non-
peptide  
 
Probucol 
 
Decreases superoxide production in 
rabbit aorta, which may be attributed 
to down-regulation of p22phox. 
 
Free radical scavenger. 
 
(577-
580) 
Non-
peptide 
 
Plumbagin 
 
OH O
O
 
Inhibits NAD(P)H-dependent 
superoxide production in various cell 
lines that express NOX4. Mechanism 
of action is unknown. 
 
Napthoquinone structure 
may impart ROS-
scavenging effects. 
(589, 
590) 
Non-
peptide  
 
VAS2870 
 
Undefined mechanism of action. 
Inhibits NOX activity in NOX2-
containing HL-60 cell line and in 
vascular ECs containing NOX2 and 
NOX4. Does not scavenge 
superoxide. 
 
No other reported effects. 
 
(591, 
592) 
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 Table 1. 6. Continued. 
Non-
peptide  
 
Nitrolinoleate 
 
A nitrated lipid which inhibits PMA- 
and FMLP-dependent superoxide 
production and degranulation in 
human neutrophils by increasing 
cAMP but not cGMP levels. 
 
Other effects associated 
with raising cAMP. 
Vasorelaxation. 
 
(585, 
586) 
Non-
peptide  
 
Mycophenolat
e acid 
O
O
HO
O
O
OH
 
A fungal derivative that inhibits 
endothelial and neutrophil derived 
superoxide by reducing Rac levels 
and activation in the membrane. Does 
not alter mRNA levels of NOX2, 
NOX4 and p47phox. 
 
A potent inhibitor of inosine 
monophosphate 
dehydrogenase involved in 
purine synthesis in B and T-
lymphocytes. 
 
(587, 
588) 
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Table 1. 6. Continued. 
Non-
peptide  
 
Curcurmin 
 
Decreases superoxide production in 
intact macrophages and homogenates. 
Does not scavenge superoxide in cell 
free system. 
 
Is a potent irreversible 
inhibitor of thioredoxin 
reductase via alkylation of 
cysteine residues? 
 
(581, 
584) 
Abbreviation: AEBSF, 4-(2-aminoethyl)-benzenesulphonyl fluoride; Ang II, angiotensin II; AT1 receptor, angiotensin II receptor type 1; 
cAMP, cyclic adenosine monophosphate; cGMP, cyclic guanosine monophosphate; CYP450, cytochrome P450; DPI, diphenylene 
iodonium; eNOS, endothelial nitric oxide synthase; FMLP, N-Formyl-Met-Leu-Phe; HMG-CoA, 3-hydroxy-3-methyl-glutaryl-CoA; 
H2O2, hydrogen peroxide; NADPH, nicotinamide adenine dinucleotide phosphate; NOS, nitric oxide synthase; NOX, NADPH oxidase; 
NO, nitric oxide; PGE2, prostaglandin E2; PKC, protein kinase C; PMA, para-methoxyamphetamine; PR-39, proline-arginine-rich 
antimicrobial peptide; ROS, reactive oxygen species; S178341, 4-dimethyl-2,3,5,6-tetraiodobenzene; SDS, sodium dodecyl sulphate; 
SKF 525A, 2-diethylaminoethyl 2:2-diphenylvalerate hydrochloride; TNF-α, tumor necrosis factor-alpha; TPA, 12-O-
tetradecanoylphorbol-13-acetate; VAS-2870, 3-benzyl-7-(2-benzoxazolyl)thio-1,2,3-triazolo(4,5- d) pyrimidine; XO, xanthine oxidase. 
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1.5.3 BH4  
As mentioned in Section 1.5.1.1, an increasing body of evidence demonstrates BH4 
as a key regulator of eNOS in the setting of endothelial dysfunction and a number of 
biological processes and pathological states (593). Substantial evidence shows that 
supplementation of BH4 or augment endogenous BH4 level can produce beneficial 
effects on cardiovascular diseases such as hypertension, peripheral arterial disease, 
coronary artery disease, and pulmonary arterial hypertension and so on. (438, 594). 
These findings suggest that regulation of BH4 level is a potential strategy to improve 
endothelial function and prevent or treat cardiovascular diseases.  
 
1.5.4 Natural products 
Substantial studies showed that numerous natural products have antioxidant 
beneficial actions in the prevention or treatment of cardiovascular diseases either by 
scavenging the excessive ROS and/or inhibiting ROS generating enzymes to block 
the ROS generation (501). Since the NOXs family is the major contributor of 
vascular ROS, identifying novel and specific NOX inhibitors from natural products 
represents a promising approach. For example, polyphenols and flavonoids, naturally 
occurring in a wide range of plants, are capable of reducing oxidative stress and 
prevention of cardiovascular diseases (501, 595, 596). It has been reported that 
polyphenols not only scavenge superoxide radicals but also modulate the activity and 
expression of NOXs (597). In agreement with previous results, Ryszawa et al. (598) 
showed that various polyphenols inhibited NOXs in a number of tissues including 
vessels and platelets. On the other hand, accumulating evidence showed that 
numerous natural products can also regulate NO bioavailability by targeting NOS. 
For example, Chung et al. (599) recently showed that syringaresinol produced 
vasorelaxtative effect through phosphorylation and demerization of eNOS. These 
findings suggest that natural products can be a promising source of therapeutic drug 
to treat cardiovascular diseases by alleviating oxidative stress and amelioating NO 
bioavailability.  
 
Of note, Danshen is a very commonly used natural product in the treatment of 
cardiovascular and cerebrovascular diseases such as atherosclerosis, coronary artery 
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disease, stroke in the Chinese medicine setting. Substantial evidence suggests that its 
vascular beneficial actions are attributable to its numerous pharmacologically active 
components (600, 601). The vascular protective effects of Danshen components will 
be discussed in Section 1.6 and 1.7.  
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1.6 Overview of Danshen 
Danshen is the dried root of Salvia miltiorrhiza Bunge which belongs to the family 
of Labiatae. It has been widely used to in Asian countries such as China and Japan, 
to a lesser extent, in western countries such as U.S. (600, 601). Danshen is indexed 
in Chinese Pharmacopoeia (2010) with more than 35 formulations and concoctions 
containing its water extracts, ethanol extracts or their combination (602). There are 
numerous dosage forms of Danshen or Danshen combination available on market 
including tablets, capsules, granules, injectables, oral liquids, sprays and dripping 
pills (600, 601). Of all dosage forms been available, Fufang Danshen Tablet and 
Fufang Danshen Dripping Pills are the two most widely used products (602). 
 
1.6.1 Chemical constituents  
There are numerous chemical compounds isolated and identified from the Danshen. 
These compounds are mainly classified into lipophilic and hydrophilic categories. 
Most of the lipophilic compounds are diterpene chinone compounds of tanshinone 
type, and so far there are about 40 deterpene quinones have been isolated and 
identified including tanshinone I (Tan I), tanshinone IIA (Tan IIA), tanshinone IIB 
(Tan IIB), cryptotanshinone (CT) and others (603). The majority of hydrophilic 
compounds are phenolic acids. There are over 40 phenolic acids have been isolated 
from aqueous extracts of Danshen (604), such as salvianolic acids, danshensu and so 
on. In addition to those two major groups, other compounds such as baicalin, ursolic 
acid and flavanone have also been found. The structural properties of some Danshen 
compounds are listed in (Table 1. 7). 
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Table 1. 7. Chemical characteristics of some Danshen compounds.  
Compound ClogP ClogD/
pH5.5 
ClogD/
pH7.4 
H-bond 
acceptors 
H-bond 
donors 
Freely 
rotating 
bonds 
PSA 
(Å2) 
MW 
(Da) 
Molar 
refractivity 
(cm3) 
Molecular 
volume 
(cm3) 
1,2,15,16-
Tetrahydrotanshiquinone 
3.30 3.3 3.3 3 0 0 43.37 280 77.26 216.01 
1,2-Dihydrotanshinquinone 4.35 4.35 4.35 3 0 0 47.28 278 76.89 216.24 
15,16-Dihydrotanshinone I 3.68 3.68 3.68 3 0 0 43.37 278 78.66 210.37 
2,10,11-Trihydroxy-8-
methoxy-1,6,7,8-tetrahydro-
2H-benzo[e]azecine-3,5-dione 
0.73 -0.73 -0.73 7 4 4 116.09 295 71.92 202.79 
2-Allyl-3,4-
dihydroxybenzaldehyde 
1.89 1.89 1.7 3 2 5 57.53 178 50.68 142.38 
3,4-dihydroxyphenyl lactic 
acid 
-0.54 -3.4 -4.25 5 4 6 97.99 198 46.52 127.68 
3-
Hydroxymethylenetanshinqui
none 
2.47 2.47 2.47 4 1 1 67.51 294 78.16 210.78 
6,12-Dihydroxyabieta-
5,8,11,13-tetraen-7-one 
3.83 3.83 3.77 3 2 3 57.53 314 90.11 266.62 
Ailanthoidol 2.77 2.77 2.76 5 2 7 72.06 326 93.65 256.54 
Caffeic acid 1.42 0.11 -1.67 4 3 4 77.76 180 47.47 121.89 
Cryptotanshinone 4.13 4.13 4.13 3 0 0 43.37 296 82.21 239.47 
Danshensu -1.14 -3.32 -4.73 5 4 6 97.99 198 47.26 128.13 
Danshenxinkun A 3.54 2.5 0.73 4 2 4 74.6 296 82.55 215.53 
Danshenxinkun D 4.25 4.25 4.25 4 1 2 63.6 336 94.09 256.77 
Dehydromiltirone 4.28 4.28 4.28 2 0 1 34.14 280 82.48 251.19 
Dihydroisotanshinone I 4.39 4.39 4.39 3 0 0 43.37 278 78.66 210.37 
Ferruginol 7.37 7.37 7.37 1 1 2 20.23 286 89.54 289.90 
Ferulic acid 1.64 0.36 -1.42 4 2 4 66.76 194 52.27 147.47 
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Table 1. 7. Continued. 
Hydrotanshinone IIA 3.07 3.07 3.07 4 1 1 67.51 310 83.49 240.37 
Isocryptotanshinone 5.24 5.24 5.24 3 0 0 43.37 296 82.21 239.47 
Isoferulic acid 0.79 -0.26 -2.06 4 2 4 66.76 194 52.27 147.47 
Isopropyl 3-(3, 4-
dihydroxyphenyl)-2-
hydroxypropanoate 
0.74 0.74 0.73 5 3 8 86.99 240 61.32 186.88 
Isosalvianolic acid C 2.43 -0.32 -1.3 10 6 12 173.98 492 126.60 309.98 
Isotanshinone I 4.60 4.6 4.6 3 0 0 47.28 276 78.46 208.53 
Isotanshinone IIA 5.72 5.72 5.72 3 0 0 47.28 294 81.90 243.38 
Lithospermate B 2.14 -2.52 -2.61 16 9 21 201.04 740   
Lithospermic acid 0.59 -5.15 -5.35 12 7 14 211.28 538 132.95 327.83 
Magnesium  
lithospermate B 
2.14   16 9 21 201.04 740   
Methyl rosmarinate 1.85 1.85 1.84 8 4 12 133.52 374 96.20 258.20 
Methylenetanshinquinone 4.19 4.19 4.19 3 0 0 47.28 278 76.64 212.79 
Methyltanshinonate 3.87 3.87 3.87 5 0 2 73.58 338 88.14 261.00 
Miltionone II 2.74 2.73 2.26 4 1 1 63.6 312 83.74 236.38 
Miltirone 4.92 4.92 4.92 2 0 1 34.14 282 82.87 257.90 
Neocryptotanshinone  3.31 2.27 0.51 4 2 4 74.6 314 85.99 250.38 
Neocryptotanshinone II 3.85 2.81 1.04 3 1 1 54.37 270 75.30 220.76 
Neotanshinlactone 5.09 5.09 5.09 3 0 0 39.44 264 75.32 203.07 
Protocatechualdehyde 0.93 0.93 0.72 3 2 3 57.53 138 36.77 97.96 
Protocatechuic acid 1.01 -0.31 -1.88 4 3 3 77.76 154 36.95 98.82 
Przewalskin 7.90 7.9 7.9 4 1 2 63.6 330 89.31 269.15 
Przewaquinone A 3.32 3.32 3.32 4 1 2 67.51 310 83.53 240.92 
Przewaquinone B 2.80 2.8 2.8 4 1 2 67.51 292 80.09 206.07 
Przewaquinone C 2.50 2.5 2.5 4 1 1 67.51 296 78.78 220.37 
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Table 1. 7. Continued. 
Rosmarinic acid 0.87 -1.87 -2.84 8 5 11 144.52 360 91.35 232.84 
Salviaflaside -1.77 -4.46 -5.48 13 8 17 223.67 522 125.18 321.49 
Salvianolic acid A 4.74 1.99 1.01 10 7 15 184.98 494 132.51 312.90 
Salvianolic acid B -0.68 -5.34 -5.43 16 9 21 278.04 718 176.84 438.77 
Salvianolic acid C 2.15 -0.61 -1.59 10 6 13 177.89 492 127.97 313.46 
Salvianolic acid F 3.95 2.61 0.83 6 5 8 118.22 314 88.63 201.96 
Salviol 5.42 5.42 5.42 2 2 3 40.46 302 91.13 286.89 
Sodium rosmarinate 1.70 -1.04 -2.01 8 5 11 100.52 382   
Sodium tanshinone IIA 
sulfonate 
3.72 0.22 0.22 6 1 1 110.03 396   
Sugiol 6.30 6.3 6.28 2 1 2 37.3 300 89.67 286.40 
Tanshinaldehyde 2.14 2.14 2.14 4 0 1 60.44 310 82.56 236.53 
Tanshindiol A 1.98 1.98 1.98 5 2 3 65.74 312 80.30 218.90 
Tanshindiol B 2.25 2.25 2.25 5 2 2 87.74 312 80.37 217.36 
Tanshindiol C 2.25 2.25 2.25 5 2 2 87.74 312 80.37 217.36 
Tanshinlactone 5.09 5.09 5.09 3 0 0 39.44 264 75.32 203.00 
Tanshinol A 2.80 2.8 2.8 4 1 2 67.51 292 80.09 206.07 
Tanshinol B 2.50 2.5 2.5 4 1 1 67.51 296 78.78 220.37 
Tanshinone I 4.31 4.31 4.31 3 0 0 47.28 276 78.46 208.53 
Tanshinone IIA 4.93 4.93 4.93 3 0 0 47.28 294 81.90 243.38 
Tanshinone IIB 2.99 2.99 2.99 4 1 2 67.51 310 83.42 241.96 
Tanshinone VI 2.86 1.82 0.06 4 2 4 74.6 296 82.55 215.53 
Ursolic acid 8.73 7.85 6.05 3 2 2 57.53 456 33.52 415.72 
Vanillic acid 1.30 0.1 -1.52 4 2 3 66.76 168 41.74 124.40 
All date were generated by ACD/PhysChem Suite. 
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1.6.2 Pharmacology 
The capability of promoting blood circulation and removing blood stasis is the basis 
of medical use of Danshen for the treatment of numerous ailments. It is commonly 
used for the treatment of cardiovascular and cerebrovascular diseases such as 
coronary artery disease and stroke. The beneficial actions include improving 
microcirculation, vasodilating coronary artery, suppressing the formation of 
thromboxane, inhibiting platelet adhesion and aggregation, and protecting against 
myocardial ischemia (600, 601).  
 
1.6.2.1 ADME/Tox 
There is still not enough data on absorption, distribution, metabolism, extraction and 
toxicity (ADME/Tox) of Danshen or Danshen related products except several active 
components (600, 601). For example, danshensu and Tan IIA, the two major 
components in Danshen, exhibited a rapid absorption after oral administration of 
either extract formulation or individual components in both animal and human (600, 
601, 605). The half-life of danshensu following sublingual administration was 
reported to be much longer than that after oral dosing. On the contrary, salvianolic 
acid B (Sal B), a major hydrophilic component, was poorly absorbed in animal 
studies (606). Protocatechuic aldehyde exhibited a double peak concentration after 
absorbed orally (607), and protocatechuic acid was a potential oxidative metabolite 
of protocatechuic aldehyde (605). CT was converted to Tan IIA after intravenous 
administration (608).  
 
It has been reported that Danshen products may be associated with a number of 
clinically important herb-herb and herb-drug interactions leading to adverse 
outcomes (609-611). The most well-known adverse effect of Danshen is that it 
causes a therapeutic failure of warfarin, a highly efficacious oral anticoagulant with a 
narrow therapeutic index. The findings showed that Danshen could influence the 
pharmacokinetic and pharmacodynamic profiles of warfarin. The underlying 
mechanism is that tanshinones can alter the metabolism of warfarin by modulating 
the metabolizing enzyme CYP1A2, 2C9 and 3A4. Danshen has been shown to cause 
inhibition and induction of certain CYPs (612-616) as well as drug transporters such 
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as P-glycoprotein (P-gp) (617), thus, it is possible to affect ADME of many drugs 
metabolized by CYPs and transporter. For example, diazepam and midazolam 
exhibited a rapid metabolism due to CYP induction caused by Danshen (614, 618). 
In addition to herb-drug interaction, Danshen related herb-herb interactions have 
been reported as well. Yang et al. (619) showed that the herb-herb interactions were 
involved in pharmacokinetic profiles of Sal B, Tan IIA, ginsenoside Rb1, 
ginsenoside Rg1 and notoginsenoside R1 in the single form or the combination form. 
Moreover, pharmacokinetic interactions among danshensu, protocatechuic aldehyde, 
salvianolic acid A (Sal A) and Sal B has been also reported (620).  
 
To ensure the clinical use of Danshen of Danshen related product, further 
investigations on ADME and drug interactions are needed. However, due to the 
multiple components and complex nature of Danshen, challenge remains.  
 
1.6.3 Clinical application 
The main clinical application of Danshen is for treating cardiovascular and 
cerebrovascular diseases such as coronary artery disease and stroke. It has also been 
used for the treatment of hyperlipidaemia and hypertension (600, 601). It has been 
suggested that the therapeutic effect of Danshen on angina pectoris is attributable to 
its properties of improving microcirculation and coronary vasodilatation, inhibiting 
platelet adhesion and aggregation, protecting against myocardial ischemia, and 
suppressing the formation of thromboxane (600, 601).  
 
1.6.3.1 Coronary artery disease 
The most important indication of Danshen is coronary artery disease including 
angina pectoris, coronary artery spasm, and myocardial infarction. Danshen has been 
widely used to treat patients with angina pectoris either alone or in combination with 
other conventional drugs or herbal ingredients, and the efficacy has been confirmed 
by systematic assessment on randomized controlled trials (621), non-inferiority trial 
(622), and meta-analysis (623). Moreover, it has been reported that Danshen relieved 
symptoms of angina as several other traditional Chinese aromatic and warm herbal 
medicines (624). In addition, Danshen has been shown to be effective in protecting 
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myocardial infarction (625). It reduced the infarct size and mortality in rats 
comparable to ramipril (625).  
 
1.6.3.2 Stroke 
Danshen has been indicated as a standard treatment for cerebrovascular diseases, 
including stroke, in China (600, 601). However systematic reviews on randomized 
controlled trials suggest that there is a lack of support on its efficacy in disability 
improvement after ischemic stroke. This might be due to the small size of clinical 
trials (many of these trials were not placebo controlled), or the criteria for efficacy 
were not clearly defined. Furthermore, the benefits of Danshen in stroke may be 
negated or outweighed by the high bleeding complications in stroke from its 
antiplatelet effect (vide supra). As such, larger size of randomized controlled trials 
with defined efficacy end points are warranted to evaluate the therapeutic effect of 
Danshen for the treatment of acute ischemic stroke. 
 
1.6.3.3 Hyperlipidaemia 
Substantial studies showed that Danshen exerted beneficial effect on regulating 
cholesterol, triglyceride, and LDL and high density lipoprotein (HDL) cholesterol 
levels. Increased plasma cholesterol levels, especially the LDL cholesterol, 
predispose to coronary atherosclerosis. A study of 96 elderly patients with 
hyperlipidaemia showed that Danshen was capable of decreasing the levels of total 
plasma cholesterol and LDL, and reducing the ratio of thromboxane B2 to 6-keto-
prostaglandin F1α, D-dimer and fibrinogen, which in turn improved the blood 
coagulation system and endothelial functions (626). Xiang et al (627) also observed a 
greater reduction of cholesterol and triglyceride after Fufang Danshen Dripping Pill 
treatment compared to isosorbide dinitrate. Furthermore, there are several studies 
showing that total cholesterol, triglyceride, and LDL cholesterol levels were 
significantly reduced, and HDL cholesterol was significantly raised after the Fufang 
Danshen Dripping Pill treatment (600, 601).  
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1.6.3.4 Hypertension 
Traditionally, Danshen has been used for treatment of hypertension in Asian 
countries including China, Korea and Japan (600, 601). It is suggested that the 
antihypertensive effect of Danshen is attributable to the inhibition of angiotensin 
converting enzyme, an essential regulatory enzyme of the renin-angiotensin system 
(628), and  acting on eNOS (629), as well as salutary property on the rheology of 
erythrocytes (630). In addition, Danshen has been reported as a complementary 
therapy for pregnancy induced hypertension (631).  
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1.7 Effects of bioactive compounds of Danshen on endothelial function 
There is an increasing interest in pharmacologically effective Danshen compounds 
and theirs derivatives. Recently, increasing attentions were attracted on the 
underlying mechanisms of actions for Danshen active components such as Tan I, Tan 
IIA, Tan IIB, CT, danshensu, Sal A/B, ursolic acid and their related compounds (600, 
601).  
 
1.7.1 Lipophilic constituents  
Tanshinone, as the main lipophilic bioactive constituents (Figure 1. 6) isolated from 
Danshen, have been used either alone or combination form for treating 
cardiovascular diseases. Tan I, Tan IIA, Tan IIB, CT and dihydrotanshinones are the 
major tanshinones which have been extensively studied both in vitro and in vivo. The 
other hydrophobic constituents such as 1,2-dihydrotanshinquinone, 1,2,15,16-
tetrahydrotanshiquinone, dihydroisotanshinone I, acetyltanshinone IIA, 
isotanshinone IIA, tanshinone VI, isocryptotanshinone, neocryptotanshinone II, 
oleoyl neocryptotanshinone, oleoyl danshenxinkun A, neo-tanshinlactone, 
tanshinlactone A, methylenetanshinquinone, methyltanshinonate, 11-
hydroxymiltiodiol, 1-oxomiltirone, miltirone, ferruginol, tanshinol A, tanshinol B, 
danshenxinkun A, B, D. also have been studied.  
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Figure 1. 6. Lipophilic compounds isolated from Danshen. 
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1.7.1.1 15, 16-Dihydrotanshinone I 
It has been showed that 15,16-dihydrotanshinone I was capable of down-regulating 
the levels of TNF-α, IL-4,COX-2-mediated prostaglandin E2 (PGE2) and iNOS 
derived NO; it has also been demonstrated that 15,16-dihydrotanshinone I was able 
to suppress the activation of NF-κB and AP-1 and inhibit the expression of  IL-1β, 
TNF-α, and TNF-α converting enzyme and iNOS (632-635). It has been suggested 
that down-regulation of pro-inflammatory cytokine and chemokine production 
(PGE2, TNF-α, IL-1β, ΙL-4 and NO) by inactivating NF-κB and AP-1 pathways and 
inhibition of platelet aggregation are involved in actions of 15,16-dihydrotanshinone 
I contributing to its cardiovascular protective effects (632-635). Moreover, Park et al. 
(636) showed that 15,16-Dihydrotanshinone I concentration-dependently inhibited 
platelet aggregation with IC50 of 8.7±5.6 µM, and suppressed intracellular calcium 
Ca2+ mobilization and collagen induced liberation of [3H] arachidonic acid from [3H] 
arachidonic acid-incorporated rabbit platelet, which indicates that the underlying 
mechanism of the inhibitory effect of 15,16-dihydrotanshinone I on platelet 
aggregation was through suppression of Ca2+ mobilization and arachidonic acid 
liberation.  
 
1.7.1.2 Dihydrotanshinone 
The bioactive actions of dihydrotanshinone have been reported, including regulation 
of Ca2+ influx and inhibition of the production of inflammatory cytokines and 
chemokines (635). The relaxant effect of dihydrotanshinone was studied in rat-
isolated coronary artery by Lam et al. (637), which found involving suppressing the 
Ca2+ influx in the vascular smooth muscle without affecting endothelium, muscarinic 
receptors, β-adrenoceptors, adenylyl cyclase, and guanylyl cyclase involved 
pathways. The negative regulation of IL-12 and IFN-γ production of 
dihydrotanshinone has been reported with down-regulation of inflammatory 
cytokines and chemokines production by suppressing the promoter activation of IL-
12 p40 gene and NF-κB binding to the κB site (638). These results suggest that the 
regulation of inflammatory response and the influx of Ca2+ are at least partially 
accountable for the vascular protective effects of dihydrotanshinone.    
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1.7.1.3 Dihydrotanshinone I 
The anti-angiogenesis effect of dihydrotanshinone I was studied in vitro and in vivo 
by Bian et al. (639). The results showed that dihydrotanshinone I had an inhibitory 
effect on angiogenesis by inhibiting cell proliferation, migration, invasion and tube 
formation as well (639).  
 
1.7.1.4 Tanshinone I 
Tan I is one of the most abundant pharmacologically active tanshinones isolated 
from Danshen. A number of experimental studies have showed that Tan I can 
prevent or slow the progression of a wide range of diseases including cardiovascular 
diseases and cancer (640, 641). Nizamutdinova et al. (640) examined the effect of 
Tan I on the expression of ICAM-1 and VCAM-1, and found that Tan I exhibited a 
dose-dependent inhibitory effect on ICAM-1 and VCAM-1 expressions in HUVECs 
under the simulation of TNF-α for 6 hr; and an inhibitory effect on adesion of 
monocyte U937 to HUVECs was also observed by pretreating with Tan I which can 
be mimicked by RNA interference with ICAM-1 and VCAM-1 siRNA. Given 
adhesion molecules play a key role in endothelial function, the action of Tan I on 
adhesion molecules may be implicated in its anti-inflammation actions.   
 
1.7.1.5 Tanshinone IIA 
The cardiovascular effects of Tan IIA have been extensively studied both in vitro and 
in vivo (642). It has been demonstrated that tanshinone IIA can modulate various 
intracellular targets such as lowering the concentration of Ca2+ through ATP 
sensitive K+ channel (643), suppressing miR-1 expression through p38 MAPK signal 
pathway (644, 645), blocking Calcineurin/NFATc3 pathway (646), rescuing cardiac 
myocytes from oxidative stress induced damage and apoptosis (647), agonizing 
human cardiac KCNQ1/KCNE1 potassium channels (648), preventing cell 
proliferation (649), regulating estrogen receptor (650, 651), modulating angiogenesis 
(652), mediating platelet aggregation (653), suppressing monocyte chemoattractant 
protein-1 expression (654).  
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1.7.1.6 Sodium tanshinone IIA sulfonate  
Sodium tanshinone IIA sulfonate is a derivative of Tan IIA and has been used in 
China for treating cardiovascular diseases including myocardial infarction and angina 
pectoris (600). The underlying mechanisms have been proposed that sodium 
tanshinone IIA sulfonate may prevent the generation of superoxide in endothelium 
(655). Recently, it has been shown that sodium tanshinone IIA sulfonate inhibited 
TNF-α and IFN-γ production through modulating NF-κB and IFN-γ/STAT1 
signalling pathways (656). In addition, it has been reported that sodium tanshinone 
IIA sulfonate also down-regulated the level of Ca2+ in cells (657). It is believed that 
the beneficial effect of sodium tanshinone IIA sulfonate may act by regulating 
oxidative stress, inflammation response and Ca2+ level in cells.  
  
1.7.1.7 Tanshinone IIB 
Tan IIB, a major active ingredient of Danshen hydroxylase by CYP2A6, exhibits 
protective effects against ECs injury, inhibiting platelet aggregation and ameliorating 
the microcirculatory disturbance (658). 
 
1.7.1.8 Tanshinone VI 
Tanshinone VI is an abietane diterpene extracted from the root of S. miltiorrhiza 
Bunge. Studies have shown that tanshinone VI can protect the myocardium against 
ischemia induced derangements and hypoxia/reoxygenation injury (659). It also 
attenuated progression of in vitro myocardial remodeling (660).  
   
1.7.1.9 Cryptotanshinone 
CT is structurally similar to Tan IIA except C-15 position of dihydrofuran ring. It has 
well-documented antioxidative and anti-inflammatory effects (661, 662). CT has 
been shown to scavenge peroxyl radicals (663), down-regulate inflammatory 
cytokines and chemokines (eg TNF-α, IL-6, IL-12, IFN-γ) through inhibiting NF-κB, 
MAPK and AP-1 signalling pathways (635, 638, 664). It also inhibited iNOS-
mediated NO production and the activation of extracellular-regulated kinase (ERK) 
and mobilization of NF-κB (665), down-regulated COX-2-mediated PGE2 (632), 
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inhibited MMP-9 production and ERK, c-Jun NH2-terminal kinase (JNK) and 
MAPK signalling pathways (666), decreased ET-1 expression and increases activity 
and expression of eNOS via NF-κB involved pathway (667), reduced the activity of 
COX2, and down-regulated the level of prostaglandin E2 and reactive oxygen 
species generation mediated by COX-2 (668). In addtion, CT was showed to 
attenuate myocardial ischemia/reperfusion injury in vivo by reducing the infarct size 
and improving ischemia and reperfusion induced myocardial contractile dysfunction. 
In vitro experiments indicated that CT suppressed the expressions of VCAM-1 and 
ICAM-1 induced by TNF-α  (662), reduced lactate dehydrogenase leakage, 
glutathione (GSH) depletion, lipid peroxidation and free radical generation (669), 
down-regulated the expression of ICAM-1 and VCAM-1, increased NO generation, 
and inhibited monocyte adhesion to HUVECs (661). These findings indicate that the 
mechanisms of beneficial actions of cryptotanshinone are largely due to its anti-
inflammation and anti-oxidant effects.   
 
1.7.1.10 Other compounds 
Oleoyl neocryptotanshinone and oleoyl Danshenxinkun A are two new fatty 
tanshinones isolated from S. miltiorrhiza Bunge with an inhibitory effect on rabbit 
platelet aggregation induced by arachidonic acid (670). Besides, tanshinlactone A is 
a new diterpenoid tanshinone compound isolated and identified from S. miltiorrhiza 
(671). The bioactivities of tanshinlactone A has been drawn interest from 
pharmacologist and life scientist. The inhibitory effect of tanshinlactone A on pro-
inflammatory cytokines (IL-2 and IFN-γ) gene expression has been observed (672). 
These observation suggest that tanshinlactone A’s anti-inflammatory effect may 
partially account for its putative pharmacological activities.  
 
1.7.2 Hydrophilic constituents 
Hydrophilic constituents (Figure 1. 7) from S. miltiorrhiza are comprised of 
numerous active compounds. Salvianolic acids are the most abundant hydrophilic 
compounds extracted from Radix S. miltiorrhiza containing polyphenolic structure 
with antioxidation effect, to a less extent, Danshensu, ursolic acid, rosmarinic acid, 
caffeic acids, lithospermic acids and protocatechuic acid and other related 
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compounds were isolated and identified from Danshen. Recently, there is increasing 
number of studies focused on hydrophilic compounds. These compounds have been 
demonstrated with various activities including anti-oxidation, anti-platelet 
aggregation, anti-atherosclerosis and so on (601, 673-677). It is believed that the 
activities of the hydrophilic extract partially explain the beneficial effects of Danshen. 
90 
 
OH
OH
COOH
O
OH
COOH
Caffeic acid
(65)
Isoferulic acid
(71)
OH
OH
COOH
OH
Danshensu
(66)
OH
OH
OO
OH
OH
O
O
Methyl rosmarinate
(75)
HO
HO O O
COOH
OH
Lithospermic acid
(73)
O
OH
O
OH
OH
HO
HO O O
COOH
OH
O
O
O
OH
OH
Ethyl lithospermate
(68)
HO
HO O O
OH
O
O
O
OH
OH
OO
Demethyl lithospermate
(67)
HO
HO O O
COOH
OH
Isosalvianolic acid C
(72)
O
OH
OH
Lithospermic acid B
(74)
HO
HO O O
COOH
OH
O
O
HOOC
OH
HO
OH
OH
O
HO
HO O O
COOH
OH
O
O
OH
HO
OH
OH
O
O
O
Ethyl lithospermate B
(69)
HO
HO
HO
OH
O O COOH
OH
OH
Salvianolic acid A
(82)
HO
OH
O
OH
O
O
OH
OH
OH
HO
COOH O
Salviaflaside
(81)
OH
OH
OO COOH
OH
OH
Rosmarinic acid
(79)
O
OH
COOH
COOH OH
OH
Prolithospermic acid
(76)
O
O
OH
O
O
HO
Salvinal
(80)
OH
OH
CHO
Protocatechualdehyde
(77)
OH
OH
COOH
Protocatechuic acid
(78)
O
OH
COOH
Ferulic acid
(70)
 
Figure 1. 7. Hydrophilic compounds isolated from Danshen. 
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Figure 1. 7. Continued.  
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1.7.2.1 Salvianolic acid A 
Sal A is the most potent anti-oxidant in water-soluble phenolic acids from S. 
miltiorrhiza. Accumulating evidence suggests that the clinical beneficial effects of 
Danshen on vascular disorders are in part attributable to the activities of Sal A 
including inhibitory effect on platelet aggregation, cell adherence, lipid peroxidation 
(678), in particular, the anti-oxidation effect (679, 680). Yang et al. (681) suggested 
that Sal A protected against vascular endothelial dysfunction by reducing oxidative 
stress, meanwhile, Sal A exhibited a regulatory effect on the activity and expression 
of eNOS in cultured cells (682). Sal A exhibited high scavenging activity on free 
radicals (683-685). It also was found to inhibit potently lipid peroxidation (684, 686, 
687). Sal A has shown with antithrombotic and anti-platelet aggregation activities 
(688, 689). Jiang et al. (690) showed that Sal A also inhibited leukocyte adhesion by 
suppressing expression of ICAM-1 in brain micro-vascular endothelial cells. These 
findings suggest that Sal A has therapeutic potential in treating vascular disorders.      
 
1.7.2.2 Salvianolic acid B 
Sal B is a most abundant active phenolic acid in Danshen. Accumulating evidence 
suggests that Sal B possesses a broad range of activities, among these, the anti-
oxidative stress property of Sal B is a major contributor to its cardiovascular 
protective actions. A number of studies have shown that Sal B exhibited a potent 
superoxide anion radical scavenging activity in vitro model by targeting 
ROS/PI3K/AKT/ MEK/ERK1/2 pathway and NOX system (687, 691-697). In 
hypercholesterolemic animal model in rabbits, it also has been shown that Sal B 
inhibited endothelial damage and LDL oxidative (698). Recently, it has been 
reported that Sal B prevented ECs free oxidative injury by scavenging radicals (693, 
699). Hung et al. (700) showed that the oxidative stress induced by homocysteine can 
be attenuated by Sal B. Besides, Sal B has been reported to scavenge peroxides and 
suppressed the expression of adhesion molecules in vascular endothelium and 
leukocytes, which may be related to the ameliorating effect of Sal B on 
microcirculation disturbance (658, 701).  
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In addition, the anti-inflammatory effect of Sal B may also contribute to its vascular 
protection. For example, Sal B exhibited anti-inflammatory effect both in vitro and in 
vivo by suppressing VCAM-1 and ICAM-1 expressions (TNF-α and IL-1β) (702, 
703), and regulating activation of NF-κB and AP-1 DNA binding activities in 
vascular ECs which play a role in the development of atherosclerosis (704, 705). 
Besides, Sal B has been shown to modulate EC hyperpermeability which is 
implicated in development and progression of inflammation and subsequent ischemic 
reperfusion injury and atherosclerosis (706, 707). Moreover, Sal B has been 
demonstrated with vasodilating effect through its regulatory effect on ion channel 
(708, 709), platelet adhesion (710) and MMP-1, -2, and -9 activities (711). 
 
1.7.2.3 Danshensu 
Danshensu (3-(3,4-dihydroxyphenyl) lactic acid) has been extensively investigated 
on its vascular protective actions. It is believed that antioxidant activities and anti-
inflammatory effects of danshensu contribute to the beneficial actions of Danshen. 
Danshensu has shown with protective effects on ECs from oxidative injury (699, 
712). It reduced lipid peroxidation and the expression of IL-6 and TNF-α (713, 714); 
enhanced the production and activity of SOD (712, 714); increased protein level of 
Cx43 (712); scavenged xanthine- and xanthine oxidase-generated superoxide (715), 
and protected ECs from superoxide induced damage by suppressing cell apoptosis 
and increased the expression of CD40 (716). It seems that the free radical scavenging 
activity and eNOS-NO modulator properties of danshensu may be mainly 
responsible for its actions including those coronary arteries dilation, platelet 
aggregation inhibition, microcirculation improvement, and protection of myocardium 
from reperfusion injury of the ischemic heart, prevention of cell apoptosis (601). 
 
Danshensu has been found with beneficial effects on homocysteine induced 
endothelial dysfunction by reversing decrease in cell viability and disruption of 
capillary-like structure formation (717), and maintaining the HUVECs integrity (706, 
707). Besides, danshensu has been reported with regulation of intracellular level of 
Ca2+ and K+. Lam et al. (718) showed that danshensu relaxed 5HT-precontracted 
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coronary artery rings and abolished CaCl2-induced vasoconstriction, suggesting that 
the inhibition of Ca2+ influx in the vascular smooth muscle cells contributes to the 
vasorelaxant effect of danshensu. Danshensu may also activate K+ channels (708). 
 
1.7.2.4 Ursolic acid  
The cardiovascular protective activities of ursolic acid have been showed in HUVEC 
(719). Ursolic acid suppressed the NOX-dependent ROS generation and inhibited the 
expression of NOX4, a subunit of NOX, increased eNOS expression and NO 
production (719). These results indicate that ursolic acid may regulate the activity 
and expression of NOXs and eNOS.     
 
1.7.2.5 Salvianolate 
Salvianolate has been shown to suppress the release of endothelin (720). Recent 
work showed that it affected cell adhesion by regulating inflammatory cytokines and 
chemokines. Sui et al. reported that salvianolate down-regulated the expression of 
IL-1β and TNF-α (721).  
 
1.7.2.6 Magnesium lithospermate B  
Magnesium lithospermate B is has been shown with vascular protective activities in 
vitro and in vivo, including scavenging superoxide and regulating intracellular Ca2+ 
(722-724). Yokozawa et al. demonstrated that magnesium lithospermate B had renal 
protective effect by scavenging superoxide and prevent cell injury (725, 726). 
Magnesium lithospermate B regulated Ca2+ influx and NO release in ECs (724), 
protected vascular ECs from superoxide damage (727). Recent work showed that 
magnesium lithospermate B also inhibit XO derived superoxide (728). These 
findings indicate that magnesium lithospermate B may have a potential to treat 
vascular disorders.        
 
1.7.2.7 Magnesium tanshinoate B  
Magnesium tanshinoate B is an active compound isolated and purified from Danshen. 
A substantial attention has been received on the bioactivity of magnesium 
95 
 
tanshinoate B, especially, its vascular protective activity. It has been shown that 
magnesium tanshinoate B was able to modulate NO bioavailability by enhancing the 
activity and the expression of eNOS in human ECs (729). It also inhibited LDL 
oxidation in cultured cells (730, 731). These effects suggest that magnesium 
tanshinoate B may be used to treat vascular disorders associated to lipid peroxidation 
and NO deficiency.    
   
1.7.2.8 Rosmarinic acid 
Rosmarinic acid, a caffeic acid dimmer, is one of the major phenolic constituents in 
Danshen with a broad range of bioactivities. It has been reported that rosmarinic acid 
had a strong anti-lipid-peroxidation activity by scavenging O2– in vitro (687), and 
antiplatelet effects as well (732). A recent study has shown its anti-lipid peroxidation, 
radical scavenging, antioxidation of LDL activities (733). These findings suggest 
rosmarinic acid is, may contribute to the beneficial actions of Danshen on oxidative 
damage related disease.    
 
1.7.2.9 Caffeic acid 
Caffeic acid (3,4-dihydroxycinnamic acid) is one of the most common phenolic acids 
occurring in a broad range of plants including S. miltiorrhiza (733). S. miltiorrhiza is 
a rich source of caffeic acid derivatives with a wide spectrum of biological activities. 
The main biological activities of caffeic acid include antioxidant, anti-ischemia-
reperfusion, anti-thrombosis and anti-hypertension. The anti-lipid peroxidation, 
radical scavenging and antioxidation of LDL may be responsible for the antioxidant 
effects of caffeic acid. It has been shown that caffeic acid inhibited lipid peroxidation 
(686), and had a free radical scavenging activity on 1,1-diphenyl-2-picrylhydrazyl 
(DPPH) (734).     
  
1.7.2.10 Lithospermic acid  
Lithospermic acid has been demonstrated with bioactivities including anti-
inflammatory and hypouricemic activities (735), anti-HIV activity (736) and 
hormone-regulatory effects (737). Chen et al. suggested that lithospermic acid may 
act as therapeutic agent to treat atherosclerosis due to the potent inhibitory effect on 
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ROS generation and vascular smooth muscle cells proliferation and migration (738). 
Furthermore, it has been reported that lithospermic acid was capable of directly 
scavenging superoxide and inhibiting superoxide production by blocking XO 
involved the process of superoxide production (735). These observations indicate 
that lithospermic acid may have therapeutic potential in the prevention of oxidative 
stress associated diseases including atherosclerosis.    
   
1.7.2.11 Lithospermic acid B  
Lithospermic acid B is an active component isolated from S. miltiorrhiza with a 
broad range of pharmacological activities including antihypertensive effect (739), 
and protective actions against hepatitis and renal injury (725, 740, 741). It has been 
reported that lithospermic acid B had endothelium-dependent vasodilating activity 
(742). Recent work has shown that lithospermic acid B reduced oxidative stress by 
suppressing the production of malondialdehyde (MDA) via the inhibition of lipid 
peroxidation (743). These findings suggest that lithospermic acid B may be a new 
therapeutic agent to treat oxidative stress associated diseases.   
     
1.7.2.12 Lithospermate B 
The anti-oxidative stress effect of lithospermate B has been reported. Soung et al. 
showed that lithospermate B exhibited a potent peroxynitrite scavenging activity 
(744). The study also showed that the determinants of the peroxynitrite scavenging 
activity are the dihydroxyl group and the double bond in structure (744).  
 
1.7.2.13 Dimethyl lithospermate 
Dimethyl lithospermate is bioactive component isolated from S. miltiorrhiza. Kim et 
al. reported that dimethyl lithospermate was capable of reducing oxidative stress by 
scavenging peroxynitrite (745), which may be involved in the beneficial actions of 
Danshen. 
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1.7.2.14 Protocatechuic aldehyde  
Protocatechuic aldehyde (3,4-dihydroxybenzaldehyde) is an active water-soluble 
component from Danshen. It has been shown that protocatechuic aldehyde exhibited 
a potent anti-oxidation activity and anti-inflammatory effects in cultured vascular 
ECs (746). Zhou et al. showed that protocatechuic aldehyde was capable of targeting 
gene and protein expressions of VCAM-1 and ICAM-1 and down-regulating the 
release of those two vascular adhesion molecules in ECs (746). Furthermore, 
protocatechuic aldehyde suppressed the activation of NF-κB and AP-1 DNA binding 
activities (746). These findings suggest that protocatechuic aldehyde may be 
attributable to the anti-oxidation activity and anti-inflammatory activity of Danshen 
through targeting NF-κB and AP-1 involved signalling pathway.     
   
1.7.2.15 Protocatechuic acid 
Protocatechuic acid, a structurally typical active phenolic acid compound, has been 
reported with capability of scavenging of oxygen free radicals and protecting 
vascular ECs from homocysteine induced endothelial dysfunction (717, 747).   
    
1.7.2.16 Ailanthoidol 
Ailanthoidol (3-deformylated 2-arylbenzo[b]furan) is a neoligan from S. miltiorrhiza 
or Zanthoxylum ailanthoides Bunge and is used in Chinese traditional herbal 
medicine. Lee et al. reported that ailanthoidol had a radical quenching property and 
an inhibitory effect of ailanthoidol on TPA induced oxidative stress and anti-
inflammatory effects as well (748). Recently, Kim et al. observed that ailanthoidol 
could strongly suppress the production of inflammatory cytokines and chemokines 
including IL-1β, IL-6, TNF-α, iNOS, and COX-2 through inhibiting NF-κB 
activation (749). These findings indicate ailanthoidol may be a potential resource for 
treating oxidative stress and inflammatory associated diseases.  
 
1.7.2.17 3,4-Dihydroxyphenyl lactic acid  
Like the effects of other hydrophilic compounds, the pharmacological activities of 
3,4-dihydroxyphenyl lactic acid have been investigated both in vitro and in vivo 
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(658). It has been shown as a superoxide anion free radicals scavenger removing 
superoxide generated from the reaction system of xanthine and xanthine oxidase and 
also protects the mitochondrial membrane from the ischemia-reperfusion injury and 
lipid peroxidation (715). 3,4-dihydroxyphenyl lactic acid was capable of reducing the 
expression of adhesion molecules CH11b and CD18 as well as the production of 
TNF-α, superoxide anion and hydrogen peroxide by neutrophils induced by LPS 
(701, 750, 751). Recently, 3,4-dihydroxyphenyl lactic acid has been reported with a 
significant inhibitory effect on polymorphonuclear cell infiltration, IL-6 production, 
IκB-α degradation and the nuclear translocation of NF-κB p65 subunit protein. It has 
been found that 3,4-dihydroxyl group may play an important role as modification or 
depletion of dihydroxyl group eliminated its peroxide scavenging potential (734).  
 
1.7.2.18 2,10,11-trihydroxy-8-methoxy-1,6,7,8-tetrahydro-2H-
benzo[e]azecine-3,5-dione 
2,10,11-trihydroxy-8-methoxy-1,6,7,8-tetrahydro-2H-benzo[e]azecine-3,5-dione is a 
new cyclic phenyllactamide, namely salviamiltamide, isolated from the rhizome of S. 
miltiorrhiza. It has been shown that 2,10,11-trihydroxy-8-methoxy-1,6,7,8-
tetrahydro-2H-benzo[e]azecine-3,5-dione had radical scavenging activity on DPPH 
with a comparable IC50 value to that of L-ascorbic acid (752).  
 
1.7.2.19 2-Allyl-3,4-dihydroxybenzaldehyde 
2-Allyl-3,4-dihydroxybenzaldehyde (S-3-1) is a salvianolic acid A derived synthetic 
derivative with various bioactivities (753-755). It has been reported that S-3-1 
possesses an effective antioxidant activities. S-3-1 exhibited a superoxide scavenging 
activities on DPPH, superoxide anion and hydroxyl radicals (753). Moreover, S-3-1 
had inhibitory effect on lipid peroxidation in microsome fraction from rat liver 
induced by FeSO4 and cysteine (753).  
 
1.7.2.20 (+)-1-Hydroxypinoresinol-1-O-β-D-glucoside 
(+)-1-hydroxypinoresinol-1-O-β-D-glucoside is a furanofuranoid lignan glycoside 
isolated from the rhizome of S. miltiorrhiza. It has been reported that (+)-1-
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hydroxypinoresinol-1-O-β-D-glucoside had superoxide scavenging activity. Kang et 
al. showed that (+)-1-hydroxypinoresinol-1-O-β-D-glucoside scavenged 
peroxynitrite, total ROS and DPPH radical with IC50 values of 3.23 ± 0.04, 2.26 ± 
0.07 and 32.3 ± 0.13 µM, respectively (756). These radical scavenging activities 
were comparable to that of L-ascorbic acid.  
 
1.7.2.21 2-(3'-Methoxy-4'-hydroxy-phenyl)-5-(3-hydroxypropyl)-7-methoxy-
benzo[b]furan-3-carbaldehyde  
2-(3'-Methoxy-4'-hydroxy-phenyl)-5-(3-hydroxypropyl)-7-methoxy-benzo[b]furan-
3-carbaldehyde (XH-14) is bioactive ingredient isolated from S. miltiorrhiza, being a 
member of benzo[b]furan lignan family. The lignans have been reported with a broad 
spectrum of biological activities including antiplatelet (757), antioxidant (758, 759), 
anti-inflammatory (760). XH-14 has been known as a relatively potent adenosine 
antagonist proposed to treat ischaemic bradyarrhymias, cardiac arrest and renal 
disease with an advantage of relatively high water solubility and binding affinity and 
good bioavailability (761). Recently, Sung et al. reported that three novel XH-14 
derived benzo[b]furan derivatives inhibited inflammatory responses and may have a 
potential to treat obesity-associated inflammatory and metabolic diseases (762).    
   
1.7.2.22 Isopropyl-β-(3,4-dihydroxyphenyl)-α-hydroxypropanoate  
Isopropyl-b-(3,4-dihydroxyphenyl)-a-hydroxypropanoate is a new metabolite of 
Danshen found in rat brain, designated ND-309 (763). It has been shown that ND-
309 reduced the production of reactive oxygen species, down-regulated the content 
of MDA, increased the activity of SOD, glutathione-peroxidase (GSH-Px) in middle 
cerebral artery occlusion (MCAO) rat model (763). Moreover, ND-309 increased the 
brain ATP content and improve mitochondrial energy metabolism (763). Thus, it 
may be potentially useful in developing new treatment for cerebral ischemia injury.  
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1.7.2.23 (2E)-2-{6-[(E)-2-carboxylvinyl]-2,3-dihydroxyphenyl}-3-(3,4-
dihydroxyphenyl)propenoic acid 
(2E)-2-{6-[(E)-2-carboxylvinyl]-2,3-dihydroxyphenyl}-3-(3,4-dihydroxyphenyl) 
propenoic acid is a novel compound designated SMND-309 and has a brain 
distribution (764). SMND-309 is a new derivate of salvianolic acid B which is the 
most abundant salvianolic acids possessing many beneficial action including 
reducing lipid peroxides and scavenging free radicals (678). It has been shown that 
SMND-309 decreased mitochondria production of reactive oxygen species and MDA 
and enhanced activities of mitochondrial respiratory chain complex, SOD and GSH-
Px in MCAO rat model (764). These results indicate that SMND-309 may be used 
for treating stroke.    
 
1.7.2.24 Isopropyl 3-(3, 4-dihydroxyphenyl)-2-hydroxypropanoate  
Isopropyl 3-(3, 4-dihydroxyphenyl)-2-hydroxypropanoate (IDHP) is one of the major 
bioactive metabolites of Danshen with vasodilating acivity (765). Wang et al. 
reported that IDHP showed concentration-dependent vasorelaxant effect through 
inhibition of Ca2+ release from intracellular stores and Ca2+ influx via voltage-
dependent calcium channels and receptor-operated calcium channels, and positive 
regulation of vascular tetraethylammonium-sensitive K+ channels.  
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1.8 Computational approaches in evaluation of chemical characteristics and 
ADME/Tox 
Recently, the use of natural products, including herbal medicine, has been becoming 
increasingly popular worldwide for improving body function or manage numerous 
ailments, despite, in many cases, the lack of evidence for efficacy or long term 
toxicological data. This is not surprising as products have been recognised as sources 
for new drugs. However, due to the complex nature of natural product, the paucity of 
experimental information, and limited applicability and availability of experimental 
tools in ADME/Tox analysis, the natural product derived new drug development 
seems to be hampered in recent times.  
 
The increasing use of natural products in the general population in recent years 
highlights the need for proper safety assessment of these products as many of these 
products do not need rigorous toxicology tests before they enter into market (766). 
The lack of rigorous toxicology tests of these products may be associated with 
increasing number of relevant adverse events reported for these products including 
herbal toxicity. Such as Callilepis laureola induced acute kidney injury, convulsions, 
abdominal pain, diarrhea and vomiting (767-769), herbal extracts or preparations of 
cat’s claw (770) and propolis (771) caused acute renal failure, and Ephedra sinica 
(Ma huang) with hepatoxic effect (772, 773). Thus, the safety issue of natural 
products has been raised.  
 
One of the main reasons hindering many early drug candidates reaching market is the 
unfavourable ADME properties and drug induced toxicity. From a commercial 
perspective, fast and reliable in vitro assessment strategies are needed to filter out 
problematic molecular at the earliest stages of discovery rather than during the more 
costly drug development phases. As a consequence, over the past decade, 
ADME/Tox screening studies have been incorporated earlier in the drug discovery 
phase. Predicting biological fate and toxicological properties of compound has been 
a critical step in early stage of drug development process to avoid late stage attrition 
with huge cost (774-776). It has been widely accepted that not only the efficacy but 
also the ADME/Tox profiles of drug candidates are of importance in optimizing a 
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chemical compound. There have been a number of drugs withdrawn from market due 
to at least partly poor ADME/Tox properties (Table 1. 8), including nomifensine,  
temafloxacin, flosequinan, mibefradil, rezulin, and rofecoxib. It is therefore of 
importance to evaluate both efficacy and ADME and toxicological properties of 
natural compounds.  
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Table 1. 8. Drugs withdrawn from the market. 
Drug name Year of withdrawal Reason for withdrawn 
Drotrecogin alfa (Xigris) 2011 Lack of efficacy  
Rosiglitazone (Avandia)  2010 Risk of heart attacks and death (withdrawn in Europe) 
Gemtuzumab ozogamicin (Mylotarg) 2010 Risks of veno-occlusive disease (withdrawn in the U.S. due to increased)  
Sibutramine (Reductil/Meridia) 2010 Risk of cardiovascular disease (withdrawn in Europe, Australasia, Canada, and the 
U.S).  
Efalizumab (Raptiva) 2009 Risk of progressive multifocal leukoencephalopathy 
Rimonabant (Acomplia)  2008 Risk of severe depression and suicide 
Lumiracoxib (Prexige) 2007–2008 Liver damage 
Pergolide (Permax)  2007 Risk of heart valve damage (withdrawn in the U.S.)  
Tegaserod (Zelnorm)  2008 Heart attack and stroke 
Aprotinin (Trasylol)  2008 Risk of complications or death  
Inhaled insulin (Exubera)  2007 Long-term safety issue and high cost (withdrawn U.K.) 
Ximelagatran (Exanta)  2006 Hepatotoxicity  
Thioridazine (Melleril)  2005 Cardiotoxicity (withdrawn in U.K.) 
Pemoline (Cylert)  2005 Hepatotoxicity  (withdrawn in U.S.) 
hydromorphone extended-release 
(Palladone)  
2005 Overdose dangers when administered with alcohol 
mixed amphetamine salts (Adderall 
XR)  
2005 Risk of stroke  (withdrawn in Canada) 
Co-proxamol (Distalgesic)  2004 Overdose dangers (Withdrawn in U.K.) 
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Table 1. 8. Continued. 
Rofecoxib (Vioxx)  2004 Risk of myocardial infarction  
Trovafloxacin (Trovan)  2001 Risk of liver failure  
Cerivastatin (Baycol, Lipobay)  2001 Risk of rhabdomyolysis 
Rapacuronium (Raplon) 2001 Risk of fatal bronchospasm 
Cisapride (Propulsid)  2000 risk of cardiac arrhythmias  
Troglitazone (Rezulin)  2000 Risk of hepatotoxicity  
Phenylpropanolamine (Propagest, 
Dexatrim)  
2000 Risk of stroke  
Amineptine (Survector)  2000 Hepatotoxicity, dermatological side effects, and abuse potential. 
Temazepam (Restoril, Euhypnos, 
Normison, Remestan, Tenox, 
Norkotral)  
1999 Diversion, abuse, and a relatively high rate of overdose deaths  
( withdrawn in Sweden and Norway)  
Grepafloxacin (Raxar)  1999  Prolonged QT interval 
Astemizole (Hismanal)  1999 Arrhythmias because of drug interactions  
Levamisole (Ergamisol)  1999 Agranulocytosis  
Terfenadine (Seldane, Triludan) 1998 Risk of cardiac arrhythmias  
Tolcapone (Tasmar)  1998 Hepatotoxicity 
Mibefradil (Posicor)  1998  Dangerous durg interactions 
Tolrestat (Alredase)  1997  Hepatotoxicity 
Chlormezanone (Trancopal)  1996  Toxic epidermal necrolysis 
Alpidem (Ananxyl) 1996  Hepatotoxicity 
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 Table 1. 8. Continued. 
Flosequinan (Manoplax)  1993  Risk of hospitalization or death (Withdrawn in U.S.) 
Temafloxacin  1992  Allergic reactions and cases of hemolytic anemia (Withdrawn in U.S.) 
Terodiline (Micturin)  1991  Prolonged QT interval 
Triazolam  1991 Risk of psychiatric adverse drug reactions (withdrawn in U.K.) 
Etretinate  1990s  Risk of birth defects and narrow therapeutic index 
Nomifensine (Merital)  1986  Risk of hemolytic anemia  
Methaqualone  1984  Risk of addiction and overdose 
Phenacetin  1983  Risk of cancer and kidney disease 
Zimelidine  1983  Risk of Guillain-Barré syndrome 
Ticrynafen  1982  Risk of hepatitis 
Phenformin and Buformin  1978  Risk of lactic acidosis 
Diethylstilbestrol  1970s Risk of teratogenicity 
Lysergic acid diethylamide  1950s–1960s  Drug abuse 
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Chemical characteristics of a molecule determine the drug’s behaviour in 
pharmacokinetic, pharmacodynamic and toxicitity aspects (Figure 1. 8). The 
structural properties of compounds, including molecular weight, H-bonds, 
lipophilicity, polar surface area (PSA), ionization constant (pKa), shape and 
reactivity, interact with the physicochemical environment affecting physicochemical 
properties, including solubility, permeability and chemical stability. When these 
structural properties interact with proteins, they affect biochemical properties, 
including metabolism, transporter affinity, binding and target affinity. At the highest 
level, when the physicochemical and biochemical properties interact with living 
systems they cause pharmacokinetics (PK), pharmacodynamics (PD), and toxicity, 
including clearance, half-life, bioavailability and LD50. By modifying the structure 
we may be able to control the PK, PD and toxicity properties of the compounds.  
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Figure 1. 8. Chemical characteristics determine the profiles of pharmacokinetics, 
pharmacodynamics and toxicity. 
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There are a number of chemical descriptors in evaluation the profile of ADME/Tox 
(Table 1. 9). The most important physicochemical properties include pKa, 
lipophilicity (logP/D), solubility (logS), and permeability. pKa is a useful 
physicochemical property accounting for thermodynamics, which modulates the 
charge state and eventually solubility and other key properties of drug candidate. It is 
helpful for understanding binding of drug candidate to targets. LogP/D is a 
determinant to quantitatively describe a drug candidate’ ability to partition in the oily 
phase or biological membranes. It is also frequently utilized in explaining behaviour 
of some compounds in the ADME/Tox assays. Lipophilicy greatly affects solubility, 
permeability, and the other drug properties. Being a critical parameter affecting both 
in vitro and in vivo attributes, solubility measures the ability of drug candidates to 
dissolve and remain in aqueous or other physiological media. 
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Table 1. 9. Chemical descriptors in evaluation the profile of ADME/Tox.  
Chemical 
property 
Description ADME relevance 
LogP Water-octanol partition coefficient. The ratio of the respective concentrations of a 
compound in the octanol and water phases of a 2-phase system at equilibrium. Measures 
lipophicility.  
Oral bioavailability; BBB 
partitioning; intestinal absorption; 
plasma protein binding 
LogS Aqueous or water solubility usually expressed as mol/L or mg/mL Oral bioavailability; BBB 
partitioning; plasma protein 
binding 
LogD The apparent water-octanol partition (or distribution) coefficient measured for ionic 
species. A combination of logP and pKa 
Permeability coefficient; volume 
of distribution 
pKa The negative log of the acid ionisation constant. It describes the ability of an ionisable 
group of an organic compound to donate a proton in an aqueous medium 
Water solubility; volume of 
distribution 
MW The sum of the atomic weights of all the atoms in a molecule  Oral bioavailability; BBB 
partitioning; CYP interactions 
PSA The surface area  of N, O, P and S atoms  
 
Oral bioavailability; intestinal 
absorption; BBB partitioning 
No. of H-bond 
donors  
Number of relatively electronegative atoms such as N, O, S or F with attached hydrogen 
atoms 
Oral bioavailability; BBB 
partitioning; intestinal absorption 
No. of H-bond 
acceptors  
Number of relatively electronegative atoms such as N, O, S or halogens with an available 
lone pair 
Oral bioavailability; BBB 
partitioning 
No. of rotatable 
bonds 
Number of sp3 (single) bonds, not in a ring, bound to a non-terminal heavy atom Oral bioavailability; BBB 
partitioning 
Molar refractivity Molar refractivity is a measure of the volume occupied by an atom or group. It varies with 
temperature, index of refraction and pressure 
Oral bioavailability; intestinal 
absorption 
Molecular 
volume  
Volume occupied by 1 mole of molecule; it equals the molecular weight divided by the 
density 
CYP interactions; water 
solubility; intestinal absorption; 
oral 
bioavailability; BBB partitioning 
Dipole moment  A measure of the electrical polarity of a molecule with partially charged atoms Water solubility, CYP 
interactions; serum protein 
binding 
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Table 1. 9. Continued. 
Free water 
solvation energy 
Free energy of dissolving a compound in water BBB partitioning; permeability 
coefficient 
Radius of 
gyration 
Distance between the axis of a rotating body and its centre of gyration. A combined 
measure of molecular volume and shape 
CYP interactions 
Miscellaneous 
topological 
descriptors 
These features describe the bond connectivity, bond types and overall shape for a given 
molecule 
Water solubility; oral absorption; 
serum protein binding 
Adapted from Wishart et al. (777).  
Abbreviation: BBB,blood-brain barrier; CYP, cytochrome P450; F, fluoride; H-bond, hydrogen bond;  N, nitrogen; O, oxygen; P, 
phosphate; pKa, ionisation constant; PSA, polar surface area; S, sulphate; WM, molecular weight.  
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These key physicochemical parameters are critical for the predictability of drug 
ADME/Tox properties such as absorption, cell penetration, access to the brain, 
volume of distribution, plasma protein binding, metabolism, and toxicity, as well as 
biopharmaceutical behaviour. Ionization constant is a critical physicochemical 
parameter on thermodynamic property to manipulate the charge state. Consequently, 
it affects solubility, permeability, and other key properties of drug candidate. 
Lipophilicity is the key determinant factor in many ADME processes including 
absorption and distribution and is also a factor influencing the interaction with drug 
metabolizing enzymes and transporters. Solubility and permeability drive the oral 
absorption and bioavailability.  
 
Due to the high attrition rate from leads to drug candidate, it is necessary to assess 
and optimize the comprehensive drug physicochemical properties. The challenge in 
optimization is that the physicochemical properties of a molecule are all strongly 
interlinked. To date, there are numerous studies on analyzing and manipulating 
physicochemical properties of a molecule, pKa, log P/D, logS, and permeability (778, 
779). The advance in in silico approaches in last decades has brought significant 
changes in drug discovery and development process, in particular, in studying 
ADME/Tox properties in early drug discovery and development stage and avoids 
late-stage expensive drug attrition (774, 780). Compared to traditional cell- or 
animal-based experimental procedures, which are particularly expensive, lengthy, 
uninformative, or offensive ones, in silico methods provide a rapid and inexpensive 
option to study the biological fate or properties of new chemical entity or drug 
candidates by using powerful computational approaches. Due to the complex nature, 
and high risk and cost in drug discovery and development, proper predication of the 
biological fate and toxicity of a new chemical entity or drug candidate in the early 
stage of drug discovery process will be important in improving the success rate of 
drug discovery. However, in some cases, these profiles are often difficult to be 
ascertained due to the complex process of ADME and toxic features of new chemical 
entity (781-783).  
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There are recognised difficulties in conventional drug discovery and development 
including the large number of compounds for in vivo studies; the lack of reliable 
high-throughput in vitro assays; the inability of in vitro and animal models to predict 
the toxicities for the large number of compounds. Thus, in silico approaches are 
highly valuable in studying the ADME/Tox properties of compounds in early stage 
of drug development including various metabolic events with the participation of 
Phase I and/or Phase II enzymes (e.g. metabolic stability or microsomal stability, 
biotransformations, prediction of metabolites and sites of metabolism, and 
determination of rate of metabolic reaction and ligand regioselectivity), binding to 
specific metabolic enzymes or drug transporters (prediction of ligand-enzyme 
interactions, calculation of binding energy, discrimination inhibitor versus substrate 
and identification of mechanism-based inhibition), and alteration on metabolizing 
enzymes, drug transporters, or nuclear receptors (784-791).  
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1.9 Aim of thesis 
Endothelial dysfunction has been implicated in the pathogens of vascular diseases. 
eNOS uncoupling, characterized as reduced NO generation and increased superoxide 
production by eNOS,  is a mechanism of endothelial dysfunction with a disturbance 
of vascular homeostasis. Danshen, a versatile natural product with a wide spectrum 
of activities, is mainly used to treat vascular diseases including cardiovascular and 
cerebrovascular diseases. The vascular protective effects of Danshen is attributable 
to beneficial actions of its numerous pharmacologically active components.  
 
However, the physicochemical properties of numerous Danshen compounds have not 
been evaluated. These properties are accounting for the ADME/Tox profile of 
Danshen compounds and are determinant factors responsible for the varying 
pharmacological activities, and the relationship between chemical characteristics and 
the drug potential of Danshen compounds. Thus, it is necessary to analyse the 
physicochemical properties of Danshen compounds. Additionally, the increasing 
application of natural products for various conditions rises safety concerns associated 
with natural products. Thus, it needs to evaluate the biological fate, toxicity and drug 
interaction of natural products.   
 
In addition, the effect of Danshen components including Tan I, Tan IIA and CT on 
eNOS uncoupling have not been previously studies. Thus, it is necessary to 
investigate in greater detail the effect of active Danshen compounds on eNOS 
uncoupling and the underlying molecular mechanism.   
 
Therefore, the specific aims of this thesis are:  
1) To analyse the physicochemical properties of Danshen compounds. We will 
evaluate the physicochemical parameters including most important 
physicochemical properties Based on physicochemical parameters; we will 
assess potential toxicity and predict drug-likeness of Danshen components.  
2) To evaluate biological fate, toxicity and drug interaction of natural products 
by in silico approaches. Particularly, we will focus on drug metabolizing 
enzymes, transporters and nuclear receptors, including CYP450, uridine 
diphosphate glucuronosyltransferases (UGTs), P-gp, organic cation 
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transporters (OCTs), constitutive androstane receptor (CAR) and pregnane X 
receptor (PXR).  
3) To set up an in vitro cell based model of high glucose induced eNOS 
uncoupling in EA.hy926 cells. In this part, we will employ biochemical 
approaches to examine experimental hyperglycaemia condition on cellular 
productions of superoxide and NO; test the expression of NOX4 and HSP90 
and the ratio of BH4 to BH2.  
4) To examine the effects of Tan I, Tan IIA and CT on high glucose induced 
eNOS uncoupling in EA.hy926 cell line, including their effects on superoxide 
and NO production, eNOS expression, BH4 and BH2 levels, the expressions 
of NOX4 and HSP90. 
5) To examine the effects of new tanshinone derivatives on high glucose 
induced eNOS uncoupling in EA.hy926 cell line by assessing the effect on 
superoxide and NO production, the ratio of eNOS dimer to monomer and 
BH4 to BH2, the expressions of NOX4 and HSP90. 
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2 Chapter 2. Methodology  
2.1 Materials and Methods 
2.1.1 Chemicals and reagents 
All cell culture reagents were purchased from sigma (St. Louis, MO). Primary 
antibodies for PI3K p110β subunit (sc-100407), HSP90 (sc-69703), β-actin (sc-
47778), GTPCH1 (sc-271482) and DHFR (sc-74594) were obtained from Santa Cruz 
Biotechnology (Santa Cruz, CA); NOX4 antibody (ab109225) was purchased from 
Abcam (Cambridge, UK); eNOS antibody (SAB4300435), protease inhibitor cocktail 
(P8340), diphenylene iodonium (DPI) and dimethyl sulfoxide (DMSO) were 
obtained from sigma (St. Louis, MO). MnTBAP, DAF2-DA, L-arginine 
hydrochloride and NG-nitro-L-arginine methyl ester (L-NAME) were purchased from 
Cayman Chemical (Ann Arbor, MI). Tan I, Tan IIA and CT was purchased from 
National Institute for the Control of Pharmaceutical and Biological Products (Beijing, 
China). AC1 and AC2 were synthesized by department of Chemistry, RMIT 
University. All tested Danshen compounds were dissolved initially in DMSO and 
subsequently diluted to the desired experimental concentrations with culture media.  
 
2.1.2 Computational approach 
To carry out the in silico study, we retrieved the structure of Danshen compounds 
from two databases: PubChem Compound 
(http://www.ncbi.nlm.nih.gov/pccompound/) and ChemSpider 
(http://www.chemspider.com/). To draw the 2D structure, ChemBiodraw Ultra 12.0 
was used. To analyse the physicochemical properties of Danshen compounds, the 
softwares: OSIRIS Property Explorer (http://www.organic-chemistry.org/prog/peo/), 
ALOGPS (http://www.vcclab.org/lab/alogps/) and ACD/ChemSketch 
(http://www.acdlabs.com/products/draw_nom/draw/chemsketch/) were used. To 
assess the toxicity and drug potential, OSIRIS Property Explorer 
(http://www.organic-chemistry.org/prog/peo/) was employed.  
 
2.1.3 Computational approach work-flow 
To conduct the computational evaluation of Danshen compounds, we follow the 
work flow as in (Figure 2. 1). Briefly, literature review was conducted and a 
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chemical library of Danshen compounds was established. Then, the structural and 
physicochemical properties of Danshen compounds were analysed, followed by 
assessing drug-like and nondrug-like properties according to Rule of 5 (Ro5) (792). 
If a compound violated Ro5, then it was categorized into non drug-like group; if not, 
it was classified into drug-like group. Finally, the potential toxicity risks and drug 
potential were analysed.  
117 
 
 
Figure 2. 1. Work flow for computational study to evaluate pharmacological effect of Danshen compounds.  
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2.1.4 Drug-likeness value 
Drug-likeness value was evaluated by OSIRIS Property Explorer 
(http://www.organic-chemistry.org/prog/peo/) according to the following Equation 2. 
1. 
 
 
Equation 2. 1  
 
 
 
This approach was based on a list of about 5300 distinct substructure fragments with 
associated drug-likeness scores. The fragment list was created by shredding 3300 
traded drugs as well as 15000 commercially available chemicals (Fluka) yielding a 
complete list of all available fragments (http://www.organic-
chemistry.org/prog/peo/). 
 
2.1.5 Drug score 
The drug score of Danshen compounds was calculated by multiplying contributions 
of the individual properties with the Equation 2. 2. It combined with drug-likeness, 
clogP, clogS, molecular weight and toxicity risks. ds was the drug score. si was the 
contributions calculated directly from of clogP, clogS, molweight and drug-likeness 
(pi) via Equation 2. 3, which describes a spline curve. Parameters a and b were (1, -
5), (1, 5), (0.012, -6) and (1, 0) for clogP, clogS, molweight and drug-likeness, 
respectively. ti was the contributions taken from the 4 toxicity risk types. The ti 
values were 1.0, 0.8 and 0.6 for no risk, medium risk and high risk, respectively 
(http://www.organic-chemistry.org/prog/peo/). 
 
 
Equation 2. 2 
 
 
 
 
 
 +  
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Equation 2. 3 
 
 
 
 
2.1.6 Cell culture 
The HUVEC cell line EA.hy926 was kindly provided by Dr. Shanhong Ling (793, 
794), Monash University Central and Eastern Clinical School, Melbourne, Victoria, 
Australia. The EA.hy926 cell line was previous established in the pathology 
department, University of North Carolina (Chapel Hill, NC, USA). The cells were 
cultured in low glucose (5.5 mM) or high glucose (35 mM) Dulbecco’s modified 
Eagle’s medium supplemented with 10% FBS, 0.5% streptomycin/penicillin and 
HAT media supplement (100 µM hypoxanthine, 0.4 µM aminopterin, and 16 µM 
thymidine) in 5% CO2 humidity atmosphere at 37℃. Cells at passage 29-35 were 
used in the study.  
 
2.1.7 MTT assay 
MTT assay was used to test the viability of EA.hy926 cell line, which was performed 
mainly according to the method of Mosmann (795) with some modifications. All the 
experiments were repeated five times with four parallel wells. The spectrophotometer 
(BMG Labtech) was calibrated to zero absorbance using culture without cells. The 
relative cell viability (%) related to control wells containing cell culture media 
without Danshen compounds was calculated by [A]test/[A]control×100. 
 
2.1.8 Cell treatment 
Tan I, Tan IIA, CT, AC1 and AC2 were dissolved into DMSO with a stock 
concentration of 1.0 mM, and were freshly diluted to the desired concentration (1, 3, 
and 10 µM) with culture media. The final concentration of DMSO in the five 
Danshen compounds treated cells was at 0.08% (v/v). The control cells received the 
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same amount of DMSO treatment without Danshen compounds. For experiments, 
cells were cultured for 4-6 hr in reduced serum media (4%) prior to treatment in 6-
well or 12-well plates at a density of 4×105 cells/well. Cells were treated with 
Danshen compounds for 24 hr after culturing in 35 mM high glucose for 24 hr 
without specific indication (Figure 2. 2).  
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Figure 2. 2. Cell treatment.  
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2.1.9 Detection of NOXs-dependent superoxide production 
NOXs-dependent superoxide production produced by ECs was measured by the 
lucigenin (5 µM) enhanced chemiluminescence assay (796, 797). In brief, cells were 
cultured in reduced serum media for 4 hr after seeding in 12-well plates for 24 hr, 
and then treated with high glucose for 24 hr initially, followed by the treatment with 
Danshen compounds for another 24 hr under high glucose condition. Cell samples, 
prepared by homogenizing with a freezing-thawing method in Kreps-HEPES buffer, 
were transferred into 96-well OptiPlate. NADPH (100 µM) and lucigenin (5 µM) 
were added after the background reading. Luminescence was then measured every 
15s along an interval of 45min using a plate reader luminometer (BMG Labtech).  
 
2.1.10 NO measurement 
Cells were washed with Krebs Ringer Buffer (120 mM NaCl, 4.8 mM KCl, 0.54 mM 
CaCl2, Mg2SO4•7H2O, 11 mM glucose, 15.9 mM NaH2PO4, pH 7.2) and pre-
incubated with L-arginine (100 µM in KRP, 5 min, 37℃) (798, 799). In some 
experiments, L-NAME (100 µM) was added 5min before the addition of L-arginine. 
Subsequently, 1 µM DAF-2DA was added and cells were incubated in the dark (37℃ 
for 5 min). Then the fluorescence was measured at room temperature using a 
spectrofluorimeter with excitation wavelength set at 495 nm and emission 
wavelength at 515 nm (BMG Labtech). The band width was 10 nm for both 
excitation and emission.  
 
2.1.11 Western blot analysis 
Cells were washed with pre-cold PBS, lysed with lysis buffer [50 mmol Hepes (pH 
7.5), 150 mmol NaCl, 10% Glycerol, 1.5 mmol MgCl2 , 1% Triton x 100, 1 mmol 
EDTA (pH 8.0), 10 mmol NaPPi, 10 mmol NaF and protease inhibitor cocktail] and 
centrifuged for 10 min at 13,000 rpm at 4℃ (800). Equal amounts of cellular proteins 
were resolved by SDS-PAGE sample loading buffer (4×+2% mercaptoethanol). 
Samples were electrophoresed on 12% SDS-PAGE mini gels after thermal 
denaturation for 5 min at 95℃, and were transferred to nitrocellulose membranes. 
Membranes were probed with targeted primary antibodies and blotted with 
respective secondary antibodies. Low temperature western blot assay was used to 
examine the ratio of eNOS dimer and monomer (53). Protein samples without 
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thermal denaturation were electrophoresed on 6% SDS-PAGE mini gels and 
transferred to nitrocellulose membranes. Membranes were probed with anti-eNOS 
primary antibody and blotted with respective secondary antibody. Proteins levels 
were normalized to the matching densitometric values of internal control. 
 
2.1.12 Measurement of intracellular levels of biopterins 
The intracellular biopterin levels (oxidized and reduced forms) were determined by 
HPLC as previously described (431, 801, 802)[13,45,58]. Briefly, ECs were lysed 
and suspended in 12-well plates with cold extract buffer (50 mM Tris-HCl, pH7.4; 1 
mM DTT; 1mM EDTA; containing 0.1 µM neopterin). Protein concentration was 
measured using BCA protein assay. Proteins were removed by adding 10 µl of a 1:1 
mixture of 1.5 M HClO4 and 2 M H3PO4 to 90 µl of extracts, followed by 
centrifugation. To determine total biopterins (BH4, BH2, and biopterins) by acid 
oxidation, 10 µl of 1% iodine in 2% KI solution was added to 90 µl protein-free 
supernatant. To determine BH2 and biopterins by alkaline oxidation, 10 µl of 1 M 
NaOH was added to 80 µl of extract, then 10 µl of 1% iodine/KI solution. Samples 
were incubated at room temperature for 1 hr in the dark. After incubation, Alkaline-
oxidation samples were then acidified with 20 µl of 1M H3PO4. Excessive iodine 
was reduced by adding 5 µl of fresh ascorbic acid (20 mg/ml). Samples were 
centrifuged and 10 µl of supernatant was auto-injected in reverse phase HPLC 
system (Shimazu, Class-VP, Kyoto, Japan) equipped with a welchrom-C18 column 
(5 µm, 4.6×150 mm). The mobile phase was methanol–water (5:95, v/v) running at 
0.8 ml/min. Fluorescence detection (350 nm excitation, 450 nm emission) was 
performed using an RF-10AXL (Shimazu, Kyoto, Japan). BH4 concentration, 
expressed as pmol/mg protein, was calculated by subtracting BH2+biopterin from 
total biopterins. 
 
 
2.1.13 Statistical Analysis 
Results are expressed as mean ± S.E.M. Statistical analyses were performed by one-
way ANOVA with Dunnett test. Values of p < 0.05 were considered statistically 
different. 
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3 Chapter 3. Evaluation of physicochemical properties and drug potential of 
Danshen compounds 
3.1 Introduction 
The structure properties of a compound determine its physicochemical and 
biochemical properties, which drive the profiles of ADME/Tox in living system 
(Figure 1. 8). Unfavourable ADME/Tox profiles such as pharmacokinetic failure or 
toxicity are the major reasons for preventing drug candidate reaching the market or 
withdrawal of drug from the market at huge cost (803) (Table 1. 8). In order to avoid 
this situation, filtering out high risk compounds at the earliest stages of drug 
discovery is needed. To do this, it needs to take into account all physicochemical 
properties, such as logP, logS. These physicochemical properties are valuable in the 
prediction of ADME/Tox profiles of candidate compounds.  
 
Drug-likeness aids in optimizing the ADME/Tox profile by analyzing the properties 
of a given compound. A number of molecular descriptors have emerged as 
reasonable informative and predictive, in particular, Rule-of-Five (Ro5), and been 
accepted and applied in drug discovery and development (792). The Lipinski’s Ro5 
states that an orally active drug should respect: 1) a molecular weight < 500 Daltons, 
2) a limited lipophilicity (expressed by LogP < 5, with P=[drug]org./[drug]aq.), 3) H-
bond donors < 5 (expressed as the sum of OHs and NHs), 4) H-bond acceptors < 10 
(expressed as the sum of Os and Ns). The Ro5 does not predict whether the 
compound is pharmacologically active, although it describes possible 
pharmacokinetics and properties of the compound in the human body, including 
ADME/Tox.  
 
Danshen consists of over 100 of compounds showing a great diversity of 
physicochemical properties. Among of them, there are a number of compounds 
exerting pharmacological activities. However, so far, the relationship between 
physicochemical characteristics and drug potential has not been fully elucidated. 
Therefore, the work described in this chapter aims to analyse the physicochemical 
characteristics and properties for all known Danshen compounds using opened 
computational approaches. 
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3.2 Materials and methods 
See Chapter 2, Section 2.1.2 to 2.1.5.  
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3.3 Results 
3.3.1.1 Physicochemical property of Danshen compounds 
The physicochemical properties of Danshen compounds are summarized in Table 3. 
1. There were 64 lipophilic compounds and 34 hydrophilic compounds evaluated. 
The distribution of clogP and clogS were graphed in Figure 3. 1 and Figure 3. 2. 
The value of logP was from -0.46 to 6.87; the range of logS was from -9.9 to 5.06. 
The molecular weight ranged from 138 to 746 Da.  
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Table 3. 1. Physicochemical properties of 94 collected Danshen compounds. 
Compound 
number 
Compound name Drug 
score 
Drug-
likeness 
LogS LogP MW 
(Da) 
1 Cryptotanshinone 0.36 -7.06 -4.49 3.38 296 
2 Danshenxinkun A 0.42 -1.27 -4.77 3.16 296 
3 Danshenxinkun B 0.41 0.91 -5.28 4.11 280 
4 1,2 Didehydromiltirone △1,2 0.24 -7.61 -4.98 4.46 282 
5 Dehydromiltirone 0.23 -5.94 -5.11 4.43 280 
6 Didydroisotanshinone I 0.58 1.57 -5.25 3.48 278 
7 15,16-Dihydrotanshinone I 0.37 -2.67 -4.69 3.42 278 
8 15,16-Dihydrotanshinol B 0.42 -3.8 -3.69 2.84 298 
9 Dihydronortanshinone 0.4 -7.04 -4.01 2.55 282 
10 Dihydrotanshinone I 0.37 -2.67 -4.69 3.42 278 
11 1,2-Dihydrotanshiquinone 0.25 -6.03 -5.27 3.69 278 
12 1,2-Dihydrotanshinone I △15,16 0.33 -4.87 -3.69 3.09 280 
13 6,12-Dihydroxyabieta-5,8,11,13-
tetraen-7-one 
0.31 -5.15 -4.91 4.19 314 
14 Ferruginol 0.26 -6.42 5.06 5.18 286 
15 7a-hydroxyallyl-royleanone 0.4 -5.44 3.47 3.18 330 
16 3-Hydroxycryptotanshinone 0.4 -4.04 -4.09 2.44 312 
17 17-Hydroxycryptotanshinone 0.4 -7.9 -3.98 2.32 312 
18 17-Hydroxytanshindiol B 0.44 -4.6 -3.19 1.88 314 
19 3-Hydroxymethylenetanshinquinone 0.34 -6.88 -5.03 2.79 294 
20 3-Hydrotanshinone IIA 0.3 -5.11 -5.66 3.05 310 
21 3-Hydroxytanshinone IIB 0.34 -7.21 -5.15 2.09 326 
22 Hydrotanshinone IIA 0.31 -5.8 -5.51 3.1 310 
23 Isocryptotanshinone 0.35 -2.82 -5.05 3.33 296 
24 Isotanshinone I 0.31 -0.57 -6.71 4.43 276 
25 Isotanshinone II 0.24 -5.08 -6.51 4.28 294 
26 1-Ketoisocryptotanshinone 0.36 -4.87 -4.67 2.77 310 
27 Methyldihydornortanshinonate 0.25 -9.27 -4.09 2.38 340 
28 4-Methylenemiltirone 0.27 -9.08 -4.35 4.21 266 
29 Methylenetanshiquinone 0.3 -9.93 -5.43 3.62 278 
30 Methyltanshinonate 0.19 -10.4 -5.66 2.98 338 
31 Methylenetanshinone 0.33 -9.91 -5.09 3.31 264 
32 Miltirone 0.24 -7.61 -4.98 4.46 282 
33 Miltirone I 0.23 -3.27 -5.18 4.61 264 
34 Miltionone II 0.47 -2.04 -3.02 2.88 312 
35 Monodydroxytanshinone I 0.28 -4.28 -5.96 3.73 292 
36 Neocryptotanshinone 0.36 -5.78 -4.57 3.01 314 
37 Neocryptotanshinone II 0.37 -3.91 -4.65 3.16 270 
38 Neo-przewaquinone A 0.1 -9.38 -9.9 6.87 542 
39 Neotanshinlactone 0.63 0.74 -4.39 2.92 266 
40 1-Oxomiltirone 0.24 -5.4 -5.16 3.96 296 
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Table 3. 1. Continued. 
41 3,4-Phenanthrenedione 0.26 -5.23 -3.39 2.97 310 
42 Przewaquinone A 0.3 -8.49 -5.6 2.94 310 
43 Przewaquinone B 0.3 -4.01 -5.8 3.09 292 
44 Przewaquinone C 0.32 -4.81 -5.27 3.44 296 
45 Royleanone-4 0.43 -4.73 -2.89 1.96 346 
46 Salviol 0.32 -3.7 -4.66 4.35 302 
47 Sugiol 0.27 -5.84 -4.96 4.99 286 
48 Sodium tanshinone IIA sulfonate 0.3 -8.63 -4.82 3.84 396 
49 Tanshinaldehyde 0.23 -10.3 -4.19 2.33 310 
50 Tanshindiol A 0.18 -13.38 -5.55 2.92 310 
51 Tanshindiol B 0.36 -3.76 -4.87 2.61 312 
52 Tanshindiol C 0.36 -3.76 -4.87 2.61 312 
53 Tanshinlactone 0.58 0.18 -4.48 2.73 266 
54 Tanshinol A 0.3 -4.33 -5.8 3.09 292 
55 Tanshinol B 0.32 -4.81 -5.27 3.44 296 
56 Tanshinone I 0.26 -3.95 -6.26 4.03 276 
57 Tanshinone IIA 0.27 -8.52 -6.06 3.88 294 
58 Tanshinone IIB 0.18 -13.38 -5.55 2.92 310 
59 Tanshinone V 0.39 -10.08 -4 2.95 314 
60 Tanshinone VI 0.38 -5.55 -4.21 3.1 296 
61 1,2,15,16-Tetrahydrotanshiquinone 0.33 -4.87 -3.69 3.09 280 
62 Trijuganone 0.25 -9.27 -4.09 2.38 340 
63 Trijuganone A 0.61 1.41 -4.96 3.18 294 
64 Trijuganone B 0.33 -4.87 -3.69 3.09 280 
65 Caffeic acid 0.19 1.62 -1.41 1.03 180 
66 Danshensu 0.86 1.2 -0.87 0.15 198 
67 Demethyl lithospermate 0.33 -1.59 -3.5 3.04 566 
68 Ethyl lithospermate 0.28 -5.24 -3.67 3.02 566 
69 Ethyl lithospermate B 0.19 -5.24 -4.49 3.64 746 
70 Ferulic acid 0.3 1.12 -1.72 1.23 194 
71 Isoferulic acid 0.89 1.78 -1.72 1.23 194 
72 Isosalvianolic acid C 0.26 -3.09 -5.28 3.62 492 
73 Lithospermic acid 0.36 -1.69 -3.24 2.13 538 
74 Lithospermic acid B 0.26 -1.6 -4.06 2.75 718 
75 Methyl rosmarinate 0.48 -1.97 -2.36 2.1 374 
76 Prolithospermic acid 0.85 -2.62 -2.42 1.51 358 
77 Protocatechualdehyde 0.18 -3.64 -1.35 1.07 138 
78 Protocatechuic acid 0.43 -0.12 -1.04 0.9 154 
79 Rosmarinic acid 0.49 -2.07 -2.23 1.65 360 
80 Salvinal 0.15 -6.71 -4.88 3.48 356 
81 Salviaflaside 0.35 -6.77 -2.12 -0.46 522 
82 Salvianolic acid A 0.35 -1.94 -3.78 3.08 494 
83 Salvianolic acid B 0.26 -1.6 -4.06 2.75 718 
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Table 3. 1. Continued. 
84 Salvianolic acid C 0.3 -1.94 -4.87 3.48 492 
85 Salvianolic acid D 0.47 -1.82 -2.21 0.97 418 
86 Salvianolic acid E 0.27 -1.41 -3.8 2.45 718 
87 Salvianolic acid F 0.8 1.72 -2.95 2.47 314 
88 Salvianolic acid G 0.52 -1 -3.68 2.03 340 
89 Salvianolic acid H 0.31 -2.46 -3.71 3 538 
90 Salvianolic acid I 0.41 -0.41 -3.71 3 538 
91 Salvianolic acid J 0.36 -1.6 -3.36 1.98 538 
92 Salvianolic acid K 0.53 0.7 -2.69 1.17 556 
93 Salvianolic acid L 0.35 1.15 -4.32 3.54 716 
94 Vanillic acid 0.35 -1.31 -1.35 1.1 168 
All data were generated by OSIRIS Property Explorer. 
Abbreviation: Da, Dalton; MW, molecular weight.  
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Figure 3. 1. Distribution of calculated lipophicility of 94 Danshen compounds. LogP 
was calculated by using OSIRIS Property Explorer.  
 
 
 
 
 
Figure 3. 2. Distribution of calculated solubility of 94 Danshen compounds. LogS 
was calculated by using OSIRIS Property Explorer. 
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3.3.1.2 Violation of Ro5 
After analysing physicochemical properties, all tested Danshen compounds were 
categorized into drug-like or nondrug-like according to Ro5. Among ninety four 
Danshen compounds, there were eighteen compounds which violated Ro5 (Table 3. 
2). There were two lipophilic compounds, ferruginol and neo-przewaquinone A, 
violated the Ro5 with a logP value of 5.18 and 6.87, respectively. However, there 
were sixteen hydrophilic compounds broke Ro5, which was mainly due to the 
violation of molecular weight, to a lesser extent, H-bond donor and acceptor. Thus, 
Danshen compounds were druggable. The result was summarised in Table 3. 2.  
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Table 3. 2. Violation of Ro5 among 94 collected Danshen compounds. 
Compound number Compound name Violation of Ro5 
14 Ferruginol LogP 
38 Neo-przewaquinone A MW,LogP 
67 Demethyl lithospermate MW 
68 Ethyl lithospermate MW, H-bond donor 
69 Ethyl lithospermate B MW, H-bond donor 
73 Lithospermic acid MW, H-bond donor 
74 Lithospermic acid B MW, H-bond donor 
81 Salviaflaside MW, H-bond donor 
82 Salvianolic acid A H-bond donor 
83 Salvianolic acid B MW, H-bond donor 
84 Salvianolic acid C H-bond donor 
85 Salvianolic acid D H-bond donor 
86 Salvianolic acid E MW, H-bond donor 
89 Salvianolic acid H MW, H-bond donor 
90 Salvianolic acid I MW, H-bond donor 
91 Salvianolic acid J MW, H-bond donor 
92 Salvianolic acid K MW, H-bond donor 
93 Salvianolic acid L MW, H-bond donor 
All data were generated by OSIRIS Property Explorer and ACD/ChemSketch. 
Abbreviation: H-bond, hydrogen bond; MW, molecular weight; Ro5, Rule-of-Five.  
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3.3.1.3 Toxicity risk assessment 
The toxicity risks for the drug-like Danshen compounds were assessed on 
mutagenicity, tumorigenicity, irritating effects and reproductive effects. For 
lipophilic compounds, 15 compounds were predicted to be irritating, 3 compounds to 
be mutagenic and 1 compound to have reproductive effects. No lipophilic compound 
predicted to be tumorigenic. For hydrophilic compounds, 5 with mutagenicity, 2 with, 
tumorigenicity, 3 with, irritanting effects and 1 with reproductive effects (Table 3. 3). 
The majority of evaluated compounds had low toxicity and only a small number of 
compounds possessed high toxicity risk. Therefore, most 94 Danshen compounds 
were predicted as low toxicity (Figure 3. 3).  
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Table 3. 3. Potential toxicity risks of drug-like Danshen compounds.  
Compound 
number 
Compound name Mutagenicity Tumorgenicity Irritating effect Reproductive effect 
1 Cryptotanshinone L L L L 
2 Danshenxinkun A L L L L 
3 Danshenxinkun B L L M L 
4 1,2 Didehydromiltirone △1,2 L L M L 
5 Dehydromiltirone L L M L 
6 Didydroisotanshinone I L L L L 
7 15,16-Dihydrotanshinone I L L L L 
8 15,16-Dihydrotanshinol B L L L L 
9 Dihydronortanshinone L L L L 
10 Dihydrotanshinone I L L L L 
11 1,2-Dihydrotanshiquinone L L M L 
12 1,2-Dihydrotanshinone I △15,16 L L M L 
13 6,12-Dihydroxyabieta-5,8,11,13-tetraen-7-one L L L L 
15 7a-hydroxyallyl-royleanone L L L L 
16 3-Hydroxycryptotanshinone L L L L 
17 17-Hydroxycryptotanshinone L L L L 
18 17-Hydroxytanshindiol B L L L L 
19 3-Hydroxymethylenetanshinquinone L L L L 
20 3-Hydrotanshinone IIA L L L L 
21 3-Hydroxytanshinone IIB L L L L 
22 Hydrotanshinone IIA L L L L 
23 Isocryptotanshinone L L L L 
24 Isotanshinone I L L L L 
25 Isotanshinone II L L L L 
26 1-Ketoisocryptotanshinone L L L L 
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Table 3. 3. Continued. 
27 Methyldihydornortanshinonate M L M L 
28 4-Methylenemiltirone L L M L 
29 Methylenetanshiquinone L L L L 
30 Methyltanshinonate M L M L 
31 Methylenetanshinone L L L L 
32 Miltirone L L M L 
33 Miltirone I L L M L 
34 Miltionone II L L L L 
35 Monodydroxytanshinone I L L L L 
36 Neocryptotanshinone L L L L 
37 Neocryptotanshinone II L L L L 
39 Neotanshinlactone L L L L 
40 1-Oxomiltirone L L M L 
41 3,4-Phenanthrenedione L L M M 
42 Przewaquinone A L L L L 
43 Przewaquinone B L L L L 
44 Przewaquinone C L L L L 
45 Royleanone-4 L L L L 
46 Salviol L L L L 
47 Sugiol L L L L 
48 Sodium tanshinone IIA sulfonate L L L L 
49 Tanshinaldehyde L L H L 
50 Tanshindiol A L L H L 
51 Tanshindiol B L L L L 
52 Tanshindiol C L L L L 
53 Tanshinlactone L L L L 
54 Tanshinol A L L L L 
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Table 3. 3. Continued. 
55 Tanshinol B L L L L 
56 Tanshinone I L L L L 
57 Tanshinone IIA L L L L 
58 Tanshinone IIB L L H L 
59 Tanshinone V L L L L 
60 Tanshinone VI L L L L 
61 1,2,15,16-Tetrahydrotanshiquinone L L M L 
62 Trijuganone M L M L 
63 Trijuganone A L L L L 
64 Trijuganone B L L M L 
65 Caffeic acid H H L H 
66 Danshensu L L L L 
70 Ferulic acid H L L H 
71 Isoferulic acid L L L L 
72 Isosalvianolic acid C L L L L 
75 Methyl rosmarinate L L L L 
76 Prolithospermic acid L L L L 
77 Protocatechualdehyde H L H L 
78 Protocatechuic acid H L L L 
79 Rosmarinic acid L L L L 
80 Salvinal L M H L 
87 Salvianolic acid F L L L L 
88 Salvianolic acid G L L L L 
94 Vanillic acid H L L L 
All data were generated by OSIRIS Property Explorer.  
Abbreviation: H, high risk;  L, low risk; M, medium risk.  
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Figure 3. 3. Potential toxicity risks for 94 collected Danshen compounds.  
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3.3.1.4 Drug potential 
The drug-likeness scores calculated according to Equation 2. 1 ranged from -13.38 
to 1.78 (Table 3. 4). The most compounds were distributed between -5 to 2. Among 
those compounds, isoferulic acid was the top scored compound; tanshindiol A had a 
lowest drug-likeness value. In comparison to traded drugs, the majority of drug-like 
Danshen compounds possessed a favourable drug-likeness value. We also calculated 
the drug score for 77 Danshen compounds using Equation 2. 2 and Equation 2.3.  
The overall drug-likeness score ranged from 0.15 to 0.89 (Table 3. 4). Danshensu 
and isoferulic acid were the top two ranked compounds with the score of 0.86 and 
0.89, respectively. The lowest one was salvinal. Tan I, Tan IIA and CT possessed an 
acceptable drug score, which was 0.26, 0.27 and 0.36, respectively. 
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Table 3. 4. Drug potential of drug-like 77 Danshen compounds.  
Compound 
number 
Compound name Drug-
likeness 
Drug 
score 
1 Cryptotanshinone -7.06 0.36 
2 Danshenxinkun A -1.27 0.42 
3 Danshenxinkun B 0.91 0.41 
4 1,2 Didehydromiltirone △1,2 -7.61 0.24 
5 Dehydromiltirone -5.94 0.23 
6 Didydroisotanshinone I 1.57 0.58 
7 15,16-Dihydrotanshinone I -2.67 0.37 
8 15,16-Dihydrotanshinol B -3.8 0.42 
9 Dihydronortanshinone -7.04 0.4 
10 Dihydrotanshinone I -2.67 0.37 
11 1,2-Dihydrotanshiquinone -6.03 0.25 
12 1,2-Dihydrotanshinone I △15,16 -4.87 0.33 
13 6,12-Dihydroxyabieta-5,8,11,13-tetraen-7-one -5.15 0.31 
15 7a-hydroxyallyl-royleanone -5.44 0.4 
16 3-Hydroxycryptotanshinone -4.04 0.4 
17 17-Hydroxycryptotanshinone -7.9 0.4 
18 17-Hydroxytanshindiol B -4.6 0.44 
19 3-Hydroxymethylenetanshinquinone -6.88 0.34 
20 3-Hydrotanshinone IIA -5.11 0.3 
21 3-Hydroxytanshinone IIB -7.21 0.34 
22 Hydrotanshinone IIA -5.8 0.31 
23 Isocryptotanshinone -2.82 0.35 
24 Isotanshinone I -0.57 0.31 
25 Isotanshinone II -5.08 0.24 
26 1-Ketoisocryptotanshinone -4.87 0.36 
27 Methyldihydornortanshinonate -9.27 0.25 
28 4-Methylenemiltirone -9.08 0.27 
29 Methylenetanshiquinone -9.93 0.3 
30 Methyltanshinonate -10.4 0.19 
31 Methylenetanshinone -9.91 0.33 
32 Miltirone -7.61 0.24 
33 Miltirone I -3.27 0.23 
34 Miltionone II -2.04 0.47 
35 Monodydroxytanshinone I -4.28 0.28 
36 Neocryptotanshinone -5.78 0.36 
37 Neocryptotanshinone II -3.91 0.37 
39 Neotanshinlactone 0.74 0.63 
40 1-Oxomiltirone -5.4 0.24 
41 3,4-Phenanthrenedione -5.23 0.26 
42 Przewaquinone A -8.49 0.3 
43 Przewaquinone B -4.01 0.3 
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Table 3. 4. Continued. 
44 Przewaquinone C -4.81 0.32 
45 Royleanone-4 -4.73 0.43 
46 Salviol -3.7 0.32 
47 Sugiol -5.84 0.27 
48 Sodium tanshinone IIA sulfonate -8.63 0.3 
49 Tanshinaldehyde -10.3 0.23 
50 Tanshindiol A -13.38 0.18 
51 Tanshindiol B -3.76 0.36 
52 Tanshindiol C -3.76 0.36 
53 Tanshinlactone 0.18 0.58 
54 Tanshinol A -4.33 0.3 
55 Tanshinol B -4.81 0.32 
56 Tanshinone I -3.95 0.26 
57 Tanshinone IIA -8.52 0.27 
58 Tanshinone IIB -13.38 0.18 
59 Tanshinone V -10.08 0.39 
60 Tanshinone VI -5.55 0.38 
61 1,2,15,16-Tetrahydrotanshiquinone -4.87 0.33 
62 Trijuganone -9.27 0.25 
63 Trijuganone A 1.41 0.61 
64 Trijuganone B -4.87 0.33 
65 Caffeic acid 1.62 0.19 
66 Danshensu 1.2 0.86 
70 Ferulic acid 1.12 0.3 
71 Isoferulic acid 1.78 0.89 
72 Isosalvianolic acid C -3.09 0.26 
75 Methyl rosmarinate 0.48 -1.97 
76 Prolithospermic acid 0.85 -2.62 
77 Protocatechualdehyde 0.18 -3.64 
78 Protocatechuic acid 0.43 -0.12 
79 Rosmarinic acid 0.49 -2.07 
80 Salvinal 0.15 -6.71 
87 Salvianolic acid F 0.8 1.72 
88 Salvianolic acid G 0.52 -1 
94 Vanillic acid 0.35 -1.31 
All data were generated by OSIRIS Property Explorer.  
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3.4 Discussion 
In this study, the physicochemical properties of 64 lipophilic and 30 hydrophilic 
Danshen compounds were analysed. There were 80 compounds categorized into 
drug-like compound. The majority of those drug-like compounds possessed a 
comparable profile of drug-likeness and drug score to the traded drugs. In addition, 
potential toxicity risk analysis revealed that the irritating effect was the main 
potential toxicity risk for the Danshen compounds.  
 
There are many approaches to assess a compound's drug-likeness based on 
topological descriptors, fingerprints of MDL struture keys or other properties as 
cLogP and molecular weights. In this study, we used OSIRIS Property Explorer 
(http://www.organic-chemistry.org/prog/peo/) to evaluate drug-likeness. The 
approach is based on a list of about 5300 distinct substructure fragments with 
associated drug-likeness scores.  The drug-likeness values of Danshen compounds 
ranged from -13.38 to 1.78. Compared to 3300 traded drugs (http://www.organic-
chemistry.org/prog/peo/druglikeness.html), most compounds possessed a favourable 
distribution. A positive value implies that a compound contains predominatly 
fragments which are frequently present in commercial drugs. It doesn't necessarily 
mean that these fragments have been well ballanced against other properties of test 
compounds. For instance, a molecule may be composed of drug-like, but for 
lipophilic fragments only. It may have a high drug-likeness score but may be failed 
for being a drug because of its high lipophilicity. The overall drug-likeness scores 
respresent drug potential of a given compound. It is a combination of logP, logS, 
drug-likeness and toxicity risk. According to Equation 2. 2 and Equation 2.3, the 
drug score is ranging from 0 to 1. In our study, the tested Danshen compounds 
scored from 0.15 to 0.89. 
 
It has been established that physicochemical property of a compound, such as logP 
and logS determines its ADME/Tox profile (779). LogP is a well-established 
measure of the compound's lipophilicity. High logP values or high lipophilicities 
indicates a poor absorption or permeation. It has been shown that for compounds to 
have a reasonable probability of being well absorbed their logP value must not be 
greater than 5.0 (792).  The logP value has been relevant to ADME profile, such as 
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oral bioavailability, blood brain barrier partitioning, intestinal absorption, and plasma 
protein binding. For the 94 Danshen compounds evaluated, only two lipophilic 
compounds had a logP value over 5.0. This suggests that the most Danshen 
compounds exhibit a favourable lipophicility. Likewise, the aqueous solubility of a 
compound significantly affects its absorption and distribution characteristics. 
Typically, drugs with a low solubility are likely to have a low absorption. LogS is 
relevant to oral bioavailability, blood brain barrier partitioning and plasma protein 
binding (804). More than 80% of the traded drugs have a logS value greater than -4. 
In our study, 64 out of 94 compounds are lipophilic. Thus, the overall logS 
distribution was shifted to left and the logS of most compounds ranged from -6 to -4, 
indicating that most compounds may have a relative low absorption.  
 
Molecular weight is a crucial structural parameter (779). It has been showed that an 
increase in molecular weight leads to a decrease in solubility, permeability and 
distribution, which in turn result in a unfavourable profile of ADME (779). On the 
other hand, optimizing compounds for high activity on a biological target often goes 
along with increased molecular weights (779). Thus, to balance the ADME profile 
and efficacy, it often tries to keep molecular weights as low as possible. It has been 
showed that more than 80 % of all traded drugs have a molecular weight below 450. 
In the present study, among 64 lipophilic compounds, only neo-przewaquinone A 
had a molecular weight of 542. For hydrophilic compounds, molecular weight is the 
main reason for the violation of Ro5. Almost 50% evaluated hydrophilic compounds 
had a molecular weight over 500. Nevertheless, molecule weight is not the only 
factor determining the drug-like property of a compound; it should be considered 
with other properties such as bioactivity and ADME.  
 
Toxicity risk is the most likely reason for a drug withdrawn from the market or 
preventing a drug candidate reaching to market (805). Therefore, it is necessary to 
test the toxic effects of drug candidates in the early stage of drug development. In 
order to ensure the fast and reliable result, computational approaches have been 
employed to evaluate the potential toxicity risk (806). In our study, the predicted 
toxicity results showed that most drug-like Danshen compounds had a low toxicity, 
but irritating effect may be the major potential toxicity risk. This toxicity assessment 
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is consistent with the fact that certain Danshen compounds, such as tanshinones, 
have been clinically used as drugs to treat various diseases or conditions (642, 807). 
 
In a summary, the findings from this study indicate that the majority of Danshen 
compounds possess a favourable druggable potential. Understanding the 
physicochemical properties of Danshen compounds may help to understand the 
mechanisms of actions of Danshen and also provide a basis for further development 
of better effective drugs derived from Danshen compounds.   
 
 
Figure 3. 4. Distribution of drug-likeness values of Danshen compounds.  
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4 Chapter 4. Evaluation of biological fate, toxicity and drug interaction of 
natural products 
4.1 Introduction 
In recent years, there has been a significant increase in the use of herbal medicines to 
manage various chronic diseases or to promote health in many Western countires 
including Australia, New Zealand, the U.S. and Europe (808). To date, more than 
11,000 species of plants for medicinal use have been documented and about 300 of 
them are commonly used (809). An estimated one third of adults in developed 
countries and more than 80% of the population in many developing countries use 
herbal medicines for promoting health or managing various diseases ranging from 
common cold, inflammation, heart disease, liver cirrhosis, diabetes to central nervous 
system diseases (810). This has occurred despite a lack of clinical evidence for the 
efficacy, targets and safety data of most commonly used herbal medicines. 
 
There is a significant gap between the high demand in usage of herbal medicines and 
low regulatory controls on these products. Quite often, the ADME/Tox of herbal 
remedies is not required by regulatory authorities. However, this does not mean this 
issue is not important. To optimize the use of herbal remedies, including dosage, 
regimen and administration route, it is needed to examine their biological fate 
including the disposition pathways and kinetics in the human body. Only based on 
this knowledge, we can establish the potential dose-effect and dose-concentration 
relationships, which would allow us to conduct proper therapeutic monitoring for 
herbal remedies. Pharmacokinetic studies of herbal remedies also provide important 
information of potential herb-herb and herb-drug interactions. On the other hand, the 
unknown safety profiles of some herbal remedies may cause organ injuries in 
humans without knowing the underlying mechanisms. Herbal consumption has 
sometimes been associated with toxicities of the heart, liver, blood, kidney, central 
nervous system, and skin and less frequently carcinogenesis (811-817). Indeed, herb 
induced organ toxicities are often associated with herbal bioactivation in the body, 
possibly resulting in toxic species from the herbal remedies administered to the 
patients (818). In this regard, understanding the biotransformation pathways of 
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herbal remedies is important to explore the biochemical mechanisms of herbal 
toxicities.    
  
Herbal medicines are often co-administered with therapeutic drugs, raising the 
potential of pharmacokinetic and/or pharmacodynamic herb-drug interactions. 
Clinically, a number of herb-drug interactions have been documented and many of 
them resulted in significant alterations in efficacy and/or adverse events (819-824). 
Herb-drug interactions are due to altered ADME of drugs. Induction or inhibition of 
hepatic and intestinal CYPs is one of the underlying mechanisms of altered drug 
concentrations at sites of action by co-administrated herbal medicines. Particularly, 
the mechanism-based inhibition of CYPs by herbal compounds may have important 
pharmacokinetic implications, in particular CYP3A4 (825, 826). 
 
Thus, it is very important to evaluate the biological fate, toxicity and drug interaction 
of natural products. Recently, there is an increasing interest in using in silico 
approaches to study the biological fate, toxicity and drug interaction of natural 
products. There has been a significant progress in this field, although the evidence 
accumulated has not been properly reviewed. To update our knowledge on this, this 
chapter describes a literature review to highlight the pharmacokinetic properties and 
disposition pathways of plant natural products, and also discuss the relevant clinical 
and toxicological implications. 
 
146 
 
4.2 Data search 
To retrieve relevant data, the authors have searched through computer-based 
literatures by full text search in Medline (via Pubmed), ScienceDirect, Current 
Contents Connect (ISI), Cochrance Library, CINAHL (EBSCO), CrossRef Search 
and Embase (all from inception to 28/08/2012). Keyword search terms included 
structure based computational analysis, ligand based computational analysis, virtual 
screening, high throughput screening, cytochrome P450, drug metabolizing enzyme, 
drug transporter, nuclear receptor and herbal medicine together with combination 
terms including drug interaction, drug design and in silico approaches.  
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4.3 Methods used in in silico approaches  
In recent years, the application of in silico approaches in modeling ADME/Tox 
properties has been receiving increased attention in order to minimise or reduce the 
risk in late stage attrition in drug discovery and development process (827-829). 
Various computational methods for predicting the profile of ADME/Tox, drug 
interactions, drug targets for new chemical entity, potential drug or natural 
compounds have been developed (788, 791, 830, 831). Currently, a wide range of 
computational methods are available, ranging from hit identifications to lead 
optimization and beyond (832-834) The most commonly used techniques include 
ligand- (833) or structure based virtual screening (835). There are a number of 
commercially available ligand and protein based in silico methods, such as DOCK, 
Autodock , FlexX and GOLD. 
 
Ligand-based virtual screening relies on chemical structure and characteristics of the 
molecules to identify the interaction between the compound and the target (i.e. CYPs, 
UGTs & transporters) (836, 837). These approaches include quantum mechanical 
methods, various descriptor based methods (e.g., classificators, quantitative structure 
activity/property relationships (QSPR) or quantitative structure activity relationships 
(QSAR) and pharmacophore generation. Based on the assumption that the biological 
fate of a compound mainly depends on its physicochemical properties with the 
involvement of drug metabolizing enzyme, transporters and receptors, models 
developed by this method are largely based on the structural information of the 
molecules, without taking into account the information of the target.  
 
On the other hand, structure-based methods use the structure information solved by 
experimental protein structures and/or homology models, and often adopt automated 
docking approaches to identify the binding site of protein (838) and assess the 
binding affinity (835, 839, 840). For example, it is now capable of determining the 
binding mode of particular human CYPs in complex with various compounds and 
their probable metabolite(s) for predicting possible CYP mediated drug interactions. 
Similar the structure based methods have been used for studying other valid 
therapeutic target proteins such as P-gp, NOS and aromatase.  
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In addition, other computational approaches have also been used to predict the 
biological fate and toxic profile of a compound such as rule based methods and the 
ligand-protein interaction based approaches. Rule based approaches use data mining 
techniques based upon large databases to predict drug metabolism. The mixed 
approach is the combination of information related to both structure of ligands and 
proteins for better predictions on the biological fate and toxic profile of a compound. 
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4.4 Biological fate of natural compounds 
Biological fate of natural compounds has been recognized as one of the most 
challenging areas investigating the complex biological process with the involvement 
of complex molecules, enzymatic systems, transporters, and receptors. Over 95% 
drugs and some natural products undergo Phase I and/or Phase II metabolism 
following excretion through renal route, to a lesser extent, fecal route, and respiratory 
route. Phase I reactions including oxidation, reduction and hydrolysis are mainly 
catalyzed by CYPs, which introduce new groups to a substance and make it more 
susceptible to Phase II conjugative reactions, which are carried out by flavin-
containing monooxygenases, epoxide hydrolase, carboxylesterase and amidase, 
peroxidase, alcohol/aldehyde dehydrogenease, monoamine oxidase, or NADPH 
quinone reductase. Phase II reactions, such as glucuronidation,  which is catalyzed by 
various UGTs and sulfation, which is catalyzed by sulfotransferases (SULTs), 
generally yield molecules, which are more amenable to biliary or renal excretion. 
Drug transporters such as P-gp plays a critical role in absorption and excretion of a 
compound, thus have a major influence in oral bioavailability and half-life of natural 
compounds. Nuclear receptors, such as CAR, have an important role in drug 
disposition and are capable of regulating drug metabolizing enzymes such as CYPs. 
Thus, identification of actions of drug candidates on drug metabolizing enzymes, 
drug transporters and nuclear receptors will have important implication in 
predication of the ADME profile of drugs and natural products.   
 
In silico ADME studies have been developed in a wide range of models such as 
modeling CYPs (789-791), UGTs (841), P-gp (842, 843), OCTs (844, 845), CAR 
(846) and PXR (788).  
 
4.4.1 Phase I enzymes 
CYP is the major Phase I drug metabolizing enzyme family accounting for 
metabolism of more than 95% drugs and some natural products. It is one of the major 
determinants of the metabolic kinetics of a substance, and plays a critical role in drug 
interactions and metabolism-dependent toxicity. The human CYP superfamily 
contains 57 functional genes and 58 pseudogenes 
(http://drnelson.utmem.edu/CytochromeP450.html, access date: 28/08/2012). CYP1, 
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CYP2 and CYP3 are responsible for the metabolism of over 90% of clinical drugs, 
while other subfamilies (e.g. CYPs 4, 7, 11, 17, 19, and 21) also involved in the 
metabolism of some endogenous including steroids, bile acids, and eicosanoids (847, 
848). In particular, CYP1A1, 2D6, 2C9, 3A4 are the most important CYP isoforms 
in metabolism of drugs and natural compounds. Table 4. 1 summarized all in vitro 
studies on metabolism of natural compounds involving CYPs. A large number of 
natural compounds, such as curcumin and Tan IIA can be metabolized by different 
CYP isoforms. CYP related mechanism is important for the pharmacological action 
of natural compounds, however, in some cases, it is also related to some toxic effects 
of natural compounds (849).  
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Table 4. 1. Natural compounds that are metabolized by human CYP enzymes. 
Compounds Sources CYP isoforms Ref. 
Aristolochic acid* Aristolochia fanchi CYP1A1 & 1A2 (850, 
851) 
Bergamottin* Grapefruit juice CYP3A4, 2B6 & 3A5 (852) 
Capsaicin*  Hot peppers CYP1A1, 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 & 3A4 (853) 
Coumarin* Cinnamon, cassia, lavender & peppermint CYP1A1, 1A2, 2B6, 2E1 & 3A4 (854, 
855) 
Curcumin Curcuma longa CYP2D6 (856) 
Diallyl sulfide Garlic CYP2E1 (857) 
5,4’-Dimethoxyisoflavone Plant flavonoid CYP1A2 (858) 
Emetine  Ipecac  CYP2D6 & 3A4 (859) 
Emodin  Rhubarb CYP1A2 (860) 
Estragole*  Nutmeg, tarragon, basil, anise, lemongrass, 
fennel, and pimento 
CYP1A2, 2A6, 2C19, 2D6 & 2E1 (861-863) 
Formononetin  Plant flavonoid CYP1A2 (858) 
Galangin  Cystus incanus L.  CYP1A1, 1A2 & 2C9 (864) 
Genistein  Plant flavonoid CYP1A1, 1A2, 1B1, 2E1 & 3A4 (858, 
865) 
Harmaline  Plant carboline alkaloid CYP1A1, 1A2 & 2D6  (866) 
Harmine Plant carboline alkaloid CYP1A1, 1A2, 2C9, 2C19 & 2D6 (866) 
Hesperetin Plamt flavonoid CYP1A2 & 1B1 (867) 
Ibogaine  Tabernanthe iboga CYP2D6 (868) 
Kempferide  Cystus incanus L.  CYP1A1, 1A2 & 2C9 (864) 
Lasiocarpine  Plant alkaloid CYP2D6 (869, 
870) 
Limonene  Lemon CYP2C9 & 2C19 (871) 
Liquiritigenin Plant flavonoid CYP3A4 & 3A5 (872) 
8-Methoxypsoralen* Parsnips & parsley CYP2A6 & 2B1 (873, 
874) 
Menthofuran*  Pennyroyal oil CYP2E1, 1A2 & 2C19 (875) 
Methyleugenol* Nutmeg, tarragon, basil, anise, lemongrass, 
fennel, and pimento 
CYP1A2, 2C9, 2D6, & 2C19  
 
(876, 
877) 
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Table 4. 1. Continued. 
Monocrotaline  Plant alkaloid CYP2D6 (869, 
870) 
Paeonol Moutan Cortex CYP1A2 (878) 
Prunetin  Plant flavonoid CYP1A2 (858) 
Pulegone*  Pennyroyal oil CYP2E1, 1A2 & 2C19 (875) 
trans-Resveratrol* Grape seeds CYP1A1, 1A2, & 1B1 (879) 
Rutaecarpine Herbal alkaloid CYP1A2, 2D6 & 3A4 (880) 
Safrole* Nutmeg, mace, cinnamon, anise, black pepper, 
and sweet basil 
CYP2A6, 2C9,  2D6 & 2E1 (862, 
881) 
Silybin* Milk thistle CYP2C8 (882) 
Tanshinone IIA Danshen CYP2A6 (883) 
Teuchamaedryn A* Germander CYP3A4 (884-888) 
Teucrin A* Germander  CYP3A4 (884-888) 
α-Thujone Absinthe  CYP3A4 (889) 
β-Thujone Absinthe  CYP3A4 (889) 
(-)-Verbenone Rosemary species CYP2A6 & 2B6 (890) 
*The asterisk indicates a potential for bioactivation to reactive intermediate by human CYPs. 
Abbreviation: CYP: cytochrome P450. 
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With the elucidation of crystal structures of human CYPs, there is considerable 
interest in using in silico approaches to study CYP mediated metabolic profiles of 
new chemical entities and their interactions with CYPs, including toxicity and drug 
interactions (Table 4. 4). For example, a homology modeling has been successfully 
applied to study mammalian CYP1A1, 2A6, 2B6, 2C9 and 3A4 (891). Kemp et al. 
(892) used a homology modeling together with molecular docking approaches for 
studying human CYP2D6 and a range of substrates of CYP2D6. The method was 
able to discriminate between weak and tight binding compounds; and it was able to 
identify several novel inhibitors and the site of metabolism of the atypical substrate 
spirosulfonamide (892). Such computational studies have helped differentiating 
various substrates and inhibitors, and assisted in understanding their binding to the 
major human CYPs including CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6 and 3A.  
 
Recently, a number of new studies have provided insights into the molecular 
mechanisms of interaction of synthetic and herbal compounds of CYPs and 
identification of potential herb-drug interaction (788-791). Yang et al. (791) 
identified 19 out of the 56 natural compounds as potential inhitors of CYP1A2. Mo 
et al. (790) identified 18 out of 40 compounds from S. baicalensis as potential 
inhibitors of CYP2D6.  
 
 
4.4.2 Phase II enzymes 
Phase II enzymes are responsible for the conjugation reactions, such as 
glucuronidation and sulfation and changes in these reactions may lead to altered drug 
efficacy and undesired effects. UGT is capable of metabolizing a number of drugs 
and natural compounds (Table 4. 2). Numerous natural compounds from different 
sources can be metabolized by UGT isoforms, such as UGT1A1 and 1A3. This 
conjugation reaction is related to the excretion of natural compounds, and in some 
cases, the detoxification of toxic natural compounds or their metabolites by 
increasing hydrophilicity. It is noted that FDA has highly encouraged evaluations of 
phase II enzymes if applicable (http://www.fda.gov). 
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Table 4. 2. Natural compounds that are metabolized by human UGT enzymes. 
Compounds Sources UGT isoforms Ref. 
Alizarin Plant anthraquinone UGT1A3 (893) 
Anthraflavic acid Plant anthraquinone UGT1A3 (893) 
Apigenin Plant flavonoid UGT1A3, 1A8 & 1A10 (893, 894) 
Aspalathin  Plant flavonoid UGTs (895, 896) 
Carvacrol Plant phenolic compound UGT1A8 & 1A10 (894) 
Curcumin Plant polyphenolic compound UGT1A8, 1A9, 1A10 & 2B7 (897) 
Daidzein  Plant flavonoid UGT1A1, 1A4, 1A6, 1A7 & 1A9 (898, 899) 
Emodin Plant anthraquinone UGT1A3, 1A8 & 1A10 (893, 894) 
(-)-Epigallocatechin gallate Tea catechin UGT1A1, 1A8 & 1A9 (900) 
Esculetin Plant coumarin derivative UGT1A3 & 1A8 (893, 894) 
Eugenol Plant phenolic compound UGT1A3, 1A8 & 1A10 (893, 894) 
Eupatilin  Artemisia plants UGT1A1, 1A3, 1A7, 1A8, 1A9 & 1A10 (901) 
Farnesol Plant isoprenoid UGT1A1 & 2B7 (902) 
Fisetin Plant flavonoid UGT1A3, 1A8 & 1A10 (893, 894) 
Galangin Plant flavonoid UGT1A1, 1A3, 1A9 & 2B15 (893, 903) 
Genistein Plant flavonoid UGT1A1, 1A4, 1A6, 1A7, 1A8, 1A9 & 1A10 (893, 898, 899) 
6-Gingerol Ginger UGT1A1, 1A3, 1a9 & 2B7 (897, 904) 
Luteolin  Plant  UGT1A1, 1A4, 1A8, 1A9, 1A10, 2B7 & 2B15 (905) 
Naringenin Plant flavonoid UGT1A1, 1A3, 1A8, & 1A10 (893, 894) 
4-Nitrophenol Plant phenolic compound UGT1A3 (893) 
Pelargonidin  Plant flavonoid UGTs (906) 
Protocatechuic aldehyde S. miltiorrhiza  UGT1A6 & 1A9 (907) 
Quercetin Plant flavonoid UGT1A1, 1A3, 1A4, 1A8, 1A9, 1A10, 2B7 & 2B15 (893, 894) 
Quinalizarin Plant anthraquinone UGT1A3 (893) 
Resveratrol  Grape seeds UGT1A1, 1A9 & 1A10 (908-911) 
Scopoletin Plant coumarin derivative UGT1A3, 1A8, & 1A10 (893, 894) 
Scutellarin  S. radix (Huang qin) UGTs (912) 
Thymol Plant phenolic compound UGT1A3 (893) 
Umbelliferone Plant coumarin derivative  UGT1A3 (893) 
Abbreviation: UGT: uridine diphosphate glucuronosyltransferase. 
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There is an increasing number of in silico studies reported on structural 
characteristics of the ligands, which are able to influence molecular recognition and 
metabolism by the Phase II metabolizing enzymes (Table 4. 4).  
 
For example, several studies have used computational methods to study the features 
of the ligands for UGT, including pharmacophore elucidation, two/three dimension 
quantitative structure activity relationships (2/3D-QSAR), and non-linear pattern 
recognition techniques. Said et al. (913) firstly reported a 3D-QSAR study of the rat 
liver bilirubin UGT using comparative molecular field analysis (CoMFA). In this 
study, 18 compounds with related structures to phenolphthalein and a 
triphenylalkylcarboxylic acid were examined as inhibitors (913). The 2/3D-QSAR 
and pharmacophore approaches were also employed to model UGT1A1, UGT 1A4 
and UGT1A9, which demonstrated the characteristics of ligands for the recognition 
and metabolism (914, 915). These findings provide useful information on 
discriminating UGT substrates and inhibitors, identifying the characteristics of 
ligands and their molecular recognition and/or metabolism by UGT, which can be 
used to qualitatively and quantitatively predict the drug glucuronidation parameters.  
 
4.4.3 Drug transporters 
Drug transporters, including P-gp, OCTs, bile acid transporters, nucleoside 
transporters, human proton-coupled small peptide carrier (hPEPT1) and organic 
anion-transporting polypeptide (OATP), play an important role in the process of 
ADME and drug toxicity. It has been shown that many natural compounds, such as 
berberine, Tan I, Tan IIA and CT, are substrates of P-gp (Table 4. 3). This 
mechanism is related to the absorption, distribution and excretion of natural 
compounds, which in turn affects their pharmacological actions.  
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Table 4. 3. Natural compounds that are reported to be substrates of P-gp/MDR1. 
Compounds Sources Test system(s) Ref. 
Baohuoside I Epimedium koreanum Nakai (Yin Yanghuo) Caco-2 monolayers (916) 
Berberine Berberis (e.g. Hydrastis canadensis) Caco-2 monolayers (917, 918) 
Chrysophanol Plant anthraquinone Caco-2 monolayers (919) 
Cryptotanshinone S. miltiorrhiza  (920) 
Emodin Rhubarb Caco-2 monolayers (919) 
Ginsenoside Rh2 Ginseng Caco-2 monolayers (921) 
Glabridin Glycyrrhiza glabra (licorice) Caco-2 monolayers, MDR1 overexpressed cell line (922) 
Gomisin N S. chinensis  Caco-2 monolayers (923) 
Isorhamnetin Plant flavonoid Caco-2 monolayers (924) 
Kaempferol Plant flavonoid Caco-2 monolayers (924) 
Matrine Herbal alkaloid Caco-2 monolayers (925) 
Protopanaxadiol  Ginseng Caco-2 monolayers (921) 
Quercetin  Plant flavonoid (e.g. Ginkgo & St John’s 
wort) 
Caco-2 monolayers (924) 
Rutin deca (H-) sulfonate sodium Flavonoid glycoside found in buckwheat Caco-2  monolayers (926) 
Tanshinone I S. miltiorrhiza (Danshen) Caco-2 monolayers, MDR1 overexpressed cell line (927) 
Tanshinone IIA S. miltiorrhiza (Danshen) Caco-2 monolayers, MDR1 overexpressed cell line (617) 
Tanshinone IIB S. miltiorrhiza (Danshen) Caco-2 monolayers, MDR1 overexpressed cell line (928) 
Abbreviation: MDR1, multiple drug resistance protein 1. 
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To date, in silico methods have been used for modeling the transporter’s 3D structure 
to assist in studying the drug transport process, discriminating substrate or inhibitor, 
and measuring the activity (Table 4. 4). Currently, in silico approaches include 
transporter-based methods, such as homology modeling and structure-based methods, 
such as pharmacophore and 3D-QSAR modeling. Shilling et al. (843) successfully 
established a 3D model of LmrA as a homology for human multidrug transporter P-
gp and found that all three available ABC transporters shared the same overall 
transmembrane structure.  
 
Recently, substrate-based methods such as 3D-QSAR and pharmacophore modeling 
also has been applied in studying P-gp (929-931), OCTs (932), bile acid transporters, 
nucleoside transporters (933), hPEPT1 (934, 935), OATPs (844, 845). Crivori et al. 
(836) developed two computational models for identifying P-gp substrates and 
inhibitors. One method was based on calculated molecular descriptors and 
multivariate analysis using a training set of 53 diverse drugs for discriminating P-gp 
substrates and nonsubstrates. The model was capable of predicting the feature of 
72% of an external set of 272 proprietary compounds by correlating to the 
experimental classes and using partial least squares discriminant (PLSD) (836). 
Moreover, PLSD analysis using GRIND-pharmacophore-based descriptors was 
conducted to model P-gp substrates with poor or no inhibitory effect vs inhibitors 
with no evidence of significant transport. This model is capable of identifying some 
key molecular features discriminating between substrates and inhibitors with an 
average accuracy of 82% (836). These computational approaches may help for 
identifying the substrate and inhibitor of transporter and designing new drug with 
favorite bioavailability and minimum drug resistance. 
 
4.4.4 Nuclear receptors 
Nuclear receptors play an important role in regulating the expression of the drug 
metabolizing enzymes and drug transporters such as CYP, CAR and PXR (936). 
There is evidence showing that a number of natural compounds are able to regulate 
the activity and expression of nuclear receptors. Liu et al (788) showed that physcion, 
protocatechuic aldehyde, Sal B, and sodium danshensu significantly increased the 
expression PXR mRNA, whereas, epifriedelanol, morin, praeruptorin D, 
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mulberroside A, Tan I, and Tan IIA significantly reduced the expression of PXR 
mRNA. This interaction between natural compounds and nuclear receptors may 
further alter downstream targets. For example, an increase in the activity or 
expression of PXR can result in a up-regulation of CYP3A4 expression.  
 
Recent studies have used some advanced computational tools for screening 
compounds for nuclear receptors and providing valuable information for 
understanding the metabolism of xenobiotics and detoxification regulated by nuclear 
receptors (Table 4. 4). Kublbeck et al. (846) identified 17 novel agonists of human 
CAR using a 3D pharmacophore and molecular docking approach with a sequential 
virtual screening procedure. These 17 agonists activated human CAR and then 
increased the expression level of CAR target CYPs and transporters. According to 
the crystallographic studies, the ligand binding domain of human PXR has a large 
and conformable binding pocket which can respond to compounds of diverse size 
and shape. Lemaire et al. (937) identified 9 agonists of human PXR using 
computational approach. Among the 9 agonists, compound 1-(2-chlorophenyl)-N-[1-
(1-phenylethyl)-1H-benzimidazol-5-yl] methanesulfonamide (C2BA-4) showed a 
particularly activity on activation of PXR more potent than that of the reference 
compound 4-[2,2-bis(diethoxyphosphoryl)ethenyl]-2,6-ditert-butyl-phenol (SR12813) 
(937). The activation of PXR was also studied recently using computational 
approaches. Liu et al. (788) docked 19 herbal compounds into the ligand-binding 
cavity of PXR, observed that the binding was mainly through hydrogen bond 
formation and/or π-π interactions with the residues Ser247, Gln285, His407, and 
Arg401. These findings may help to screen new chemical entities and the rational 
drug design, or to predict potential drug interactions. 
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Table 4. 4. In silico based studies on drug metabolizing enzymes, transporters and receptors. 
Topic Key aspects Major purpose/findings Ref. 
Metabolic 
alteration 
Metabolic stability; 
Identification of 
biotransformations 
and metabolites; 
Metabolic 
reactions: ligand 
regioselectivities, 
rates and 
reactivities 
QSAR model were able to correctly predict the metabolic stability for 17 of 20 selected 
analogs with a prediction performance of 85% 
(938) 
About 80% of the test set and ~70% of an additional validation set were classified correctly 
as stable or unstable using proprietary data of up to 15000 compounds 
(939, 940) 
Used Gaussian processes and their intrinsic confidence estimator in predictive modeling for 
metabolic stability assessment in four different training set with 900-1900 compounds  
(941) 
Used MetaDrug to predict metabolites and the activity of the original compound and its 
metabolites.    
(776) 
K-PLS and possibly other similar machine learning methods (such as support vector 
machines) can be used to predict human drug metabolite formation in a classification 
manner with 61 and 79% prediction performance on different reactions 
(942) 
Presented a new method which provided the cytochrome involved and the site of metabolism 
for any human CYP mediated reaction acting on new substrates. 
(943) 
Gave valuable information about important interactions of inhibitors and substrates with 
CYP2C9 using docking and the site of metabolism predictions.  
(944) 
Examined the MetaSite algorithm by comparing its predictions with experimentally 
characterized metabolites of statins produced by CYP with 77% of correct predictions. 
(945) 
Compared MetaSite and the docking methods to predict the metabolic sites for CYP3A4-
mediated metabolic reactions 
(946) 
Explored the enzyme-ligand interactions in CYP2D6 & 3A4 homology models and crystal 
structures. 
(947) 
Developed a rapid semiquantitative model for predicting likely sites of CYP3A4-mediated 
metabolism on drug-like molecules 
(948) 
Predicted the metabolism by CYP2C9 using alignment and docking studies of a validated 
database of 70 substrates. 
(949) 
Predicted the rates and regioselectivity of CYPs-mediated reactions. (950, 951) 
Predicted metabolite for para-substituted anisoles based on ab initio complete active space 
self-consistent field calculations. 
(952) 
Evaluated the reaction energetics for CYP-mediated reactions. (953, 954) 
Constructed and evaluated models of CYP2E1 to predict metabolism from docking, 
molecular dynamics, and density functional theoretical calculations. 
(955) 
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Table 4. 4. Continued. 
  Studied the stereospecific CYP-catalyzed hydroxylation of the C(5)-H((5-exo)) bond in 
camphor using a combined quantum mechanical/molecular mechanical approach. 
(956) 
Predicted regioselectivity in CYP450/3A4 mediated metabolism using a combined model (957) 
Descript differential enantioselectivity in methoxychlor O-demethylation by CYP2C 
enzymes using in silico methods. 
(958) 
Studied comparative homology modeling of human CYP1A1 and confirmed residues 
involved in 7-ethoxyresorufin O-deethylation by site-directed mutagenesis and enzyme 
kinetic analysis. 
(959) 
Predicted the dominant CYP450 enzyme in human drug biotransformation with structure-
based methods.  
(960) 
Studied CYP2D6 and 3A4 mediated metabolic N-dealkylation reaction rates using 
quantitative structure-metabolism relationship modeling method. 
(961) 
Studied QSAR-based regioselectivity models for human CYP 3A4, 2D6, and 2C9. (962) 
Studied the metabolism of CYP2C9 and CYP2C19 for gliclazide using homology modeling 
and docking methods 
(963) 
Binding to 
specific drug 
metabolizing 
enzymes and 
transporters 
Binding pose; 
Ligand-enzyme 
interactions 
Binding energy;  
Discrimination 
inhibitor versus 
substrate; 
Mechanism-based 
inhibition 
Developed the first a pharmacophore model for inhibition of human CYP2D6. (964) 
Analysed CYP2D6 inhibitors using 3D/4D-QSAR models.  (965) 
Analysed CYP3A4 substrates using 3D-QSAR model. (966) 
Analysed CYP2B6 substrates using 3D-QSAR model. (967) 
Developed and validated an in silico CYP profiler based on pharmacophore models. (968) 
Predicted affinities for CYP2C9 with multiple computational methods. (969) 
Studied the isoform specificity of CYP 3A4, 2D6, and 2C9 substrates using ligand-based 
models. 
(970) 
Predicted catalytic site and virtual screened CYP2D6 substrates by consideration of water 
and rescoring in automated docking. 
(971) 
Evaluated the binding orientations of testosterone in the active site of homology models for 
CYP2C11 and CYP2C13 
(972) 
Studied CYP2D6 inhibitor aryloxypropanolamines using 2D and 3D descriptors by QSAR 
model. 
(973) 
Studied CYP1A2 inhibitor flavonoids using 2D and 3D descriptors by comparative QSAR 
models.  
(974) 
Analysed CYP2D6 substrate interactions using computational methods (975) 
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 Characterized molecular features of CYP2B6 substrates by 2D and 3D QSAR. (976) 
Identified new potent and selective CYP2B6 inhibitors using 3D-QSAR analysis (977) 
Studied active site architecture and ligand binding using homology model of 1alpha,25-
dihydroxyvitamin D3 24-hydroxylase CYP24A1. 
(978) 
Predicted drug binding to CYP2D6 and identified a new metabolite of metoclopramide using 
in silico methods.  
(979) 
Studied CYP3A4 inhibitors using QSAR model. (980) 
Studied active site architecture and ligand binding using a homology model of human 
retinoic acid metabolising enzyme CYP26A1. 
(981) 
Studied CYP2D6 inhibition in the aryloxypropanolamine series using a 3D-QSAR model.  (982) 
Studied the inhibition of human CYP1A2 oxidation of 5,6-dimethyl-xanthenone-4-acetic 
acid by acridines via a molecular modeling method. 
(983) 
Characterized the CYP3A4 active site by homology modeling (984) 
Characterized of the CYP2C8 active site by homology modeling (985) 
Studied quantitative binding models for CYP2C9 based on benzbromarone analogues. (986) 
Studied homology modeling of CYP3A4 and analysed typical CYP3A4 substrate 
interactions. 
(987) 
Studied the key members of the resorufin series with CYP2C5 derived models of human 
CYP1A1, CYP1A2, CYP2B6 and CYP3A4 using molecular modeling methods. 
(988) 
Studied the interaction of human cytochromes P450 CYP2 family enzymes with their 
substrates using QSAR methods. 
(989) 
Analysed the inhibition of recombinant CYP3A4 activity by structurally diverse compounds 
using a genetic algorithm-combined partial least squares method 
(990) 
Demonstrated a molecular basis for sulfotransferase substrate specificity by molecular 
modeling and quantitative structure-activity relationship analysis.  
(991) 
Predicted UGT1A1 substrates using pharmacophore and quantitative structure activity 
relationship modeling. 
(914) 
Identified potential P-glycoprotein substrates and inhibitors using computational models. (836) 
Studied Km values for sulfation of diverse phenolic substrates by human catecholamine 
sulfotransferase SULT1A3 with CoMFA modeling of enzyme kinetics. 
(992) 
Studied serotonin and its membrane transporter SERT using computational approaches and 
implied for drug design.   
(993) 
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 Elucidated the inhibition requirements of the human OCTN2 using pharmacophore to mine 
data. 
(994) 
Identified FDA-approved drugs that inhibit human ASBT and derived computational models 
for ASBT inhibition. 
(995) 
Used pharmacophore-based method to discover novel human PEPT1 inhibitors.   (934) 
Applied 3D-QSAR method to predict P-gp inhibitors and substrates (930) 
Studied the structural requirement of modulator of P-gp using 3D-QSAR method.  (929) 
Analysed peptide substrates of the mammalian H+/peptide cotransporter PEPT1 using 3D-
QSAR method. 
(935) 
Applied QSAR to analyse the behavior of Oatp1a5 substrates in the binding site.  (845) 
Studied the influence of molecular structure on substrate binding to the human organic 
cation transporter, hOCT1 using quantitative structure activity approaches 
(932) 
Studied the molecular requirements of the human nucleoside transporters hCNT1, hCNT2, 
and hENT1 using pharmacophore models. 
(933) 
Induction  Interactions with 
drug transporters 
and nuclear 
receptors 
Analysed antibiotics that activate PXR and induce CYP3A4 in liver and intestine using a 
comprehensive in vitro and in silico analysis.  
(996) 
Predicted human PXR activation using machine learning methods and docking. (997) 
Discovered a highly active ligand of human PXR with pharmacophore modeling and virtual 
screening.  
(937) 
Identified 17 substituted sulfonamides and thiazolidin-4-one derivatives as agonists of 
human CAR through a sequential virtual screening procedure using a 3D pharmacophore 
and molecular docking approach. 
(846) 
Applied 3D-QSAR method to predict P-gp inhibitors and substrates (930) 
Studied the structural requirement of modulator of P-gp using 3D-QSAR method.  (929) 
Analysed peptide substrates of the mammalian H+/peptide cotransporter PEPT1 using 3D-
QSAR method. 
(935) 
Applied QSAR to analyse the behavior of Oatp1a5 substrates in the binding site.  (845) 
Studied the influence of molecular structure on substrate binding to the human organic 
cation transporter, hOCT1 using quantitative structure activity approaches 
(932) 
Studied the molecular requirements of the human nucleoside transporters hCNT1, hCNT2, 
and hENT1 using pharmacophore models. 
(933) 
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 Analysed antibiotics that activate PXR and induce CYP3A4 in liver and intestine using a 
comprehensive in vitro and in silico analysis.  
(996) 
Predicted human PXR activation using machine learning methods and docking. (997) 
Discovered a highly active ligand of human PXR with pharmacophore modeling and virtual 
screening.  
(937) 
Identified 17 substituted sulfonamides and thiazolidin-4-one derivatives as agonists of 
human CAR through a sequential virtual screening procedure using a 3D pharmacophore 
and molecular docking approach. 
(846) 
Abbreviation: ASBT: apical sodium-dependent bile salt transporter; CAR: constitutive androstane receptor; CoMFA: comparative 
molecular field analysis; CYP: cytochrome P450; FDA: food and drug administration; hCNT: human concentrative nucleoside 
transporter; hENT 1: equilibrative nucleoside transporter 1; hOATP: human organic anion-transporting polypeptide; hOCT: human 
organic cation transporter; P-gp: P-glycoprotein; PEPT: proton-coupled small peptide carrier; PXR: pregnane X receptor; QSAR:  
quantitative structure activity relationship; SULT: sulfotransferase. 
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4.5 Toxicity of natural compounds 
There are numerous cases of toxicity induced drug development failure and 
withdrawn from market such as rofecoxib (cardiac toxicity) and ximelagatran 
(hepatotoxicity). Toxicity is the cause of around 30% of the dropouts during late 
drug development stages (998, 999). Therefore, implementing toxicity screening or 
testing as early as possible in the drug development process is important not only to 
save time and money, but also to reduce the risk to harm patients or consumers. 
Usually, toxicological tests for new compounds using conventional experimental 
methods are costly and time-consuming, moreover, there is difficulty in accessing 
and interpreting toxicological data in vitro and in vivo (1000-1002). Therefore, there 
is therefore an increased demand for new approaches to rapidly and reliably predict 
the toxicity of compounds in early stage of drug development. Computational 
approaches for toxicity prediction have been applied into drug development process 
for evaluating potential toxic effect of compounds (999, 1003, 1004).  
 
4.5.1 Computational analysis  
Natural products usually contain multiple ingredients with complex nature, which 
can cause hurdles for toxicity assessment. Thus, there is a need to develop new 
approaches for testing toxicological of natural products instead of using traditional in 
vitro and in vivo experiments. Arvidson et al (1005) screened the toxicity of six well-
known natural compounds (estragole, pulegone, aristolochic acid I, lipoic acid, 1-
octacosanol, and epicatchin) with known human exposure, chemical metabolism and 
mechanism of action using QSAR modeling. The findings showed a very good 
agreement between the in silico results and the experimental toxicity data (1005). In 
addition, virtual screening of herb-target predictions are available and prevalent. 
Ehman et al. (1006) screened a large number of compounds over 192 Chinese herbs 
and formulas and identify the multi-target anti-inflammation compounds using 
pharmacophore assisted docking. Valerio et al. (1007) successfully predicted the 
rodent carcinogenic potential of 101 naturally occurring chemicals in the human diet 
using high throughput QSAR predictive modeling. 
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4.6 Drug interactions 
Alterations on the activities of drug metabolizing enzymes, transporters or nuclear 
receptors, in particular, CYPs, UGT, P-gp, and PXR, are the major causes of known 
drug-drug and drug-herb interactions. The FDA draft drug interaction guidance has 
recommended the following CYPs for routine assessment to identify potential CYP-
mediated drug interactions: CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, 
CYP2D6 and CYP3A. Alteration of the catalytic activity of CYPs may cause 
undesired drug effects or toxicity. Theoretically, a compound with effects on drug 
metabolizing enzymes or drug transporters has potential to interact with the substrate 
for those enzymes or transporters. For example, activation of nuclear receptors can 
cause induction of CYP3A4 and P-gp expressions (1008), resulting in changes of 
circulating level of substrate for CYP3A4 and P-gp expressions.  
 
The application of in silico approaches to predict drug-drug interaction has been 
widely used to assess the effect of a compound on CYPs (1009, 1010). Classification 
of CYPs inhibitor by using in silico models can predict potential drug-drug 
interactions (1011-1016). For example, Vasanthanathan et al. (1011) classified 67% 
of 7000 compounds as CYP1A2 inhibitors. Distinguishing regulators from ligands of 
transporters may minimize potential drug interactions induced by altered activity of 
transporters (1017-1020). Yasuda et al. (996) docked dicloxacillin and nafcillin into 
PXR and found that both were able to activate PXR resulting in CYP3A4 induction, 
and those modeling results were found to be line with data from in vitro experiments.   
 
Herb-drug interactions can cause serious adverse reactions resulting from 
modification of the activity of drug metabolizing enzymes, transporters and nuclear 
receptors by co-administrated drugs, herb medicines or other food supplements. For 
example, St John’s wort, garlic, ginseng, ginkgo may interact with a range of 
conventional drugs, including some clinically important drugs with very narrow 
therapeutic index to cause, in some cases, life threating and lethal consequence (818). 
It is important therefore to identify, timely and precisely, the potential herb-drug 
interactions. Recently, Yang et al. (791) used molecular docking approach studied 
CYP1A2 inhibitors from 56 herbal compounds coupled with in vitro assays. 
Moreover, Mo et al. (790) screened a number of compounds from S. baicalensis, by 
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using pharmacophore and quantitative structure-activity relationship (QSAR) models, 
and found that 18 compound were inhibitors of CYP2D6. In addition, Liu et al. (788) 
showed that 19 tested herbal compounds were able to interact with PXR, indicating 
potential herb-drug interactions.   
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4.7 Challenges 
The value of using computational approaches in studying ADME/Tox profiles of 
compounds has been well recognised, such as the ability of screening huge number 
of compounds without costly synthesis them, which significantly accelerates drug 
discovery and development process. By using these computational methods, it is 
possible to discover valuable information at early stage of drug discovery process, 
which assists in strategic planning of drug discovery and development process.  
 
Although there have been significant developments in this area, there are still some 
challenges. For example, the in silico ADME/Tox prediction cannot completely 
replace the classic in vitro and in vivo experiments. In some cases, there is still lack 
of the true physiological representations of the chemical entity or drug candidates in 
in silico models, which limit the ability to quantitatively predict the situation in vivo, 
such as drug metabolizing enzyme and transporter interplay at various tissues (e.g., 
CYP3A4 and P-pg in the intestine vs in the liver), and the relationship between in 
vitro and in vivo ADME/Tox profiles. There is also lack of details analysis of 
predictive strength of various models developed so far, in particular on correlations 
between different parameters and endpoints. In addition, in many cases, there is a 
lack of reliable experimental data to generate proper computational model for further 
analysis of relationship between the in vitro and in vivo data. Obviously, there is a 
need for further studies on establishing and validating further proper models with 
less complexity, high predictability, and better correlations with available in vivo and 
in vitro data, Such models will have important application in drug discovery and 
drug development.  
 
In conclusion, the use of computational approaches has significantly advanced and 
improved the drug development process and performance. The accurate predication 
the biological fate and toxicity of chemicals and drugs, including natural products by 
an integration of in silico approaches with well-established in vitro and in vivo 
methods will make an important contribution in  natural product and drug research in 
the future.  
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5 Chapter 5. Establishment of high glucose induced eNOS uncoupling model 
in EA.hy926 cells 
5.1 Introduction 
Endothelial dysfunction has been implicated in the pathogenesis of cardiovascular 
and metabolic diseases (see Chapter 1, Section 1.2). Hyperglycaemia is a 
characterization of type 1 and type 2 diabetes and plays a key role in diabetes 
associated vascular complications (71, 1021). It is speculated that endothelial 
dysfunction is a consequence of metabolic alterations related to diabetes, particularly 
hyperglycaemia.  
 
The relationship between diabetes and cardiovascular diseases has been extensively 
investigated (71, 72, 1021). It has been established that hyperglycaemia related 
changes of eNOS mechanism contribute to the vascular damages (402, 413). Studies 
have demonstrated that after the exposure of high glucose, ECs showed reduced NO 
production and increased ROS generation (402, 1022, 1023), with enhanced NF-κB 
activation, inflammatory gene expression, extracellular and intracellular adhesion 
molecules expression, and leukocyte recruitment (1024-1032).  
 
Oxidative stress is a major risk factor in hyperglycemia related vascular damages 
(Chapter 1, Section 1.1). In vasculature, the activation of NADPH oxidases and 
eNOS uncoupling are the two important contributors to endothelium dysfunction. It 
has been shown that the activity and expression of NADPH oxidases are increased 
under high glucose exposure (1033-1040), NOX4, a major constitutive NADPH 
oxidase isoform expressed in the endothelium, is increased after high glucose 
exposure leading to excessive ROS generation and oxidative stress (1036, 1039, 
1040). In addition, there is substantial evidence for ROS related changes of eNOS 
function and NO production/degradation (1041). Foe example, it has been shown that 
excessive ROS reduced NO generation and BH4 bioavailability (1042). 
 
Thus, in order to study the effects of Danshen compounds on eNOS uncoupling, it is 
important to establish a proper cell model of eNOS uncoupling. Based on 
observations that endothelial dysfunction and eNOS uncoupling have been 
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demonstrated in metabolic and cardiovascular diseases, the present study was set out 
to investigate the effect of high glucose on eNOS coupling mechanims in a human 
endothelial cell line EA.hy926.  
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5.2 Materials and methods 
See Chapter 2, Section 2.2.1 and 2.1.6 to 2.1.13.  
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5.3 Results 
5.3.1 Effect of high glucose on superoxide production 
In order to identify the sources of superoxide production under high glucose 
condition, we firstly tested the effects of DPI (a flavin-containing oxidase inhibitor), 
L-NAME (a NOS inhibitor), and Apo, (a NOXs inhibitor), on superoxide production 
in EA.hy926 cells. Incubation of cells with a high glucose concentration (35 mM) for 
24 or 48 hr significantly increased the superoxide production compared to those 
incubated with a low glucose concentration (5.5 mM) (Figure 5. 1). The high 
glucose induced increase in superoxide production was significantly inhibited by 
Apo (100 µM), L-NAME (100 µM) and DPI (5 µM). These results demonstrate that 
superoxide is almost completely generated by all flavin-containing oxidases, in 
particular, by NOXs and NOS under high glucose condition.   
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Figure 5. 1. Intracellular superoxide production in cultured EA.hy926 cells. Effects 
of high glucose, L-NAME (100 µM), Apo (100 µM) and DPI (5 µM) superoxide 
production was examined in EA.hy926 cells. Cells and cell homogenates were 
treated as described in Materials & Methods. Superoxide production was evaluated 
by 5 µM/L lucigenin-enhanced chemiluminescence assay. *, p<0.05 and **, p<0.01 
versus 48 hr high glucose group. Data represent the mean ± S.E.M. derived from four 
independent experiments. -: low glucose (5.5 mM); + and ++: treatment of high 
glucose (35 mM) for 24 and 48 hr, respectively.  
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5.3.2 Effect of high glucose on NO generation 
To determine whether the activity of eNOS was changed under high glucose 
condition, we determined the NO production in cells treated with high glucose for 24 
and 48 hr. A significant lower level of NO generation was observed compared to the 
control (5.5 mM glucose), which was partly inhibited by the NOS inhibitor L-NAME 
(100 µM) (Figure 5. 2). The results in Figure 5. 1 and Figure 5. 2  demonstrated 
that eNOS uncoupling occurs with an increase in superoxide production and a 
decrease in NO generation in endothelial cell line under the high glucose condition.  
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Figure 5. 2.  NO production in cultured EA.hy926 cells. Effect of high glucose on 
NO production was examined in EA.hy926 cells. Cells were treated as described in 
Methods. The intracellular level of NO was measured using the fluorescent probe 
DAF-2-DA. *, p<0.05 and **, p<0.01 versus 48 hr high glucose group. Data 
represent the mean ± S.E.M. derived from four independent experiments. -: low 
glucose (5.5 mM); + and ++: treatment of high glucose (35 mM) for 24 and 48 hr, 
respectively. 
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5.3.3 Effect of high glucose on NOX expression 
Since NOX4 is the dominant and constitutive superoxide producing enzyme in ECs, 
it is important to investigate the expression of NOX4 in the cell model. Figure 5. 3  
showed the effects of high glucose on expressions of NOX4 in EA.hy926 cells. 
When the cells were cultured in 35 mM glucose media for 24 or 48 hr, the 
expressions of NOX4 were significantly increased (up to more than 2-fold) compared 
to the control at 5.5 mM glucose (Figure 5. 3). The results indicate that up-regulated 
expression of NOX4 occurs under the high glucose condition contributing to the 
excessive accumulation of superoxide in ECs. 
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Figure 5. 3. Effect of high glucose on the expression of NOX4 in cultured EA.hy926 
cells. Cells and cell lysates were treated as indicated in Methods. A: a representative 
experiment showing high glucose (35 mM) induced increases in NOX4 expressions. 
B: the result of densitometric analyses of graphing the expression of NOX4. Data 
represent the mean ± S.E.M. derived from three independent experiments. -: low 
glucose; + and ++: treatment of high glucose for 24 hr and 48 hr, respectively. *, 
p<0.05 and **, p<0.01 versus 48 hr high glucose group. Data represent the mean ± 
S.E.M. derived from three independent experiments. -: low glucose (5.5 mM); + and 
++: treatment of high glucose (35 mM) for 24 and 48 hr, respectively.  
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5.3.4 Effect of high glucose on eNOS expression 
To confirm the eNOS uncoupling under the high glucose condition, we examined the 
change of eNOS forms (dimer and monomer). High glucose exposure did not 
significantly change the expression of the total eNOS, compared with that in low 
glucose condition. However, it significantly reduced the ratio of the active (dimer) to 
the inactive forms (monomer) of eNOS (by 50% after 48 hr high glucose treatment) 
(Figure 5. 4). These results demonstrate that high glucose induce the changes from 
dimeric to monomeric eNOS.   
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Figure 5. 4. Effect of high glucose on the expression of eNOS in cultured EA.hy926 
cells. Cells and cell lysates were treated as indicated in Methods. The ratio of eNOS 
dimer to monomer decreased after high glucose treatment for 24 hr. A: A 
representative experiment showing high glucose (35 mM) induced decreases in 
expressions of eNOS dimer, monomer and total eNOS. B: Results of densitometric 
analyses graphing the ratio of eNOS dimer to monomer. *, p<0.05 and **, p<0.01 
versus 48 hr high glucose group. Data represent the mean ± S.E.M. derived from 
three independent experiments. -: low glucose (5.5 mM); + and ++: treatment of high 
glucose (35 mM) for 24 and 48 hr, respectively.  
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5.3.5 Effect of high glucose on intracellular BH4 and BH2 levels  
Given that BH4 is a crucial cofactor for eNOS function and coupling, we assessed 
the changes of intracellular biopterin concentrations in ECs under low and high 
glucose conditions. By measuring the levels of BH4 to BH2 and its ratio, we found 
that cells treated with high glucose for 24 hr and 48 hr showed a significant lower 
level of ratio of BH4 to BH2. Compared to the control cells exposed to 5.5 mM 
glucose, the ratio of BH4 to BH2 was reduced by 40% after cells were treated with 
high glucose (35 mM) for 48 hr (Figure 5. 5). The results indicate that high glucose 
induces eNOS uncoupling by decreasing the ratio of BH4 to BH2.  
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Figure 5. 5. Effect of high glucose on the ratio of BH4 to BH2 in cultured EA.hy926 
cells. All the samples were treated as described in Methods. The ratio of BH4 to BH2 
was markedly decreased in high glucose (35 mM) condition. *, p<0.05 and **, 
p<0.01 versus 48 hr high glucose group. Data represent the mean ± S.E.M. derived 
from four independent experiments. -: low glucose (5.5 mM); + and ++: treatment of 
high glucose (35 mM) for 24 and 48 hr, respectively.  
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5.3.6 Effect of high glucose on expressions of GTPCH1 and DHFR 
The expressions of GTPCH1, the rate-limiting enzyme in BH4 synthesis, and DHFR, 
the enzyme responsible for the conversion of BH2 to BH4 were also significantly 
suppressed under the high glucose condition (Figure 5. 6 and Figure 5. 7).  
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Figure 5. 6. Effect of high glucose on the expression of GTPCH1 in cultured 
EA.hy926 cells. Cells and cell lysates were treated as indicated in Methods. The 
expression of GTPCH1 was inhibited by high glucose (35 mM).  A: a representative 
experiment showing high glucose (35 mM) induced decreases in expressions of 
GTPCH1. B: Results of densitometric analyses graphing the expressions of 
GTPCH1.*, p<0.05 and **, p<0.01 versus 48 hr high glucose group. Data represent 
the mean ± S.E.M. derived from four independent experiments. -: low glucose (5.5 
mM); + and ++: treatment of high glucose (35 mM) for 24 and 48 hr, respectively.  
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Figure 5. 7. Effect of high glucose on the expression of DHFR. Cells and cell lysates 
were treated as indicated in Methods. The expression of DHFR was inhibited by high 
glucose (35 mM). A: a representative experiment showing high glucose (35 mM) 
induced decreases in expressions of DHFR. B: Results of densitometric analyses 
graphing the expressions of DHFR.*, p<0.05 and **, p<0.01 versus 48 hr high 
glucose group. Data represent the mean ± S.E.M. derived from four independent 
experiments. -: low glucose (5.5 mM); + and ++: treatment of high glucose (35 mM) 
for 24 and 48 hr, respectively.  
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5.3.7 Effect of high glucose on expression of HSP90 
As HSP90 is an important chaperone regulating eNOS function and superoxide 
production. We examined the expression of HSP90 under the high glucose condition. 
When the cells were cultured in 35 mM glucose media for 24 and 48 hr, the 
expression of HSP90 was significantly decreased compared to the control at 5.5 mM 
glucose (Figure 5. 8). The results demonstrate that a decrease in the expression of 
HSP90 is involved in the impaired eNOS function under high glucose condition.  
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Figure 5. 8. Effect of high glucose on the expression of HSP90 in cultured EA.hy926 
cells. Cells and cell lysates were treated as indicated in Methods. A: A representative 
experiment showing high glucose (35 mM) induced decreases in expressions of 
HSP90. B: Results of densitometric analyses graphing the expressions of HSP90. *, 
p<0.05 and **, p<0.01 versus 48 hr high glucose group. Data represent the mean ± 
S.E.M. derived from four independent experiments. -: low glucose (5.5 mM); + and 
++: treatment of high glucose (35 mM) for 24 and 48 hr, respectively.  
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5.3.8 Effect of high glucose on expression of PI3K 
Since it has been reported that NOX expression is regulated by PI3K (1043), we 
further examined the influence of PI3K inhibition on the expression of NOX4 in high 
glucose treated cells. Figure 5. 9 shows that wortmannin, a PI3K inhibitor, 
significantly inhibited the high glucose induced NOX4 expression. Figure 5. 10 
showed that the expression of PI3K was significantly increased by high glucose. 
These findings indicate that PI3K pathway plays a role in oxidative stress induced 
eNOS uncoupling under high glucose condition in human ECs.  
187 
 
 
    
Figure 5. 9. Effect of PI3K inhibitor (wortammanin, WM) on the expression of 
NOX4 in cultured EA.hy926 cells. Cells and cell lysates were treated as indicated in 
Methods. WM (100 nM) significantly suppressed the expressions of NOX4 which 
were enhanced by high glucose. A: results from a representative experiment that was 
performed three times with equivalent results. B: results of densitometric analyses 
graphing the expression of NOX4. ##, p< 0.01 versus low glucose group; **, p<0.01 
versus high glucose group; ^, p<0.01 versus 24 hr high glucose group. Data represent 
the mean ± S.E.M. derived from four independent experiments. -: low glucose (5.5 
mM); + and ++: treatment of high glucose (35 mM) for 24 and 48 hr, respectively.  
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Figure 5. 10. Effect of high glucose on the expression of PI3K subunit in cultured 
EA.hy926 cells. Cells and cell lysates were treated as indicated in Methods. The 
expression of PI3K was enhanced by high glucose. A: results from a representative 
experiment that was performed three times with equivalent results. B: results of 
densitometric analyses graphing the expression of p110β. **, p<0.01 versus 48 hr 
high glucose group. Data represent the mean ± S.E.M. derived from four independent 
experiments. -: low glucose (5.5 mM); + and ++: treatment of high glucose (35 mM) 
for 24 and 48 hr, respectively. 
 
189 
 
5.4 Discussion 
The aim of this study was to set up an experimental hyperglycaemia cell model of 
eNOS uncoupling using EA.hy926 cells treated with glucose, we found that eNOS 
uncoupling occurred with a decrease in NO generation and an increase in eNOS 
derived superoxide production with a reduced ratio of BH4 to BH2 inhibition of 
expressions of eNOS, GTPCH1, DHFR, and HSP90, whereas the expression of 
NOX4 and PI3K was up-regulated.  
 
The finding from this study is consistent with previous reports demonstrating eNOS 
uncoupling under high glucose condition in ECs, with enhanced superoxide 
generation and decreased NO production (1022, 1044, 1045). Superoxide production 
in ECs is mainly derived from NOXs (4), but can also be generated from uncoupled 
eNOS (1046). Our findings that superoxide production under a high glucose 
condition was strongly inhibited by Apo and partially inhibited by L-NAME indicate 
that both NOXs and uncoupled eNOS are likely sources of superoxide generation 
observed. This is further confirmed by our finding that the ratio of active form of 
eNOS (dimer) to its inactive form (monomer) was decreased under the high glucose 
condition without changing the total expression of eNOS, indicating that eNOS was 
uncoupled (426).  
 
NOXs are a complex family with at least seven members: NOX1 to NOX5 and 
Duox1 and Duox2 (1047). NOX4 is one of the dominant subunits of NOX and a 
constitutively active one expressing in ECs (4, 1048). The role of NOX4 in 
producing O2¯  or H2O2 is not conclusive. Knockdown of NOX4 attenuated high 
glucose induced H2O2 production in diabetic mice (1039). Production of H2O2 from 
endogenously expressed NOX4 has been observed in rat aortic smooth muscle cells 
as well (1049). Other studies have also showed that down-regulation of NOX4 
decreased O2¯  level (1050, 1051). On the other hand, recent studies have also shown 
that inhibition of the expression of NOX4 can alleviate oxidative stress in diabetic 
mice (1039). Sedeek et al. (514) also demonstrated the critical role of NOX4-based 
NOX in glucose induced oxidative stress in type 2 diabetes. On the other hand, the 
protective action of NOX4 in vasculature has also been reported. Schroder et al. 
(1052) showed that NOX4 prevented vasculature from endothelial dysfunction by 
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increasing the expression of eNOS and NO generation. Ray et al. (217) demonstrated 
a vasodilating effect of NOX4. The high glucose induced increase in the expression 
of NOX4 has been confirmed in our study, indicating its involvement in high glucose 
induced eNOS uncoupling in EA.hy926 cells. In addition, we also observed that 
wortmannin significantly decreased the expression of NOX4. It has been reported 
that NOX is regulated by PI3K, PKC and NF-κB pathways are involved in (44, 1043, 
1053). Thus, the results indicated that PI3K pathway may be involved in the 
regulation of NOX4 expression in high glucose induced EA.hy926 cells. Further 
studies are necessary to elucidate the exact role of PI3K signaling pathway in the 
regulation of NOX4 expression.   
 
BH4 is an essential cofactor for the eNOS function and an inadequate supply of 
cellular BH4 has been linked to endothelial eNOS uncoupling (430, 801, 1022, 1042). 
In the present study, we observed a significant lower intracellular level of BH4 under 
the high glucose condition, indicating the bioavailability of BH4 is reduced. 
Importantly, the ratio of BH4 to BH2 was reduced significantly after cells were 
treated with high glucose, which is consistent with previous observations that the 
relative concentration of BH4 and BH2 is important in determining the redox 
regulation of eNOS (1054). This reduction on BH4/BH2 ratio is likely to be due to 
suppressed activities of enzymes involved in BH4 synthesis or conversion. This is 
supported by the present finding that high glucose inhibited the expressions of 
GTPCH1 and DHFR, indicated that high glucose impaired both de novo biosynthetic 
and salvage pathways of BH4, leading to intracellular BH4 deficiency and eNOS 
uncoupling. Taken together, these results indicate that high glucose induces eNOS 
uncoupling by reducing the ratio of BH4 to BH2. The link between BH4 and PI3K 
pathway is not clear. It is possible that the changes of PI3K and NOX induced by 
high glucose may be responsible for reduction of BH4 bioavailability, but further 
study is necessary to elucidate the mechanism involved.   
 
HSP90 has a regulatory effect on eNOS function (411, 1055, 1056). It has been 
reported that inhibition of HSP90 caused a reduction of eNOS expression and 
phosphorylation in HUVECs (1057, 1058), leading to eNOS uncoupling with a 
decrease in enzymatic activity and NO release (412). The finding of high glucose 
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decreased the expression of HSP90 supports the involvement of this protein in eNOS 
uncoupling. Thus, it is possible that increase in HSP90 expression may salvage 
eNOS function.  
 
In summary, EA.hy926 cells under a high glucose exposure showed an eNOS 
uncoupling, with reduced NO production and increased superoxide production. High 
glucose also inhibited the activity and expression of NOX4, decreased the ratio of 
BH4 to BH2 and suppressed the expressions of GTPCH1, DHFR, and HSP90. PI3K 
signal pathway may be responsible for the up-regulation of NOX4. The study 
provides an insight into the mechanisms of high glucose induced eNOS uncoupling. 
Importantly, the study has successfully established a cell model which can be useful 
for studying the effects of Danshen compounds on eNOS uncoupling and endothelial 
dysfunction.  
 
192 
 
6 Chapter 6. Effect of Tanshinones on high glucose induced eNOS 
Uncoupling in EA.hy926 cells 
6.1 Introduction 
As mentioned as in Chapter 1, endothelial dysfunction has been implicated in the 
pathogenesis of important cardiovascular and metabolic diseases such as 
atherosclerosis, diabetes and obesity (56, 77, 78). The key mechanism of endothelial 
dysfunction is the imbalance of endothelium derived NO production and ROS 
generation, resulting in a decline in the bioavailability of NO and excessive 
accumulation of ROS (1, 78). This finally leads to oxidative stress and cellular 
injuries. In the vasculature, the main sources of ROS are those generated from NOXs, 
a family consisting of seven enzymes (NOX1-5, DUOX1 and DUOX2) which are 
composed of a number of regulatory and catalytic subunits (4, 308, 1048). Recent 
evidence indicates that NOX1, NOX2 and NOX4 play important roles in the 
regulation of cardiovascular functions (1, 1048). For example, NOX4-based NOX 
has been shown to mediate glucose induced oxidative stress in diabetes (514, 1059); 
and the overexpression of NOX2 potentiated vascular oxidative stress (104). 
 
eNOS is a critical enzyme for the maintenance of cardiovascular function by 
producing NO. It catalyzes the formation of NO from L-arginine and O2 in a reaction 
requiring several cofactors including Ca2+/CaM, FAD, FMN, NADPH, and 
BH4. However, under certain pathological circumstances and oxidative stress 
conditions, eNOS can be uncoupled, leading to generation of superoxide instead of 
NO (429-431). BH4 is a crucial cofactor for the activity of eNOS. An inadequate 
supply of cellular BH4 has been linked to eNOS uncoupling and endothelial 
dysfunction, whereas supplementation with BH4 has been shown to improve eNOS 
coupling and endothelial function (430). Endogenous BH4 is formed by a de novo 
synthesis pathway and a salvage pathway that restore BH4 from its oxidized form 
BH2 (430, 431, 456, 1060). Studies indicate that the relative concentration of BH4 
over BH2 plays a determining role in the redox regulation of eNOS-modulated 
endothelial responses since BH2 itself can cause eNOS dysfunction (1054). Elevated 
eNOS expression without further increase in BH4 level can also result in eNOS 
uncoupling due to an imbalance of eNOS enzyme and cofactors (1042). Other 
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mechanisms involved in eNOS uncoupling include S-glutathionylation of eNOS (415) 
and disruption of associations of eNOS with certain regulators such as HSP90 (411, 
1055, 1056).  
 
Tan I, Tan II and CT are the most abundant pharmacologically active tanshinones 
isolated from Danshen. The beneficial effects of these tanshinones on endothelial 
function have been extensively studied which are described in Section 1.7. However, 
it is still unclear whether these three major tanshinones affects eNOS uncoupling and 
if so, what mechanisms are involved. We hypothesize that Tan I, Tan IIA and CT can 
regulate eNOS uncoupling in ECs through targeting NOXs and cofactors of eNOS. 
In this part, we aimed to investigate the effects of Tan I, Tan IIA and CT on eNOS 
uncoupling induced by high glucose in human ECs and to identify possible 
intracellular molecular targets involved. 
 
 
 
 
194 
 
6.2 Materials and methods 
See Chapter 2, Section 2.2.1 and 2.1.6 to 2.1.13.  
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6.3 Results 
6.3.1 Effect of tanshinones on cell viability 
First, the toxic effect of Tan I, Tan IIA and CT on EA.hy926 cells was determined by 
MTT assays. The cytotoxicity of these three tanshinones is in a concentration- and 
time-dependent manner in the tested range of 0.1-30µmol/L up to 48hr (Figure 6. 1). 
Under these conditions, 0.08% DMSO had no cytotoxic effects on cells (data were 
not shown). Cytotoxicity of three tanshinones increased in relation to rising 
concentrations and incubation times as shown in. Tan I, Tan IIA and CT did not exert 
a cytotoxic effect in the range of 0.1-10µmol/L within 24 hr, whereas Tan I and Tan 
IIA had a significant cytotoxic effect at the concentration of 10µmol/L after 
incubating 48hr with a decrease in cell viability of 40%. At the concentration of 
30µmol/L, three tanshinones significantly decreased the cell viability after incubating 
24 and 48hr, respectively. Moreover, after 48 hr treatment, CT exerted a cytotoxic 
effect at the concentrations of 1 µmol/L and 10 µmol/L, respectively.  
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Figure 6. 1. Cytotoxic effects of Tan I Tan IIA and CT on cultured EA.hy926 cells. 
Cytotoxic effects of Tan I Tan IIA and CT on ECs. EA.hy926 cells were seeded into 
96-well plate at a density of 5000 cells/well. MTT assay was performed as described 
in Methods. Data represent the mean ± S.E. derived from five independent 
experiments. *, p<0.05. 
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6.3.2 Effect of tanshinones on high glucose induced superoxide production 
In order to evaluate the effect of Tan I, Tan IIA and CT on superoxide production 
under eNOS uncoupling condition, we examined the effect of Tan I, Tan IIA and CT 
on high glucose induced superoxide production in EA.hy926 cell line. Tan I, Tan IIA 
and CT, in a concentration range (1-10 µM) which did not affect the cell viability as 
determined by MTT assay, significantly and concentration-dependently inhibited 
high glucose induced superoxide production (Figure 6. 2). Tan I and Tan IIA at 1 
µM and 3 µM, respectively produced a similar inhibition as that caused by L-NAME 
at 100 µM; Among these three tanshinones, CT showed the most effective inhibitory 
effect on superoxide production (Figure 6. 2). These results demonstrate that Tan I, 
Tan II and CT has an inhibitory action on NOXs and NOS driven superoxide 
production under high glucose condition.   
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Figure 6. 2. Effect of Tan I, Tan IIA and CT on superoxide production in cultured 
EA.hy926 cells. Cells and cell homogenates were treated as described in Materials & 
Methods. Superoxide production was evaluated by 5 µM/L lucigenin-enhanced 
chemiluminescence assay. (##, p< 0.01 versus low glucose group; *, p<0.05 and **, 
p<0.01 versus 48 hr high glucose group). Data represent the mean ± S.E.M. derived 
from four independent experiments. -: low glucose (5.5 mM); + and ++: treatment of 
high glucose (35 mM) for 24 and 48 hr, respectively. 
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6.3.3 Effect of tanshinones on high glucose induced inhibition of NO 
generation 
Further to investigate the underlying molecular mechanism of tanshinones’ vascular 
protective effects, we tested the regulatory effect of Tan I, Tan IIA and CT on the 
activity of eNOS under high glucose condition. Tan I, Tan IIA and CT significantly 
increased the NO generation under high glucose condition with all tested 
concentrations, and the effect was abolished by L-NAME (100 µM) (Figure 6. 3). 
From these results, we conclude that Tan I, Tan IIA and CT improve the function of 
eNOS which was impaired by oxidative stress under high glucose condition. 
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Figure 6. 3. Effect of Tan I, Tan IIA, and CT on NO production in cultured 
EA.hy926 cells. Cells were treated as described in Methods. The intracellular level of 
NO was measured using the fluorescent probe DAF-2-DA. (##, p< 0.01 versus low 
glucose group; **, p<0.01 versus 48 hr high glucose group). Data represent the mean 
± S.E.M. derived from three independent experiments. -: low glucose; + and ++: 
treatment of high glucose for 24 hr and 48 hr, respectively.  
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6.3.4 Effect of tanshinones on NOX expression 
Since NOX4 is the dominant and constitutive superoxide producing enzyme in ECs, 
we evaluated the effect of Tan I, Tan IIA and CT on NOX4 expression under high 
glucose condition. As we observed that the expressions of NOX4 were significantly 
increased (up to more than 2-fold) compared to the control at 5.5 mM glucose 
(Figure 5. 3), when the cells were incubated with high glucose initially for 24 hr then 
treated with Tan I, Tan IIA and CT for another 24 hr, respectively, the expressions of 
NOX4 were markedly decreased, to a level similar to that at the low glucose (Figure 
6. 4). Moreover, compared to 24 hr high glucose treatment, Tan I, Tan IIA and CT 
down-regulated the expression of NOX4 significantly (Figure 6. 4). The results 
indicate that Tan I, Tan IIA and CT can regulate the expression of NOX4 to exert its 
inhibition of superoxide production under the high glucose condition. 
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Figure 6. 4. Effects of high glucose and Tan I, Tan IIA and CT on the expression of 
NOX4 in cultured EA.hy926 cells. Cells and cell lysates were treated as indicated in 
Methods. A: a representative experiment showing high glucose (35 mM) induced 
increases in NOX4 expressions and the effects of Tan I, Tan IIA and CT. B: the 
result of densitometric analyses of graphing the expression of NOX4. (#, p<0.05 and 
##, p< 0.01 versus low glucose group; ^, p<0.01 and **, p<0.01 versus 24 hr and 48 
hr high glucose group, respectively.). Data represent the mean ± S.E.M. derived from 
three independent experiments. -: low glucose; + and ++: treatment of high glucose 
for 24 hr and 48 hr, respectively. 
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6.3.5 Effect of tanshinones on eNOS expression 
To confirm the eNOS uncoupling under the high glucose condition, we examined the 
change of eNOS forms (dimer and monomer). When the cells were firstly treated 
with high glucose for 24 hr and then received a 24 hr treatment of Tan I, Tan IIA and 
CT for another 24 hr, respectively, the ratio of eNOS dimer to monomer was 
recovered without significantly changes in total eNOS (Figure 6. 5). Furthermore, 
compared to 24 hr high glucose treatment, there was a significant increase in the ratio 
of eNOS dimer to monomer at high concentration of Tan IIA at 10 µM; whereas, Tan 
I and CT exerted the most beneficial action with a concentration of 3 and 1 µM, 
respectively. These results demonstrate that Tan I, Tan IIA and CT reverse the 
changes from dimeric to monomeric eNOS induced by high glucose exposure. 
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Figure 6. 5. Effects of Tan I, Tan IIA and CT on the ratio of eNOS dimer to 
monomer in cultured EA.hy926 cells. Cells and cell lysates were treated as indicated 
in Methods. The ratio of eNOS dimer to monomer decreased after high glucose 
treatment for 24 hr. Tan I, Tan IIA and CT significantly increased the ratio of eNOS 
dimer to monomer which was decreased by high glucose. A: A representative 
experiment showing high glucose (35 mM) induced decreases in expressions of 
eNOS dimer, monomer and total eNOS, and the effects of Tan I, Tan IIA and CT. B: 
Results of densitometric analyses graphing the ratio of eNOS dimer to monomer. 
Data represent the mean ± S.E.M. derived from three independent experiments (##, 
p< 0.01 versus low glucose group; *, p<0.05 and **, p<0.01 versus 48 hr high 
glucose group; ^, p<0.01 versus 24 hr high glucose group.). -: low glucose; + and ++: 
treatment of high glucose for 24 hr and 48 hr, respectively. 
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6.3.6 Effect of tanshinones on intracellular BH4 and BH2 levels  
Given that BH4 is a crucial cofactor for eNOS function and coupling, we examined 
the effect of Tan I, Tan IIA and CT on the changes of intracellular biopterin 
concentrations in endothelial cell line under high glucose condition. By measuring 
the levels of BH4 to BH2 and its ratio, we have already found that cells treated with 
high glucose for 24 hr and 48 hr showed a significant lower level of ratio of BH4 to 
BH2. When the cells were cultured in high glucose media initially for 24 hr then 
treated with Tan I, Tan IIA and CT for another 24 hr, the ratio of BH4 to BH2 was 
significantly increased with a high concentration of Tan I, Tan IIA and CT (10 µM) 
(Figure 6. 6). Compared to the other two tanshinones, Tan I had the most effective 
action on the increase in the ratio of BH4 to BH2. The results indicate that Tan I, Tan 
IIA and CT can reduce eNOS uncoupling by increasing the ratio of BH4 to BH2.  
 
206 
 
 
Figure 6. 6. Intracellular levels of BH4 and BH2 in cultured EA.hy926 cells. All the 
samples were treated as described in Methods. The ratio of BH4 to BH2 was 
markedly decreased in high glucose (35 mM) condition. Tan I, Tan IIA and CT 
reduced the high glucose induced BH4 depletion in a concentration-dependent 
manner. Data represent the mean ± S.E.M. derived from three independent 
experiments (##, p< 0.01 versus low glucose; **, p<0.01 versus high glucose group). 
-: low glucose; + and ++: treatment of high glucose for 24 hr and 48 hr, respectively. 
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6.3.7 Effect of tanshinones on expressions of GTPCH1 and DHFR 
To determine whether the effect of Tan I, Tan IIA and CT on regulation of 
intracellular biopterin concentrations involves the de novo synthesis and conversion 
pathways, we examined the effects of Tan IIA on the expression of GTPCH1, the 
rate-limiting enzyme in BH4 synthesis, and DHFR, the enzyme responsible for the 
conversion of BH2 to BH4. Based on the effect of Tan I, Tan IIA and CT on the ratio 
of BH4 to BH2, we tested the effect of 10 µM Tan I, Tan IIA and CT. When the cells 
were cultured in high glucose media initially for 24 hr then treated with Tan I, Tan 
IIA and CT for another 24 hr, the expression of GTPCH1 and DHFR was 
significantly increased (Figure 6. 7), which were suppressed under high glucose 
condition. These results demonstrate that Tan I, Tan IIA and CT increases the ratio 
of BH4 to BH2 through enhancing the expression of GTPCH1 and DHFR.   
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Figure 6. 7. Effects of high glucose and Tan I, Tan IIA and CT on the expressions of 
GTPCH1 and DHFR in cultured EA.hy926 cells. Cells and cell lysates were treated 
as indicated in Methods. The expressions of GTPCH1 and DHFR were inhibited by 
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high glucose (35 mM). Tan I, Tan IIA and CT (10 µM) significantly enhanced the 
expressions of GTPCH1 and DHFR which were suppressed by high glucose. A: a 
representative experiment showing high glucose (35 mM) induced decreases in 
expressions of GTPCH1, and the effects of Tan I, Tan IIA and CT. B: a 
representative experiment showing high glucose (35 mM) induced decreases in 
expressions of DHFR, and the effects of Tan I, Tan IIA and CT. C: Results of 
densitometric analyses graphing the expressions of GTPCH1 and DHFR. Data 
represent the mean ± S.E.M. derived from three independent experiments (#, p<0.05 
and ##, p< 0.01 versus low glucose group; **, p<0.01 versus high glucose group). -: 
low glucose; + and ++: treatment of high glucose for 24 hr and 48 hr, respectively. 
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6.3.8 Effect of tanshinones on expression of HSP90 
As HSP90 is an important chaperone regulating eNOS function and superoxide 
production. We examined the effect of Tan I, Tan IIA and CT on expression of 
HSP90 under the high glucose condition. When the cells were incubated with high 
glucose initially for 24 hr then treated with Tam I, Tan IIA and CT for another 24 hr, 
the expressions of HSP90 were significantly increased in a concentration-dependent 
manner (Figure 6. 8). The decrease in expression of HSP90 was significantly 
reversed by 3 and 10 µM of  Tan I, Tan IIA and CT, compared to those at the high 
glucose condition at 24 and 48 hr. The results demonstrate that Tan I, Tan IIA and 
CT can reverse the impairment of HSP90 expression elicited by high glucose 
exposure, resulting in improved function of eNOS.    
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Figure 6. 8. Effects of high glucose and Tan I, Tan IIA and CT on the expression of 
HSP90 in cultured EA.hy926 cells. Cells and cell lysates were treated as indicated in 
Methods. A: A representative experiment showing high glucose (35 mM) induced 
decreases in expressions of HSP90, and the effects of Tan IIA. B: Results of 
densitometric analyses graphing the expressions of HSP90. Data represent the mean 
± S.E.M. derived from three independent experiments (#, p< 0.05 versus low glucose 
group; *, p< 0.05 and **, p<0.01 versus high glucose group; ^, p<0.01 versus 24 hr 
high glucose group). -: low glucose; + and ++: treatment of high glucose for 24 hr 
and 48 hr, respectively. 
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6.3.9 Effect of tanshinones on expression of PI3K 
Since it has been reported that NOX expression is regulated by PI3K (1043) and we 
found that inhibition of PI3K caused a reduction in the expression of NOX4 (Figure 
5. 9). Thus, we examined the effect of Tan I, Tan IIA and CT on the expression of 
PI3K in high glucose treated cells. When the cells were incubated with high glucose 
initially for 24 hr then treated with Tan I, Tan IIA and CT for another 24 hr, the 
expressions of PI3K were significantly decreased (Figure 6. 9). These findings 
indicate that PI3K pathway plays a role in oxidative stress under high glucose 
condition and it is involved in the actions of Tan II against eNOS uncoupling in 
human ECs.  
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Figure 6. 9. Effects of Tan I, Tan IIA and CT on expression of PI3K in cultured 
EA.hy926 cells. Cells and cell lysates were treated as indicated in Methods. Tan I, 
Tan IIA and CT significantly suppressed the expressions of PI3K which were 
enhanced by high glucose. A: results from a representative experiment that was 
performed three times with equivalent results. B: results of densitometric analyses 
graphing the expression of p110β. Data represent the mean ±S.E.M. derived from 
three independent experiments (##, p< 0.01 versus low glucose group; **, p<0.01 
versus high glucose group). -: low glucose; + and ++: treatment of high glucose for 
24 hr and 48 hr, respectively. 
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6.4 Discussion 
The aim of this study was to examine if Tan I, Tan IIA and CT, three main active 
constituent isolated from S. Miltiorrhiza, regulate eNOS uncoupling in EA.hy926 
cells through targeting NOXs and cofactors of eNOS. Using the high glucose 
induced eNOS uncoupling cell model as described in Chapter  5, the effects of three 
main tanshinones on eNOS uncoupling were examined. We have focused on the 
therapeutic ability of Tan I, Tan IIA and CT, in endothelial dysfunction caused by 
high glucose exposure. The main finding is that high glucose induced eNOS 
uncoupling in EA.hy926 cells can be restored by Tan I, Tan IIA and CT. To the best 
of our knowledge this is the first report of the effects of tanshinone compounds on 
eNOS uncoupling in human ECs. 
 
It has been reported that eNOS is a potential vascular target of Danshen. Tan IIA has 
been recently reported to regulate eNOS function by phosphorylation of eNOS to 
increase NO generation (1061). It is also reported that CT is capable of increasing 
NO production by upregulating eNOS expression in HUVECs (667). These 
compounds have reported with superoxide scavenging and NO stimulator properties 
in vascular ECs (642, 667, 1061-1065), anti-adhesion (640, 661, 662), and 
vasodilating effect (1066).  The findings in this study showed that Tan I, Tan IIA and 
CT may act by regulating the dimerization of eNOS rather than increase total eNOS 
enzymes. This new finding may help for further understanding of the cardiovascular 
protective actions of Danshen, in particular, the beneficial actions of  Tan I, Tan IIA 
and CT (600, 642, 1067, 1068).  
 
NOXs are the primary source of superoxide in vasculature with at least seven 
members: NOX1 to NOX5 and Duox1 and Duox2 (61, 1047, 1048). As discussed in 
Chapter 5, NOX4 contributed to the superoxide production in high glucose treated 
EA.hy926 cells. The finding that Tan I, Tan IIA and CT inhibited the expression of 
NOX4 in high glucose treated EA.hy926 cells indicates that NOX4 may play a role 
in mediating the antioxidant action of Tan I, Tan IIA and CT by inhibiting ROS 
production via inhibition of NOX4. The exact mechanism of these tanshinones 
induced NOX4 inhibition is unclear. The regulation on NOXs has been reported 
involving PI3K, PKC and NF-κB pathways (44, 1043, 1053, 1069-1072). We also 
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observed that wortmannin significantly decreased the expression of NOX4, and Tan I, 
Tan IIA and CT suppressed the expression of PI3K which was increased under high 
glucose condition. These results, suggest that tanshinones may decrease the 
expression of NOX4 and restores eNOS uncoupling via, at least partially, PI3K 
pathway. Further studies are necessary to elucidate the role of PI3K signaling 
pathway in tanshinones induced regulation of NOX4 expression.  
 
Further to the beneficial actions of three tanshinones on eNOS uncoupling, we found 
that Tan I, Tan IIA and CT increased the BH4/BH2 ratio indicates that it may 
improve eNOS uncoupling by increasing the bioavailability of BH4. BH4, which is 
an essential cofactor for the eNOS function. Inadequate supply of cellular BH4 has 
been linked to endothelial eNOS uncoupling (430, 801, 1022, 1042). The increase in 
bioavailability of BH4 by tanshinones is likely to be mediated by enzymes involved 
in BH4 synthesis or conversion. This is supported by the finding that Tan I, Tan IIA 
and CT counteracted the inhibitory effects of high glucose treatment on expressions 
of GTPCH1 and DHFR. The findings suggest that high glucose impaired both de 
novo biosynthetic and salvage pathways of BH4, leading to intracellular BH4 
deficiency and eNOS uncoupling; Tan I, Tan IIA and CT may regulate BH4 
synthesis to maintain adequate intracellular BH4 content by increasing the 
expressions of GTPCH1 and DHFR, and/or prevent BH4 from oxidation by its anti-
oxidative effects. The enhancing effect of Tan I, Tan IIA and CT on the ratio of BH4 
to BH2 in ECs has not been reported previously. We have also observed that when 
the cells were incubated with high glucose initially for 24 hr then treated with 
wortmannin for another 24 hr, the ratio of BH4 to BH2 was increased. Taken 
together, these results indicate that Tan I, Tan IIA and CT restore eNOS uncoupling 
by increasing the ratio of BH4 to BH2 which may also involve PI3K pathway.  
 
Additionally, we also investigated the involvement of HSP90 in actions of Tan I, Tan 
IIA and CT, as it has been known that HSP90 has a regulatory effect on eNOS 
function (411, 1055, 1056). It has been reported that inhibition of HSP90 caused a 
reduction of eNOS expression and phosphorylation in HUVECs (1057, 1058), 
leading to eNOS uncoupling with a decrease in enzymatic activity and NO release 
(412). Thus, increase in HSP90 expression may salvage eNOS function with an 
216 
 
increase in its enzymatic activity and NO release. The finding that Tan I, Tan IIA and 
CT restored the decrease in the expression of HSP90 under high glucose condition 
indicates that these tanshinones may regulate eNOS function by acting on HSP90. It 
was noted that the actions of Tan I, Tan IIA and CT on HSP90 expression occurred 
at a lower concentration that its action on BH4 levels (Figure 6. 8). Thus, it is 
possible that tanshinones may act on multiple mechanisms on restoring eNOS 
uncoupling, at low concentrations acting through regulating of interactions of HSP90 
with eNOS. At a higher concentration, it may regulate expressions of GTPCH1 and 
DHFR and subsequent BH4 levels. Further study is necessary to elucidate the 
mechanism involved in Tan I, Tan IIA an CT’s effect on regulation of HSP90-eNOS 
interaction. It should be pointed out that the present study does not exclude the 
possibility of involving other mechanisms such as S-glutathionylation of eNOS (415) 
in protection of Tan I, Tan IIA and CT against eNOS uncoupling.  
 
In summary, Tan I, Tan IIA and CT restored eNOS coupling in high glucose treated 
EA.hy926 cells by inhibiting the activity and expression of NOX4, increasing the 
ratio of BH4 to BH2 and promoting the expressions of GTPCH1, DHFR, and HSP90, 
the effect may involve PI3K pathway. The study provides an insight into the 
mechanisms of endothelial protections of tanshinones. Future study on the 
mechanisms involved in the restoration of eNOS uncoupling by tanshinones and 
related compounds may help to develop new agents to treat eNOS uncoupling-
mediated cardiovascular and metabolic diseases. Thus, in next part, we are going to 
test the effect of two new compounds derived from tanshinone on eNOS uncoupling.   
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7 Chapter 7. Effect of tanshinone derivatives (AC1 and AC2) on eNOS 
uncoupling in EA.hy926 cells 
7.1 Introduction 
As described in the Chapter 6, three major tanshinones, Tan I, Tan IIA and CT, are 
able to improve eNOS uncoupling by manipulating multiple intracellular molecular 
targets (eg BH4, eNOS, NOX and PI3K). This provides an inspiration to study and 
develop new compounds derived from tanshinones in order to improve certain 
feature of tanshinone, such as low bioavailability (807).  
 
Recently, the approach that modifying the known structure and manipulating 
physicochemical properties to generate new compound with better ADME/Tox 
profile and pharmacological effect is very inspiring. Tanshinones such as Tan I, Tan 
IIA and CT have a wide range of beneficial actions, in particular cardiovascular 
protective effect. However, they exhibited a low hydrophilcity and can interact with 
a number of drugs. So, if we can identify compounds with similar actions as 
tanshinones but with a better bioavailability it will help to develop new drugs to treat 
eNOS uncoupling and endsothelium dysfucntions.  
 
Thus, we will test the effect of two new tanshinone derivatives (AC1 and AC2, 
synthesised by the Department of Chemistry, RMIT Univeristy. Structures are not 
shown due to IP concerns) on eNOS uncoupling using the same model and methods 
as described in Chapter 6, and evaluated the potential molecular targets involved in 
the process.  
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7.2 Materials and methods 
See Chapter 2, Section 2.2.1 and 2.1.6 to 2.1.13.  
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7.3 Results 
7.3.1 Effect of AC1 and AC2 on cell viability 
The toxic effect of AC1 and AC2 on EA.hy926 cells was determined by MTT assays. 
Unlike the previous three tanshinones, these two tanshinone derivatives did not have 
significant cytotoxic effect on EA.hy926 cells in the tested range of 0.1-30µmol/L up 
to 48 hr (Figure 7. 1), except for AC1 with a concentration of 30µmol/L after 48 hr 
treatment.   
220 
 
       
 
Figure 7. 1. Cytotoxic effects of AC1 and AC2 on cultured EA.hy926 cells.  
Cytotoxic effects of AC1 and AC2 on ECs. EA.hy926 cells were seeded into 96-well 
plate at a density of 5000 cells/well. MTT assay was performed as described in 
Methods. Data represent the mean ± S.E. derived from five independent experiments. 
*, p<0.05. 
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7.3.2 Effect of AC1 and AC2 on high glucose induced superoxide 
production 
As showed in Chapter 3, we observed that high glucose induced increase in 
superoxide production was significantly inhibited by both L-NAME (100 µM) and 
DPI (5 µM). We next tested the effect of AC1 and AC2 on high glucose induced 
superoxide production. AC1 and AC2 in a concentration range (1-10 µM) which did 
not affect the cell viability as determined by MTT assay, significantly and 
concentration-dependently inhibited high glucose induced superoxide production 
(Figure 7. 2). Both AC1 and AC2 at 1 µM produced a similar inhibition as that 
caused by L-NAME at 100 µM. These results demonstrate that AC1 and AC2 have 
an inhibitory action on NOXs and NOS-driven superoxide production under high 
glucose condition.   
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Figure 7. 2. Effect of different concentrations of AC1 and AC2 on superoxide 
production in cultured EA.hy926 cells. Cells and cell homogenates were treated as 
described in Materials & Methods. Superoxide production was evaluated by 5 µM/L 
lucigenin-enhanced chemiluminescence assay. Effect of different concentrations of 
AC1, AC2, L-NAME (100 µM), Apo (100 µM) and DPI (5 µM) on superoxide 
production under high glucose condition. (##, p< 0.01 versus low glucose group). (##, 
p< 0.01 versus low glucose group; *, p<0.05 and **, p<0.01 versus 48 hr high 
glucose group). Data represent the mean ± S.E.M. derived from four independent 
experiments. -: low glucose (5.5 mM); + and ++: treatment of high glucose (35 mM) 
for 24 and 48 hr, respectively. 
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7.3.3 Effect of AC1 and AC2 on high glucose induced inhibition of NO 
generation 
As shown in Chapter 5, high glucose significantly reduced the NO production 
compared to the control (5.5 mM glucose). AC1 significantly increased the NO 
production under high glucose condition in all tested concentrations (Figure 7. 3). 
Likewise, AC2 exerted a similar effect on NO generation at all tested concentrations 
(Figure 7. 3). No significant difference was observed between the action of AC1 and 
AC2. The effect of AC1 and AC2 was abolished by L-NAME (100 µM).  
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Figure 7. 3. Effect of different concentrations of AC1 and AC2 on NO production in 
cultured EA.hy926 cells. Cells were treated as described in Methods. The 
intracellular level of NO was measured using the fluorescent probe DAF-2-DA. (##, 
p< 0.01 versus low glucose group; **, p<0.01 versus 48 hr high glucose group). Data 
represent the mean ± S.E.M. derived from three independent experiments. -: low 
glucose; + and ++: treatment of high glucose for 24 hr and 48 hr, respectively. 
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7.3.4 Effect of AC1 and AC2 on NOX expression 
Similar to that in Chapter 6, the expression of NOX4 was significantly increased 
under high glucose condition. Both AC1 and AC2 significantly inhibited the 
expressions of NOX4 (Figure 7. 4). AC1 exerted a significant inhibitory effect on 
the expressions of NOX4 in a dose-dependent manner. Whereas, AC2 significantly 
down-regulated the expressions of NOX4 to a level similar to that at the low glucose 
in all tested concentrations. The results suggest that AC1 and AC2 can regulate the 
expression of NOX4 to exert their inhibitory effect on superoxide production under 
the high glucose condition. 
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Figure 7. 4. Effects of high glucose and AC1 and AC2 on the expression of NOX4 
in cultured EA.hy926 cells. Cells and cell lysates were treated as indicated in 
Methods. A: a representative experiment showing high glucose (35 mM) induced 
increases in NOX4 expressions and the effects of AC1 and AC2. B: the result of 
densitometric analyses of graphing the expression of NOX4. (#, p<0.05 and ##, p< 
0.01 versus low glucose group; ^, p<0.01 and **, p<0.01 versus 24 hr and 48 hr high 
glucose group, respectively.). Data represent the mean ± S.E.M. derived from three 
independent experiments. -: low glucose; + and ++: treatment of high glucose for 24 
hr and 48 hr, respectively. 
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7.3.5 Effect of AC1 and AC2 on eNOS expression 
Similarly, high glucose significantly reduced the ratio of eNOS dimer to monomer by 
50% after 48 hr high glucose treatment. When the cells were treated with AC1 and 
AC2, the ratio of eNOS dimer to monomer was normalized. AC1 significantly 
increased the homodimerization of eNOS at all tested concentrations with similar 
efficacy (Figure 7. 5). Likewise, AC2 exerted a similar effect on the 
homodimerization of eNOS at all tested concentrations; however, the effect of 10 
µM of AC2 was weaker than that of the lower concentrations (Figure 7. 5). These 
results indicate that AC1 and AC2 can reverse the change of eNOS from dimeric to 
monomeric eNOS induced by high glucose. 
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Figure 7. 5. Effects of high glucose and AC1 and AC2 on the ratio of eNOS dimer to 
monomer in cultured EA.hy926 cells. Cells and cell lysates were treated as indicated 
in Methods. The ratio of eNOS dimer to monomer decreased after high glucose 
treatment for 24 hr. AC1 and AC2 significantly increased the ratio of eNOS dimer to 
monomer which was decreased by high glucose. A: A representative experiment 
showing high glucose (35 mM) induced decreases in expressions of eNOS dimer, 
monomer and total eNOS, and the effects of AC1 and AC2. B: Results of 
densitometric analyses graphing the ratio of eNOS dimer to monomer. Data represent 
the mean ± S.E.M. derived from three independent experiments (##, p< 0.01 versus 
low glucose group; *, p<0.05 and **, p<0.01 versus 48 hr high glucose group; ^, 
p<0.01 versus 24 hr high glucose group.). -: low glucose; + and ++: treatment of high 
glucose for 24 hr and 48 hr, respectively. 
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7.3.6 Effect of AC1 and AC2 on intracellular BH4 and BH2 levels  
Similar to tanshinones, the effects of AC1 and AC2 on intracellular biopterin 
concentrations in high glucose treated cells were examined. The ratio of BH4 to BH2 
was significantly increased by both AC1 and AC2 with concentrations of 3 and 10 
µM (Figure 7. 6). The results indicate that AC1 and AC2 can reduce eNOS 
uncoupling by increasing the ratio of BH4 to BH2. 
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Figure 7. 6. Intracellular levels of BH4 and BH2 in cultured EA.hy926 cells. All the 
samples were treated as described in Methods. The ratio of BH4 to BH2 was 
markedly decreased in high glucose (35 mM) condition. Tan IIA reduced the high 
glucose induced BH4 depletion in a concentration-dependent manner. Data represent 
the mean ± S.E.M. derived from three independent experiments (##, p< 0.01 versus 
low glucose; **, p<0.01 versus high glucose group). -: low glucose; + and ++: 
treatment of high glucose for 24 hr and 48 hr, respectively. 
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7.3.7 Effect of AC1 and AC2 on expressions of GTPCH1 and DHFR 
Further to determine whether AC1 and AC2 regulate biopterin concentrations via de 
novo synthesis and conversion pathways, the effects of AC1 and AC2 on the 
expression of GTPCH1, the rate-limiting enzyme in BH4 synthesis, and DHFR, the 
enzyme responsible for the conversion of BH2 to BH4, were examined. Treatment 
with AC1 and AC2 significantly increased the expressions of GTPCH1 and DHFR, 
respectively (Figure 7. 7). These results indicate that AC1 and AC2 increase the 
ratio of BH4 to BH2 through up-regulating the expression of GTPCH1 and DHFR.   
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Figure 7. 7. Effects of high glucose and AC1 and AC2 on the expressions of 
GTPCH1 and DHFR in cultured EA.hy926 cells. Cells and cell lysates were treated 
as indicated in Methods. The expressions of GTPCH1 and DHFR were inhibited by 
high glucose (35 mM). AC1 and AC2 (10 µM) significantly enhanced the 
expressions of GTPCH1 and DHFR which were suppressed by high glucose. A: a 
representative experiment showing high glucose (35 mM) induced decreases in 
expressions of GTPCH1, and the effects of AC1 and AC2. B: a representative 
experiment showing high glucose (35 mM) induced decreases in expressions of 
DHFR, and the effects of AC1 and AC2. C: Results of densitometric analyses 
graphing the expressions of GTPCH1 and DHFR. Data represent the mean ± S.E.M. 
derived from three independent experiments (#, p<0.05 and ##, p< 0.01 versus low 
glucose group; **, p<0.01 versus high glucose group). -: low glucose; + and ++: 
treatment of high glucose for 24 hr and 48 hr, respectively. 
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7.3.8 Effect of AC1 and AC2 on expression of HSP90 
As HSP90 has an important role in regulating eNOS function and superoxide 
generation, the effect of AC1 and AC2 on the expression of HSP90 in the eNOS 
uncoupling model was also examined. As described in Chapter 5, high glucose 
reduced the expression of HSP90, and this reduction in expression of HSP90 were 
significantly reversed by AC1 and AC2 (Figure 7. 8). AC1 normalized the 
expression of HSP90 at all tested concentrations with similar efficacy. AC2 reversed 
the decrease in the expression of HSP90 at 3 and 10 µM. The results demonstrate 
that AC1 and AC2 can reverse the impairment of HSP90 expression elicited by high 
glucose exposure, resulting in improved function of eNOS.    
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Figure 7. 8. Effects of high glucose and AC1 and AC2 on the expression of HSP90 
in cultured EA.hy926 cells. Cells and cell lysates were treated as indicated in 
Methods. A: A representative experiment showing high glucose (35 mM) induced 
decreases in expressions of HSP90, and the effects of AC1 and AC2. B: Results of 
densitometric analyses graphing the expressions of HSP90. Data represent the mean 
± S.E.M. derived from three independent experiments (#, p< 0.05 versus low glucose 
group; *, p< 0.05 and **, p<0.01 versus high glucose group; ^, p<0.01 versus 24 hr 
high glucose group). -: low glucose; + and ++: treatment of high glucose for 24 hr 
and 48 hr, respectively. 
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7.3.9 Effect of AC1 and AC2 on expression of PI3K 
Since NOX expression is regulated by PI3K (1043), and inhibition of PI3K resulting 
in decrease in the expression of NOX4 (see Chapter 5), thus, we further examined 
the effect of AC1 and AC2 on the expression of PI3K. AC1 and AC2 significantly 
inhibited the expression of PI3K at all tested concentrations showing similar efficacy 
(Figure 7. 9). These findings indicate that PI3K pathway may be involved in the 
actions of AC1 and AC2 against eNOS uncoupling in EA.hy926 cells.  
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Figure 7. 9. Effects of AC1 and AC2 on expression of PI3K in cultured EA.hy926 
cells. Cells and cell lysates were treated as indicated in Methods. AC1 and AC2 
significantly suppressed the expressions of PI3K which were enhanced by high 
glucose. A: results from a representative experiment that was performed three times 
with equivalent results. B: results of densitometric analyses graphing the expression 
of p110β. Data represent the mean ± S.E.M. derived from three independent 
experiments (##, p< 0.01 versus low glucose group; **, p<0.01 versus high glucose 
group). -: low glucose; + and ++: treatment of high glucose for 24 hr and 48 hr, 
respectively. 
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7.4 Discussion 
The aim of this study was to examine the effect of two new tanshinone derivatives 
AC1 and AC2 on endothelial function. The main finding is that high glucose induced 
eNOS uncoupling in human ECs can be restored by AC1 and AC2. This is the first 
report of the effects of AC1 and AC2 on eNOS uncoupling in human ECs.  
 
Our findings showed that AC1 and AC2 have similar actions as tanshinones to 
regualte eNOS by manipulating the dimerization of eNOS rather than increase total 
eNOS enzymes (against the decrease in the ratio of active form of eNOS (dimer) to 
its inactive form (monomer)). This is consistent with their effects on BH4 levels, 
indicating their therapeutic effects on eNOS uncoupling as eNOS monomerization is 
an indicator of eNOS uncoupling (426).  
 
It has been demonstrated that Tan I, Tan IIA and CT were capable of alleviating the 
oxidative stress through the inhibition of NOX4 expression (Chapter 6). In this part, 
we also found that AC1 and AC2 had the capability of inhibiting the expression of 
NOX4 which was increased in high glucose induced eNOS uncoupling cell model in 
EA.hy926 cell line. It is likely that AC1 and AC2 have a similar anti-oxidant action 
as tanshinones to inhibit ROS generating enzyme. In addition, since wortmannin 
significantly decreased the expression of NOX4 (Chapter 5), and AC1 and AC2 
suppressed the expression of PI3K which was increased under high glucose condition, 
AC1 and AC2 may act by decreasing NOX4 expression and restoring eNOS 
uncoupling via, at least partially, PI3K signalling pathway.  It has been previously 
reported that PI3K, PKC and NF-κB pathways are involved in the regulation on 
NOXs (44, 1043, 1053, 1069-1072). We have found that tanshinones suppressed the 
expression of PI3K under high glucose condition (Chapter 6). Further studies are 
needed to elucidate the role of PI3K signalling pathway in AC1 and AC2 induced 
regulation of NOX4 expression.   
 
Similar to tanshinones, AC1 and AC2 were able to increase the bioavailability of 
BH4 under high glucose condition. This effect is likely to involve GTPCH1 and 
DHFR, two important enzymes involved in BH4 synthesis or conversion. The 
findings suggest that high glucose impaired both de novo biosynthetic and salvage 
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pathways of BH4, leading to intracellular BH4 deficiency and eNOS uncoupling. 
AC1 and AC2 may regulate BH4 synthesis to maintain adequate intracellular BH4 
content by increasing the expressions of GTPCH1 and DHFR, and/or prevent BH4 
from oxidation by its anti-oxidative effects. The enhancing effect of AC1 and AC2 
on the ratio of BH4 to BH2 in ECs has not been reported previously. We have also 
observed that when the cells were incubated with high glucose initially for 24 hr then 
treated with wortmannin for another 24 hr, the ratio of BH4 to BH2 was increased. 
Taken together, these results indicate that AC1 and AC2 can restore eNOS 
uncoupling by increasing the ratio of BH4 to BH2 which may also involve PI3K 
pathway.  
 
We have also investigated the involvement of HSP90 in actions of AC1 and AC2, 
AC1 and AC2 restored the decrease in the expression of HSP90 under high glucose 
condition. The finding indicates that AC1 and AC2 may regulate eNOS function by 
acting on HSP90. Similarly, it was noted that the actions of AC1 and AC2 on HSP90 
expression occurred at a lower concentration that its action on BH4 levels (Figure 7. 
8). Thus it is possible, AC1 and AC2 may act on multiple mechanisms on restoring 
eNOS uncoupling, at low concentrations it may act through regulating of interactions 
of HSP90 with eNOS. At a higher concentration, it may regulate expressions of 
GTPCH1 and DHFR and subsequent BH4 levels. Further study is necessary to 
elucidate the mechanism involved in AC1 and AC2’s effect on regulation of HSP90-
eNOS interaction. Thus, the actions of AC1 and AC2 are similar to that observed for 
tanshinones (Chapter 6). Similarly, the present study does not exclude the possibility 
of involving other mechanisms such as S-glutathionylation of eNOS (415) in 
protection of AC1 and AC2 against eNOS uncoupling.  
 
In summary, both AC1 and AC2 restored eNOS coupling by inhibiting the activity 
and expression of NOX4, increasing the ratio of BH4 to BH2 and promoting the 
expressions of GTPCH1, DHFR, and HSP90, the effect may involve PI3K pathway. 
The study provides an insight into the mechanisms of endothelial protections of 
tanshinone derivatives. Future study on the mechanisms involved in the restoration 
of eNOS uncoupling by AC1 and AC2 and related compounds may help to develop 
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new agents to treat eNOS uncoupling-mediated cardiovascular and metabolic 
diseases. 
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8 Chapter 8. General Discussion 
8.1 Major finding of the study 
8.1.1 Computational analysis of Danshen compounds and other natural 
products 
Traditional drug discovery and development process involves using various in vitro 
and in vivo approaches to characterize the pharmacological actions and ADME/Tox 
profiles of compounds or drug candidates. However, the limitation of experimental 
capacity and chemical synthesis makes it a difficult and costly exercise to screen and 
test huge numbers of compounds. The development and use of in silico approaches 
in drug research has made it possible to virtually screen a large number of 
compounds without physical synthesis of these compounds. In recent years, studies 
using in silico approaches have been integrated into the process of drug discovery 
and development, which has accelerated the analysis of physicochemical properties, 
biological fate, toxicity and drug interactions. The application of in silico approaches 
has significantly enhanced the drug discovery and development process, especially 
for characterization of ADME/Tox profiles of various compounds or drug candidates 
in early stage of drug development to reduce the high cost of bench work and 
minimize the risk of late-stage undesired actions of drug candidates, such as 
undesirable ADME properties or toxicity. As many current drugs or drug candidates 
are derived from natural sources, predication of the biological fate and toxicity of 
natural products using in silico approaches in combination with in vitro and in vivo 
methods, will facilitate the development of novel drugs from natural compounds with 
reduced risks and costs. 
 
One of the aims of the present study is to evaluate the physicochemical properties, 
drug-likeness and drug scores of Danshen compounds. Structures of 94 known  
compounds isolated from Danshen were retrieved and analysed by using relevant 
softwares (OSIRIS Property Explorer, ALOGPS and ACD/ChemSketch) and Ro5 
principle. Among these, only 2 lipophilic compounds and 16 hydrophilic compounds 
showed a low drug score, indicating that most active Danshen compounds (with a 
confirmed pharmacological action) have the potential to be developed as a drug. In 
fact, Tan IIA, a major tanshinone, has been developed and used clinically in China as 
a drug for treating cardiovascular conditions (642). In this regard, some hydrophilic 
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compounds, such as danshensu, may have a high potential for being developed as a 
pharmaceutical drug. On the other hand, this study also revealed potential toxicity 
risks for the drug-like Danshen compounds. Majority of evaluated compounds 
showed a low toxicity risk. Only a small number of compounds possessed relevant 
high toxicity risks, including irritating effects for 15 lipophilic compounds (among 
64 compounds tested) and mutagenicity, tumorigenicity, irritating effects for several 
hydrophilic compounds (5, 2, and 3 compounds respectively among 34 compounds 
tested). The study also identified the factors affecting the drug like property of 
Danshen compounds including mainly molecular weight, to a lesser extent, H-bond 
donor and acceptor, especially for the hydrophilic compounds. These findings may 
help to understand the actions of Danshen compounds in vitro and in vivo and also 
provide a knowledge base for designing new pharmaceutical compounds derived 
from Danshen compounds.   
 
To further extend the computational study, a comprehensive search was conducted to 
review the current research on in silico approaches on structure-based analysis, 
virtual screening, drug metabolizing enzyme and drug transporters including drug 
interactions. A number of natural compounds have been demonstrated as substrates 
of P450s, UGTs, drug transporters such as P-gp, raising the potential of herb-drug 
interactions (Chapter 4). In silico approaches have been used successfully to study 
the metabolic reactions, induction, biotransformations, binding characteristics to drug 
metabolizing enzymes and drug transporters etc. They have also been used to predict 
potential toxicity of natural products and herb-drug interactions.    
 
It should be pointed out that in silico approaches also have some challenges, such as 
lack of representation of the chemical entity/drug candidates or reliable experimental 
data for generating proper computational models. Thus, combination of in silico 
approaches with traditional in vitro and in vivo methods, and further developing and 
validating proper in silico models with less complexity, high predictability, and 
better correlations with available in vivo and in vitro data,  are important for 
prediction of drug actions. 
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8.1.2 Experimental model of eNOS uncoupling 
Increasing evidence suggests that endothelial dysfunction has been implicated in 
many metabolic and cardiovascular diseases resulting in significant health burden to 
society. Regulation of endothelial function has been proposed to be the therapeutic 
approach to treat relevant diseases (1073). eNOS uncoupling is a mechanism driving 
endothelial dysfunction. Thus, improving eNOS coupling would result in beneficial 
effect on endothelial function and produce favourable outcome in the treatment of 
metabolic and cardiovascular diseases.  
 
One of the aims of the present study is to establish a high glucose induced eNOS 
uncoupling model in human endothelial cell line EA.hy926, then use it to investigate 
the effects of tanshinones and derivatives on eNOS uncoupling. It has been 
demonstrated that multiple metabolic abnormalities are associated with endothelial 
dysfunction with an impairment of vasodilating activity (1074-1077). Dysfunction of 
the endothelium is an important factor in the pathogenesis of vascular disease in 
diabetes (1076, 1078). Although the underlying molecular mechanism(s) by which 
metabolic syndrome induces endothelial dysfunction has not been fully revealed, 
there are many possibilities of vascular endothelial damage and increase in 
cardiovascular risk in these patients, in particular, hyperglycaemia. It has been 
reported that increased ROS production and impaired eNOS function occur under 
hyperglycaemia condition in vitro. Furthermore, both animal and human  studies 
have demonstrated an association between hyperglycaemia and endothelial 
dysfunction (71, 1079). Endothelial dysfunction is regarded as a trigger of 
hyperglycaemia associated vascular disease. Therefore, a high glucose induced 
eNOS uncoupling model will be very useful to investigate the underlying mechanism 
and also examine the therapeutic effect of various compounds on endothelial 
function and eNOS uncoupling.  
 
In the present study, we found that the EA.hy926 cells under high glucose condition 
exhibited a reduced NO production and an increased eNOS derived superoxide 
generation. Furthermore, we demonstrated that the posttranslational modulation of 
eNOS was negatively regulated under high glucose condition with reduction in the 
ratios of BH4 to BH2 and eNOS dimer to monomer. In additiion, the expression of 
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GTPCH1, DHFR, and HSP90 were down regulated, whereas the expression of 
NOX4 and PI3K was up-regulated. These results demonstrated that the high glucose 
treated cell model meets the need for studying eNOS uncoupling mechenisms.  
 
8.1.3 Effects of tanshinones and derivatives on eNOS uncoupling 
Tanshinones have been reported with a variety of activities including improvement 
of microcirculation, dilation of coronary arteries, increase in blood flow, anti-
coagulant, anti-thrombotic, anti-inflammatory, anti-angiogenesis, free radical 
scavenging, and mitochondria-protective effects (637, 639, 658, 659, 1080). Tan I, 
Tan IIA and CT are the three major active tanshinones that have been extensively 
studied, however, the effect on eNOS uncoupling has not been reported yet.  
 
We have focused on the therapeutic ability of Tan I, Tan IIA and CT in endothelial 
dysfunction using the high glucose induced eNOS uncoupling model established. We 
found that high glucose induced eNOS uncoupling in human ECs can be restored by 
Tan I, Tan IIA and CT (Figure 8. 1). The results showed that these tanshinones 
increased BH4 bioavailability and NO production, reduced superoxide generation 
and the expression of NOX4. They also up-regulated the expressions of GTPCH1, 
DHFR and HSP90, and down-regulated the expression of PI3K. In addition, two 
synthetic analogues of tanshinones were also found with similar effects on eNOS 
uncoupling. The findings indicate that these tanshinones and tanshinone derivatives 
can restore high glucose induced eNOS uncoupling by up-regulation of BH4 
bioavailability and the expression of HSP90, down regulation of NOX and PI3K 
pathway. 
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Figure 8. 1. Effects of tanshinones and its derivatives on eNOS uncoupling under high glucose condition.  
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The study provides an insight into the mechanisms of endothelial protections of 
tanshinone and tanshinone derivatives. As eNOS uncoupling is a underlying 
mechanism of endothelial dysfunction involved in the pathogenesis of many 
metabolic and cardiovascular diseases, such as atherosclerosis and diabetes (76, 
1081), the findings in the present study may help to develop new agents to treat 
eNOS uncoupling-mediated cardiovascular and metabolic diseases. 
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8.2 Limitations of this study 
The present study has achieved the research objective to identify the effects of 
tanshinone and tanshinone derivatives on eNOS uncoupling and also analysed the 
physicochemical properties and drug potential of Danshen compounds. However, the 
study has some limitations.  
 
First, we only tested the high glucose induced eNOS uncoupling. It is not clear if 
observed eNOS uncoupling and mechanism occour in other metabolic conditions 
such as hypertriglyceridemia, hyperinsulinemia and hyperglycaemia with various 
alterations such as increase in the level of fatty acid, small dense LDL-cholesterol, 
apolipoprotein B, insulin-1 growth factor, tissue Ang II, plasminogen activator 
inhibitor-1, C reactive protein, ROS and  decrease in HDL-cholesterol (78, 1081-
1084).  Further studies in these conditions are necessary.  
 
Second, the present study has used human endothelial cell line EA.hy926. Although  
human umbilical vein ECs are an ideal model system and widely used for 
cardiovascular research involving angiogenesis, arteriosclerosis, oxidative stress, 
tubule formation, wound healing, immune response and drug screening (1085-1087). 
EA.hy926 is an immortalised cell line established by fusing primary human 
umbilical vein cells with a thioguanine-resistant clone of A549 by exposure to 
polyethylene glycol (1085). There is a difference in the response to cytokines 
between EA.hy926 and between primary umbilical vein endothelial cells (1088, 
1089). Further study using primary human endothelial cells may help to confirm the 
finsings obtained in the present study.  
 
Additionally, the present study only obstained preliminary evidence on mechanism 
of regulation of NOXs by PI3K. It has been reported that the regulation of NOXs via 
PI3K pathway can have several mechanisms, including protein binding with NOXs 
(1090), phosphorylation of NOXs (327), regulation on the recruitment of NOXs 
regulatory subunits (1091). Thus, to clearly identify the regulatory effect of PI3K on 
NOXs, more functional experiment are needed. 
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Finally, for the computational studies, using computational softwares and databases 
may help to elucidate physicochemical properties and drug potential of natural 
compounds, although we did not conduct biochemical experiments to validate the in 
silico results. Besides, there is a lack of reliable experimental data to generate proper 
computational model for further analysis of relationship between the in vitro and in 
vivo data. Clearly, there is a need for establishing and validating further proper 
models with less complexity, high predictability, and better correlations with 
available in vivo and in vitro data, which will have important applications in drug 
discovery and drug development.  
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8.3 Future perspectives 
Our findings from this project suggest that: 1) EA.hy926 cdells under high glucose 
exposure exihibit eNOS uncoupling through up-regulation the activity and 
expression of NOX4; 2) tanshinones and tanshinone derivatives reverse the high 
glucse induced eNOS uncoupling by improving BH4 bioavailability; 3) analysis of 
physicochemical properties and drug potential and in silico approaches in predication 
of biological fate, toxicity and drug interactions of natural products help develop new 
drugs.  
 
In future, the following research work can be carried out: 
• design and synthesize new hydrophilic and lipophilic compounds. 
• extend the in vitro study on eNOS uncoupling to investigating the effects of 
tanshinione comoounds on eNOS uncoupling in vivo.  
• employ gene modification technique to knock down or overexpress specific 
molecular target including NOXs to verify its role in ROS generation. 
• conduct the functional experiment on PI3K to validate its role in regulation of 
NOXs. This will facilitate to elucidate the underlying molecular mechanism 
of regulation of eNOS uncoupling by PI3K pathway. 
• carry out clinical studies. This will determine the therapeutic potential of 
tanshinones and tanshinone derivatives. 
• incorporate biochemical experiments and computational studies. This will 
facilitate the study on therapeutic effect, biological fate, toxicity and drug 
interaction of natural compounds/products.  
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